{"meta":{"type":"rules","chunk":6,"total":53123},"data":[{"ingredient1":"siponimod","ingredient2":"beta-blockers","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Vaccination: Avoid live-attenuated vaccines during and for up to 4 weeks after treatment with MAYZENT. (7. 4) CYP2C9 and Dual CYP2C9/3A4 Inhibitors: Strong CYP2C9 inhibitors increase siponimod exposure; concomitant use with MAYZENT is not recommended. Monitor for adverse reactions during concomitant use of MAYZENT with moderate CYP2C9 inhibitors or moderate CYP2C9/CYP3A4 dual inhibitors. (7. 5) CYP2C9 and CYP3A4 Inducers: Dual moderate CYP2C9/strong CYP3A4 inducers decrease siponimod exposure; concomitant use with MAYZENT is not recommended. Monitor for loss of efficacy with concomitant use of MAYZENT and moderate or strong CYP3A4 inducers in patients with CYP2C91/3 or 2/3 genotypes. (7. 6) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies MAYZENT has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive im","recommendation":"Avoid live-attenuated vaccines during and for up to 4 weeks after treatment with MAYZENT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"siponimod","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Vaccination: Avoid live-attenuated vaccines during and for up to 4 weeks after treatment with MAYZENT. (7. 4) CYP2C9 and Dual CYP2C9/3A4 Inhibitors: Strong CYP2C9 inhibitors increase siponimod exposure; concomitant use with MAYZENT is not recommended. Monitor for adverse reactions during concomitant use of MAYZENT with moderate CYP2C9 inhibitors or moderate CYP2C9/CYP3A4 dual inhibitors. (7. 5) CYP2C9 and CYP3A4 Inducers: Dual moderate CYP2C9/strong CYP3A4 inducers decrease siponimod exposure; concomitant use with MAYZENT is not recommended. Monitor for loss of efficacy with concomitant use of MAYZENT and moderate or strong CYP3A4 inducers in patients with CYP2C91/3 or 2/3 genotypes. (7. 6) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies MAYZENT has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive im","recommendation":"Avoid live-attenuated vaccines during and for up to 4 weeks after treatment with MAYZENT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"siponimod","ingredient2":"ivabradine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Vaccination: Avoid live-attenuated vaccines during and for up to 4 weeks after treatment with MAYZENT. (7. 4) CYP2C9 and Dual CYP2C9/3A4 Inhibitors: Strong CYP2C9 inhibitors increase siponimod exposure; concomitant use with MAYZENT is not recommended. Monitor for adverse reactions during concomitant use of MAYZENT with moderate CYP2C9 inhibitors or moderate CYP2C9/CYP3A4 dual inhibitors. (7. 5) CYP2C9 and CYP3A4 Inducers: Dual moderate CYP2C9/strong CYP3A4 inducers decrease siponimod exposure; concomitant use with MAYZENT is not recommended. Monitor for loss of efficacy with concomitant use of MAYZENT and moderate or strong CYP3A4 inducers in patients with CYP2C91/3 or 2/3 genotypes. (7. 6) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies MAYZENT has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive im","recommendation":"Avoid live-attenuated vaccines during and for up to 4 weeks after treatment with MAYZENT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium sulfacetamide","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"DRUG INTERACTIONS This product is incompatible with silver preparations.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"mirtazapine","ingredient2":"pine o","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 5 includes clinically important drug interactions with mirtazapine orally disintegrating tablets see Clinical Pharmacology (12. 3). Table 5: Clinically Important Drug Interactions with Mirtazapine Orally Disintegrating Tablets Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact The concomitant use of serotonergic drugs, including mirtazapine orally disintegrating tablets, and MAOIs increases the risk of serotonin syndrome. Intervention Mirtazapine orally disintegrating tablets are contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue see Dosage and Administration (2. 4), Contraindications (4), Warnings and Precautions (5. 3). Examples selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drugs Clinical Impact The concomitant use of serotonergic drugs with mirtazapine orally disintegrating tablets increase the risk of serotonin syndrome. Intervention Monitor pati","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydromorphone hydrochloride","ingredient2":"extended-release","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 4 includes clinically significant drug interactions with hydromorphone hydrochloride extended-release tablets. Table 4. Clinically Significant Drug Interactions with Hydromorphone Hydrochloride Extended-Release Tablets Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing an opioid overdose reversal agent see Dosage and Administra","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydromorphone hydrochloride","ingredient2":"gaba","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 4 includes clinically significant drug interactions with hydromorphone hydrochloride extended-release tablets. Table 4. Clinically Significant Drug Interactions with Hydromorphone Hydrochloride Extended-Release Tablets Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing an opioid overdose reversal agent see Dosage and Administra","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydromorphone hydrochloride","ingredient2":"gabapentin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 4 includes clinically significant drug interactions with hydromorphone hydrochloride extended-release tablets. Table 4. Clinically Significant Drug Interactions with Hydromorphone Hydrochloride Extended-Release Tablets Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Inform patients and caregivers of this potential interaction, educate them on the signs and symptoms of respiratory depression (including sedation). If concomitant use is warranted, consider prescribing an opioid overdose reversal agent see Dosage and Administra","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"apixaban","ingredient2":"eliquis","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban. Reduce ELIQUIS dose or avoid coadministration. ( 2. 6, 7. 1, 12. 3) Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (7. 2, 12. 3) 7. 1 Combined P-gp and Strong CYP3A4 Inhibitors For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e. G. , ketoconazole, itraconazole, ritonavir) see Dosage and Administration (2. 6) and Clinical Pharmacology (12. 3). For patients receiving ELIQUIS at a dose of 2. 5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors see Dosage and Administration (2. 6) and Clinical Pharmacology (12. 3). Concomitant administration of combined P-gp and strong CYP3A4 inhibitors has not been studied in pediatric patients. Apixaban is a substra","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"apixaban","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban. Reduce ELIQUIS dose or avoid coadministration. ( 2. 6, 7. 1, 12. 3) Simultaneous use of combined P-gp and strong CYP3A4 inducers reduces blood levels of apixaban: Avoid concomitant use. (7. 2, 12. 3) 7. 1 Combined P-gp and Strong CYP3A4 Inhibitors For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e. G. , ketoconazole, itraconazole, ritonavir) see Dosage and Administration (2. 6) and Clinical Pharmacology (12. 3). For patients receiving ELIQUIS at a dose of 2. 5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors see Dosage and Administration (2. 6) and Clinical Pharmacology (12. 3). Concomitant administration of combined P-gp and strong CYP3A4 inhibitors has not been studied in pediatric patients. Apixaban is a substra","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"mycophenolate mofetil","ingredient2":"mycophenolate","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce MYCOPHENOLATE MOFETIL efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (7. 1) MYCOPHENOLATE MOFETIL may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. (7. 2) See FPI for other important drug interactions. (7) 7. 1 Effect of Other Drugs on Mycophenolate Mofetil Table 7 Drug Interactions with Mycophenolate mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure see Clinical Pharmacology (12. 3), which may reduce Mycophenolate mofetil efficacy. Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h aft","recommendation":"Monitor patients for alterations in efficacy when PPIs are co-administered with Mycophenolate mofetil.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"mycophenolate mofetil","ingredient2":"mofetil","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce MYCOPHENOLATE MOFETIL efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (7. 1) MYCOPHENOLATE MOFETIL may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. (7. 2) See FPI for other important drug interactions. (7) 7. 1 Effect of Other Drugs on Mycophenolate Mofetil Table 7 Drug Interactions with Mycophenolate mofetil that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure see Clinical Pharmacology (12. 3), which may reduce Mycophenolate mofetil efficacy. Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h aft","recommendation":"Monitor patients for alterations in efficacy when PPIs are co-administered with Mycophenolate mofetil.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide","ingredient2":"prinzide","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions L isinopril Hypotension  Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS and DOSAGE AND ADMINISTRATION). When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed (see DOSAGE AND ADMINISTRATION). Non-steroidal Anti-inflammatory Agents Including Selective ","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brimonidine","ingredient2":"alcohol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"monoamine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"cla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"mao inhibitors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug-drug interactions studies have not been conducted with brimonidine topical gel, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anaesthetics) should be considered. 7. 3 Monoamine Oxidase Inhibitors Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side-effect such as hypotension. Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ziprasidone","ingredient2":"iron","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated: Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation. (4. 1, 7. 3) The absorption of ziprasidone is increased up to two-fold in the presence of food. (7. 10) The full prescribing information contains additional drug interactions. (7). 7. 1 Metabolic Pathway Approximately two-thirds of ziprasidone is metabolized via a combination of chemical reduction by glutathione and enzymatic reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase. Less than one-th","recommendation":"Should not be used in combination with other drugs that have demonstrated QT prolongation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ziprasidone","ingredient2":"buspirone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. All interactions studies have been conducted with oral ziprasidone. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated: Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation. (4. 1, 7. 3) The absorption of ziprasidone is increased up to two-fold in the presence of food. (7. 10) The full prescribing information contains additional drug interactions. (7). 7. 1 Metabolic Pathway Approximately two-thirds of ziprasidone is metabolized via a combination of chemical reduction by glutathione and enzymatic reduction by aldehyde oxidase. There are no known clinically relevant inhibitors or inducers of aldehyde oxidase. Less than one-th","recommendation":"Should not be used in combination with other drugs that have demonstrated QT prolongation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"naproxen","ingredient2":"delayed-release","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 1 for clinically significant drug interactions with naproxen. Table 1: Clinically Significant Drug Interactions with naproxen Drugs That Interfere with Hemostasis Clinical Impact: Naproxen and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of naproxen and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of NAPROXEN Tablets, Naproxen Delayed-Release Tablets, or NAPROXEN SODIUM with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitor","recommendation":"Monitor patients with concomitant use of NAPROXEN Tablets, Naproxen Delayed-Release Tablets, or NAPROXEN SODIUM with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pregabalin","ingredient2":"erythromycin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions see Clinical Pharmacology (12). The interactions of LYRICA CR with co-administration of other drugs have not been systematically evaluated. Co-administration of the prokinetic drug erythromycin with LYRICA CR did not result in any clinically important changes in the pharmacokinetics of LYRICA CR see Clinical Pharmacology (12). Additional studies have been performed with LYRICA. No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenyto","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pregabalin","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions see Clinical Pharmacology (12). The interactions of LYRICA CR with co-administration of other drugs have not been systematically evaluated. Co-administration of the prokinetic drug erythromycin with LYRICA CR did not result in any clinically important changes in the pharmacokinetics of LYRICA CR see Clinical Pharmacology (12). Additional studies have been performed with LYRICA. No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenyto","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pregabalin","ingredient2":"gabapentin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (less than 2% of a dose recovered in urine as metabolites), and does not bind to plasma proteins, its pharmacokinetics are unlikely to be affected by other agents through metabolic interactions or protein binding displacement. In vitro studies showed that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions see Clinical Pharmacology (12). The interactions of LYRICA CR with co-administration of other drugs have not been systematically evaluated. Co-administration of the prokinetic drug erythromycin with LYRICA CR did not result in any clinically important changes in the pharmacokinetics of LYRICA CR see Clinical Pharmacology (12). Additional studies have been performed with LYRICA. No pharmacokinetic interactions were observed between LYRICA and carbamazepine, gabapentin, lamotrigine, oral contraceptive, phenobarbital, phenyto","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"epinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"mao inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"corticosteroid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine extended-release","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. ( 7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Con","recommendation":"Contraindications( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"cytokines","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"corticosteroids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"pea","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"vera","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"ustekinumab","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"warfarin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"cyclosporin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"imuldosa","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In plaque psoriasis trials the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In psoriatic arthritis trials, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In Crohns disease and ulcerative colitis induction trials, immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e. G. , IL-1, IL-6, IL-10, TNFÎ±, IFN) during chronic inflammation. Thus, ustekinumab products, antagonists of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Up","recommendation":"Monitoring for therapeutic effect (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"acitretin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"isotretinoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"tretinoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"penicillin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"anticoagulants","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxycycline","ingredient2":"olamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Patients on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ( 7. 1) Some bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. ( 7. 2) The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ( 7. 3) 7. 1 Anticoagulants Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. 7. 2 Penicillin Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. 7. 3 Methoxyflurane The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. 7. 4 Antacids and Iron Preparations Absorption of tetracycl","recommendation":"Avoid giving tetracycline-class drugs in conjunction with penicillin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ticagrelor","ingredient2":"brilinta","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Avoid use with strong CYP3A inhibitors or CYP3A inducers. (7. 1, 7. 2) Opioids: Decreased exposure to ticagrelor. Consider use of parenteral anti-platelet agent. (7. 3) Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects. (7. 4)  Rosuvastatin plasma concentrations may increase. Monitor for statin-related adverse effects. ( 7. 4 ) Monitor digoxin levels with initiation of or any change in BRILINTA. (7. 5) 7. 1 Strong CYP3A Inhibitors Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events. Avoid use of strong inhibitors of CYP3A (e. G. , ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) see Clinical Pharmacology (12. 3). 7. 2 Strong CYP3A Inducers Strong CYP3A inducers substantially reduce ticagrelor exposure and ","recommendation":"Avoid use with strong CYP3A inhibitors or CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride","ingredient2":"marcaine","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local AnestheticsThe toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see DOSAGE AND ADMINISTRATION (2. 1), WARNINGS AND PRECAUTIONS (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic AntidepressantsThe administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see WARNINGS AND PRECAUTIONS (5. 6). 7. 3 Ergot-Type Oxytocic DrugsConcurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrova","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see DOSAGE AND ADMINISTRATION (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"ros","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"atp","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"oat","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"xifaxan","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"tar","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"warfarin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifaximin","ingredient2":"cyclosporin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Warfarin: Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range. ( 7. 2) 7. 1 P-glycoprotein Inhibitors Concomitant administration of cyclosporine, an inhibitor of P-gp and OATPs significantly increased the systemic exposure of rifaximin. In patients with hepatic impairment, a potential additive effect of reduced metabolism and concomitant P-gp inhibitors may further increase the systemic exposure to rifaximin. Caution should be exercised when concomitant use of XIFAXAN and a P-gp inhibitor such as cyclosporine is needed see Warnings and Precautions ( 5. 5), Clinical Pharmacology ( 12. 3 ). 7. 2 Warfarin Changes in INR have been reported postmarketing in patients receiving rifaximin and warfarin concomitantly. Monitor INR and prothrombin time. Dose adjustment of warfarin may be needed to maintain target INR range. See prescribing information for warfarin. 7. 3 CYP3A4 Substrates An in vitrostudy has suggested that ri","recommendation":"Monitor INR and prothrombin time; dose adjustment of warfarin may be needed to maintain target INR range.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"gilenya","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"diltiazem","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"erythromycin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"teriflunomide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"fingolimod","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"verapamil","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"beta blockers","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"haloperidol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"immune-modulating","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"citalopram","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"calcium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"mitoxantrone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"natalizumab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"chlorpromazine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fingolimod hcl","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Systemic Ketoconazole: Monitor during concomitant use. (7. 2, 12. 3) Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment. (5. 2, 7. 3) 7. 1 QT Prolonging Drugs GILENYA has not been studied in patients treated with drugs that prolong the QT interval. Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia. Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e. G. , citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility see Dosage and Administration (2. 4), Warnings and Precautions (5. 1). 7. 2 Ketoconazole The blood levels of fingolimod and fingolimod-phosphate are increased by 1. 7-fold when used concomitantly with ketoconazole. Patients who use GILENYA ","recommendation":"Monitor during concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase inhibitors (MAOI) Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAOI and products containing dextromethorphan. In addition, MAOI prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide syrup and MAOI should be avoided (see CONTRAINDICATIONS ). Central nervous system (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dronedarone","ingredient2":"andromeda","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Dronedarone is metabolized by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6 and has potentially important pharmacodynamic interactions (7) Class I or III antiarrhythmics: Contraindicated. (4, 7. 1) Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels. (7. 1, 7. 3) Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability. (7. 1, 7. 2, 7. 3) Beta-blockers: May provoke excessive bradycardia. Initiate with low dose and increase after ECG verification of tolerability. (7. 1, 7. 3) CYP3A inducers: Avoid concomitant use. (7. 2) Grapefruit juice: Avoid concomitant use. (7. 2) Statins: Avoid simvastatin doses greater than 10 mg daily. Follow label recommendations for concomitant use of other statins with a CYP3A and P-gp inhibitor like dronedarone. (7. 3) CYP3A substrates with a narrow therapeutic index (e. G. , sirolimus and tacrolimus): Monitor and adjust dosage ","recommendation":"Monitor digoxin levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dronedarone","ingredient2":"pallas","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Dronedarone is metabolized by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6 and has potentially important pharmacodynamic interactions (7) Class I or III antiarrhythmics: Contraindicated. (4, 7. 1) Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels. (7. 1, 7. 3) Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability. (7. 1, 7. 2, 7. 3) Beta-blockers: May provoke excessive bradycardia. Initiate with low dose and increase after ECG verification of tolerability. (7. 1, 7. 3) CYP3A inducers: Avoid concomitant use. (7. 2) Grapefruit juice: Avoid concomitant use. (7. 2) Statins: Avoid simvastatin doses greater than 10 mg daily. Follow label recommendations for concomitant use of other statins with a CYP3A and P-gp inhibitor like dronedarone. (7. 3) CYP3A substrates with a narrow therapeutic index (e. G. , sirolimus and tacrolimus): Monitor and adjust dosage ","recommendation":"Monitor digoxin levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dronedarone","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Dronedarone is metabolized by CYP3A and is a moderate inhibitor of CYP3A and CYP2D6 and has potentially important pharmacodynamic interactions (7) Class I or III antiarrhythmics: Contraindicated. (4, 7. 1) Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor digoxin levels. (7. 1, 7. 3) Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability. (7. 1, 7. 2, 7. 3) Beta-blockers: May provoke excessive bradycardia. Initiate with low dose and increase after ECG verification of tolerability. (7. 1, 7. 3) CYP3A inducers: Avoid concomitant use. (7. 2) Grapefruit juice: Avoid concomitant use. (7. 2) Statins: Avoid simvastatin doses greater than 10 mg daily. Follow label recommendations for concomitant use of other statins with a CYP3A and P-gp inhibitor like dronedarone. (7. 3) CYP3A substrates with a narrow therapeutic index (e. G. , sirolimus and tacrolimus): Monitor and adjust dosage ","recommendation":"Monitor digoxin levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"sage","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"folic","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"trimethoprim","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"eru","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"ros","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"vera","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"bet","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"pyrimethamine","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"folic acid","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dapsone","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Rifampin lowers Dapsone levels 7 to 10-fold by accelerating plasma clearance; in leprosy this reduction has not required a change in dosage. Folic acid antagonists such as pyrimethamine may increase the likelihood of hematologic reactions. A modest interaction has been reported for patients receiving 100 mg Dapsone daily in combination with trimethoprim 5 mg/kg q6h. On Day 7, the serum Dapsone levels averaged 2. 1  1. 0 mcg/mL in comparison to 1. 5  0. 5 mcg/mL for Dapsone alone. On Day 7, trimethoprim levels averaged 18. 4  5. 2 mcg/mL in comparison to 12. 4  4. 5 mcg/mL for patients not receiving Dapsone. Thus, there is a mutual interaction between Dapsone and trimethoprim in which each raises the level of the other about 1. 5 times. A crossover study1 designed to assess the potential of a drug interaction between Dapsone, 100 mg/day and trimethoprim, 200 mg every 12 hours, in eight asymptomatic HIV positive volunteers (average CD4 count 524 cells/mm3) demonstrated ","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"methylene blue","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"linezolid","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"tranylcypromine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"omeprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine sulfate","ingredient2":"protriptyline","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Acidifying Agents Lower blood levels and efficacy of amphetamines. Increase dose based on clinical response. Examples of acidifying agents include gastrointestinal acidifying agents (e. G. , guanethidine, reserpine, glutamic acid HCl, ascorbic acid) and urinary acidifying agents (e. G. , ammonium chloride, sodium acid phosphate, methenamine salts). Adrenergic Blockers Adrenergic blockers are inhibited by amphetamines. Alkalinizing Agents Increase blood levels and potentiate the action of amphetamine. Coadministration of dextroamphetamine sulfate extended-release and gastrointestinal alkalinizing agents should be avoided. Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e. G. , sodium bicarbonate) and urinary alkalinizing agents (e. G. Acetazolamide, some thiazides). Tricyclic Antidepressants May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in the concentration of d-amphetamine in the ","recommendation":"Should be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac potassium","ingredient2":"zipsor","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2 for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of ZIPSOR with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding see Warnings and Precaut","recommendation":"Monitor patients with concomitant use of ZIPSOR with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rivaroxaban","ingredient2":"xarelto","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid combined P-gp and strong CYP3A inhibitors and inducers ( 7. 2, 7. 3) Anticoagulants: Avoid concomitant use ( 7. 4) 7. 1 General Inhibition and Induction Properties Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters. Combined P-gp and strong CYP3A inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding. Combined P-gp and strong CYP3A inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events. 7. 2 Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems Interaction with Combined P-gp and Strong CYP3A Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A inhibitors (e. G. , ketoconazole and ritonavir) see Warnings and Precautions (5. 6)and Clinical Pharmacology (12. 3). Although clarithromycin is a combined P-gp and strong CYP3A inhibitor, pharmacokinetic data suggests that no precaution","recommendation":"Avoid combined P-gp and strong CYP3A inhibitors and inducers ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"caf","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"diuretics","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"itraconazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"omeprazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"pharmacology","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"dosage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"caffeine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"eru","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"levonorgestrel","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"drug-laboratory-test","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"administration","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"norgestrel","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"clinical","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"cla","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"clarithromycin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"tar","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"estradiol","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"warfarin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"fluoxetine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"ritonavir","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"methy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"ethinyl estradiol","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"choline","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"ketoconazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolterodine","ingredient2":"caffein","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7. 2) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7. 6) 7. 1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4. 8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine  see CLINICAL PHARMACOLOGY ( 12. 1). The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the i","recommendation":"Dose adjustment is required when tolterodine and fluoxetine are co-administered  see CLINICAL PHARMACOLOGY (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"protein","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"urea","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"tradjenta","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"glyce","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"linagliptin","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong P-glycoprotein/CYP3A4 inducer: The efficacy of TRADJENTA may be reduced when administered in combination (e. G. , with rifampin). Use of alternative treatments is strongly recommended. (7. 1) 7. 1 Inducers of P-glycoprotein or CYP3A4 Enzymes Rifampin decreased linagliptin exposure, suggesting that the efficacy of TRADJENTA may be reduced when administered in combination with a strong P-gp or CYP3A4 inducer. Therefore, use of alternative treatments is strongly recommended when linagliptin is to be administered with a strong P-gp or CYP3A4 inducer see Clinical Pharmacology (12. 3). 7. 2 Insulin Secretagogues or Insulin Insulin and insulin secretagogues are known to cause hypoglycemia. The risk of hypoglycemia is increased when linagliptin is used in combination with an insulin secretagogue (e. G. , sulfonylurea) or insulin. Coadministration of TRADJENTA with an insulin secretagogue (e. G. , sulfonylurea) or insulin may require lower dosages of the insulin secre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"dalfampridine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"cosela","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"cisplatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"mate","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trilaciclib","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Certain OCT2, MATE1, and MATE-2K substrates: Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities. (7. 1) 7. 1 Effect of COSELA on Other Drugs, Certain OCT2, MATE1, and MATE-2K Substrates COSELA is an inhibitor of OCT2, MATE1, and MATE-2K. Co-administration of COSELA may increase the concentration or net accumulation of OCT2, MATE1, and MATE-2K substrates in the kidney (e. G. , dofetilide, dalfampridine, and cisplatin) see Clinical Pharmacology (12. 3). Refer to the prescribing information for these concomitant medications for assessing the benefit and risk of concomitant use of COSELA. Table 4: Potentially Significant Drug Interactions with COSELA Drugs Recommendations Comments Dofetilide The potential benefits of taking COSELA concurrently with dofetilide should be considered against the risk of QT interval prolongation. Increased dofetilide blood levels may oc","recommendation":"Avoid concomitant use with certain OCT2, MATE1, and MATE-2K substrates where minimal concentration changes may lead to serious or life-threatening toxicities.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levonorgestrel and ethinyl estradiol","ingredient2":"precautions","severity":"moderate","severity_confidence":0.5,"effect":"Drug-Drug Interactions See PRECAUTIONS section  Drug Interactions.","recommendation":"CAUTIONS section  Drug Interactions.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"levonorgestrel and ethinyl estradiol","ingredient2":"drug-drug","severity":"moderate","severity_confidence":0.5,"effect":"Drug-Drug Interactions See PRECAUTIONS section  Drug Interactions.","recommendation":"CAUTIONS section  Drug Interactions.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"chloroquine phosphate","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"polypeptides","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"veklury","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"protein","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"atp","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"oat","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"fat","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"oatp","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"remdesivir","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effects of Other Drugs on VEKLURY Due to potential antagonism based on data from cell culture experiments, concomitant use of VEKLURY with chloroquine phosphate or hydroxychloroquine sulfate is not recommended see Warnings and Precautions (5. 3) and Microbiology (12. 4). Based on drug interaction studies conducted with VEKLURY, no clinically significant drug interactions are expected with inducers of cytochrome P450 (CYP) 3A4 or inhibitors of Organic Anion Transporting Polypeptides (OATP) 1B1/1B3 and, P-glycoprotein (P-gp) see Clinical Pharmacology (12. 3). 7. 2 Effects of VEKLURY on Other Drugs Based on drug interaction studies conducted with VEKLURY, it is a weak inhibitor of CYP3A and does not inhibit OATP1B1/1B3 see Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sepiapterin","ingredient2":"sulfamethoxazole","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"vardenafil","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"tadalafil","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"dhfr","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"trimethoprim","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"folate","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"sulfasalazine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"oxide-mediated","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"sephience","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"sildenafil","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"pralatrexate","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"levodopa","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"ala","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"methotrexate","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"tyrosine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sepiapterin","ingredient2":"pemetrexed","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Dihydrofolate Reductase (DHFR) Inhibitors: Avoid concomitant use (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, or piritrexim). (7. 1) Sepiapterin Reductase (SR) Inhibitors: Avoid concomitant use (e. G. Sulfasalazine or sulfamethoxazole). (7. 1) Interaction with Levodopa: Monitor patients for a change in neurologic status. (7. 2) Drugs Affecting Nitric Oxide-Mediated Vasorelaxation: Potential for vasorelaxation; monitor blood pressure (e. G. , PDE-5 inhibitors). (7. 2) 7. 1 Effects of Other Drugs on SEPHIENCE Avoid concomitant use of drugs known to inhibit folate synthesis dihydrofolate reductase (DHFR) (e. G. , trimethoprim, methotrexate, trimetrexate, pemetrexed, pralatrexate, raltitrexed, and piritrexim) while taking SEPHIENCE. Concomitant administration of such drugs may reduce sepiapterin metabolism to tetrahydrobiopterin (BH4). If concomitant use is not avoidable, monitor blood Phe levels. Avoid concomitant use of sep","recommendation":"Avoid concomitant use (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"fluconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"efavirenz","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"tramadol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"clinical","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"vera","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"anti-retroviral","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"mirtazapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"methylene blue","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"darunavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"ritonavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"choline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"cyclobenzaprine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"stavudine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"sertraline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"erythromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"naloxone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"antibiotics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"epinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"trazodone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"didanosine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"linezolid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"calcium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"diuretic","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"diuretics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"zidovudine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"prop","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"chlorid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"pea","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"pine o","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"nalbuphine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"nevirapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"metaxalone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"protease","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"precautions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"phenobarbital","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"pharmacology","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"mental","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"chloride","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"desipramine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"warnings","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methadone","ingredient2":"others","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Inhibitors of CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 Clinical Impact: Methadone undergoes hepatic N-demethylation by several cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2B6, CYP2C19, CYP2C9, and CYP2D6. The concomitant use of methadone hydrochloride tablets and CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitors can increase the plasma concentration of methadone, resulting in increased or prolonged opioid effects, and may result in a fatal overdose, particularly when an inhibitor is added after a stable dose of methadone hydrochloride tablets is achieved. These effects may be more pronounced with concomitant use of drugs that inhibit more than one of the CYP enzymes listed above. After stopping a CYP3A4, CYP2B6, CYP2C19, CYP2C9, or CYP2D6 inhibitor, as the effects of the inhibitor decline, the methadone plasma concentration can decrease see CLINICAL PHARMACOLOGY (12. 3), resulting in decreased opioid efficacy or withdrawal symptoms in patients physica","recommendation":"CAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m medronate","ingredient2":"iron","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m medronate","ingredient2":"calcium","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m medronate","ingredient2":"alum","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m medronate","ingredient2":"but","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m medronate","ingredient2":"warnings","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m medronate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m medronate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"kit for the preparation of technetium tc99m sestamibi","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Specific drug-drug interactions have not been studied. Specific drug-drug interactions have not been studied (7).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of technetium tc99m sestamibi","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Specific drug-drug interactions have not been studied. Specific drug-drug interactions have not been studied (7).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"treprostinil","ingredient2":"fluconazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"ros","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"enzyme inhibitor","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"warfarin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"gemfibrozil","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"olamine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"ala","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"treprostinil","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS 7. 1 Effect of Cytochrome P450 Inhibitors and Inducers In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A. Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. It is unclear if the safety and efficacy of treprostinil by the inhalation route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions (5. 3). 7. 2 Effect of Other Drugs on Treprostinil Drug interaction studies have been carried out with treprostinil (oral or su","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terconazole","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Oral Contraceptives: There is no known interaction with the concomitant use of this product and oral contraceptives.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"alosetron hydrochloride","ingredient2":"itraconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"fluvoxamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"pea","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"antibiotics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"levonorgestrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"norgestrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"cisapride","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"oat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"alum","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"cimetidine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"clarithromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"50 mg","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"hydralazine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"voriconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"theophylline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"ethinyl estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"protease","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alosetron hydrochloride","ingredient2":"isoniazid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS In vivodata suggest that alosetron is primarily metabolized by cytochrome P450 (CYP) 1A2, with minor contributions from CYP3A4 and CYP2C9. Therefore, inducers or inhibitors of these enzymes may change the clearance of alosetron. CYP1A2 inhibitors: Avoid concomitant uses because of increased exposure and half-life of alosetron. Use with fluvoxamine is contraindicated. (4. 3, 7. 1) CYP3A4 inhibitors: Use with caution in combination due to increased exposure of alosetron. (7. 2) 7. 1 CYP1A2 Inhibitors Fluvoxamine is a known strong inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9 and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg/day to 200 mg/day for 16 days, with co-administration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentrations (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold. Concomitant administration of alosetron and f","recommendation":"Avoid concomitant uses because of increased exposure and half-life of alosetron.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"carbamazepine","ingredient2":"pine o","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions There has been a report of a patient who passed an orange rubbery precipitate in his stool the day after ingesting carbamazepine oral suspension immediately followed by Thorazine solution. Subsequent testing has shown that mixing carbamazepine oral suspension and chlorpromazine solution (both generic and brand name) as well as carbamazepine oral suspension and liquid Mellaril, resulted in the occurrence of this precipitate. Because the extent to which this occurs with other liquid medications is not known, carbamazepine oral suspension should not be administered simultaneously with other liquid medicinal agents or diluents (see DOSAGE AND ADMINISTRATION). Clinically meaningful drug interactions have occurred with concomitant medications and include (but are not limited to) the following:","recommendation":"Should not be administered simultaneously with other liquid medicinal agents or diluents (see DOSAGE AND ADMINISTRATION).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"antipyrine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"prednisone","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"eru","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"ros","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"skytrofa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"glyce","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"somatropin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"others","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lonapegsomatropin-tcgd","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes a list of drugs with clinically important drug interactions when administered concomitantly with SKYTROFA and instructions for preventing or managing them. Table 4: Clinically Important Drug Interactions with SKYTROFA Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. Somatropin inhibits 11Î²HSD-1. Consequently, individuals with untreated growth hormone deficiency (GHD) have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of SKYTROFA may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of SKYTROFA see Warnings and Precautions (5. 7) Examples Cortisone acetate and prednisone","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"anis","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"glucose","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"methylene blue","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"pan","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"linezolid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 describe the clinically significant drug interactions of doxepin hydrochloride with other drugs or classes. Table 2: Clinically Significant Drug Interactions with Doxepin Hydrochloride Monoamine Oxidase Inhibitors Prevention or Management Doxepin hydrochloride is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs), including MAOIs such as linezolid or intravenous methylene blue. The use of doxepin hydrochloride within 14 days of discontinuation of an MAOI or the use of MAOI within 14 days of discontinuation of doxepin hydrochloride is contraindicated. Starting doxepin hydrochloride in a patient who is being treated with an MAOI is contraindicated. Clinical Effect(s) Concomitant use of doxepin hydrochloride and MAOIs increases the risk of serotonin syndrome Warnings and Precautions ( 5. 2 ). Other Serotonergic Drugs (Besides MAOIs) Prevention or Management Monitor patients for signs and symptoms of serotonin syndrome, particularly during t","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"carboplatin","ingredient2":"kyxata","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Aminoglycosides: Avoid concomitant use with aminoglycosides. (7. 1) 7. 1 Use with Aminoglycosides Avoid concomitant use of aminoglycosides with KYXATA. Concomitant use of KYXATA with aminoglycosides increased renal toxicity and ototoxicity.","recommendation":"Avoid concomitant use with aminoglycosides.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"carboplatin","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Aminoglycosides: Avoid concomitant use with aminoglycosides. (7. 1) 7. 1 Use with Aminoglycosides Avoid concomitant use of aminoglycosides with KYXATA. Concomitant use of KYXATA with aminoglycosides increased renal toxicity and ototoxicity.","recommendation":"Avoid concomitant use with aminoglycosides.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"fosinopirl sodium","ingredient2":"fos","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"metoclopramide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"ace inhibitor","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"temsirolimus","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"electrolytes","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"cimetidine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"magnesium hydroxide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"pan","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"potassium i","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"magnesi","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"fosinopril","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"nifedipine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"chlorthalidone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"alum","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"panth","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"diuretic","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"hydrochlorothiazide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"propranolol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"aspirin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"anticoagulant","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"simethicone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"simethicone)","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"ace inhibitors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"panthe","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"aliskiren","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"renin-angiotensin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"magnesium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fosinopirl sodium","ingredient2":"sirolimus","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium tablets. The possibility of hypotensive effects with fosinopril sodium can be minimized by either discontinuing the diuretic or increasing salt intake prior to initiation of treatment with fosinopril sodium. If this is not possible, the starting dose should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ). Agents increasing serum potassium Coadministration of fosinopril with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. Lithium Increased serum lithium levels and symptoms of lithium tox","recommendation":"Should be reduced and the patient should be observed closely for several hours following an initial dose and until blood pressure has stabilized (see DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"burosumab","ingredient2":"vitamin d","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"vitami","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"vitamin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"crysvita","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"vita","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"burosumab","ingredient2":"vita a","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Oral Phosphate and Active Vitamin D Analogs Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs will increase phosphate concentrations greater than expected with CRYSVITA alone. This increase may result in hyperphosphatemia which can induce nephrocalcinosis. Concomitant use of CRYSVITA with oral phosphate and/or active vitamin D analogs is contraindicated.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brivaracetam","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"levetiracetam","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"carbamazepine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"briviact","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brivaracetam","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Rifampin: Because of decreased concentrations, increasing BRIVIACT dosage in patients on concomitant rifampin is recommended. ( 2. 6, 7. 1) Carbamazepine: Because of increased exposure to carbamazepine metabolite, if tolerability issues arise, consider reducing carbamazepine dosage in patients on concomitant BRIVIACT. ( 7. 2) Phenytoin: Because phenytoin concentrations can increase, phenytoin levels should be monitored in patients on concomitant BRIVIACT. ( 7. 3) Levetiracetam: BRIVIACT had no added therapeutic benefit when co-administered with levetiracetam. ( 7. 4) 7. 1 Rifampin Co-administration with rifampin decreases BRIVIACT plasma concentrations likely because of CYP2C19 induction see Clinical Pharmacology (12. 3). Prescribers should increase the BRIVIACT dose by up to 100% (i. E. , double the dosage) in patients while receiving concomitant treatment with rifampin see Dosage and Administration (2. 6). 7. 2 Carbamazepine Co-administration with carbamazepine ma","recommendation":"Should be monitored in patients on concomitant BRIVIACT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"lisinopril","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"spironolactone","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"corticosteroids","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"eru","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"ace inhibitor","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"temsirolimus","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"electrolytes","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"sodi","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"amiloride","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"nsaid","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"type 2","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"nsaids","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"epinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"administration","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"prinzide","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"mtor","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"acth","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"diuretic","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"diuretics","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"iron","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"prop","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"hydrochlorothiazide","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"triamterene","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"lysi","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"propranolol","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"everolimus","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"sodium","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"nephron","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"tar","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"potassium","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"eplerenone","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"losartan","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"dosage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"cholestyramine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"ace inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"aliskiren","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"warnings","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"renin-angiotensin","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lisinopril and hydrochlorothiazide tablets","ingredient2":"sirolimus","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Lisinopril Hypotension - Patients on Diuretic Therapy: Patients on diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with lisinopril. The possibility of hypotensive effects with lisinopril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with lisinopril. If it is necessary to continue the diuretic, initiate therapy with lisinopril at a dose of 5 mg daily, and provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour. (See WARNINGS and DOSAGE AND ADMINISTRATION. ) When a diuretic is added to the therapy of a patient receiving lisinopril, an additional antihypertensive effect is usually observed. (See DOSAGE AND ADMINISTRATION. ) Non-steroidal Anti-inflammatory Agents Including Select","recommendation":"Monitor renal function periodically in patients receiving lisinopril and NSAID therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"alendronate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"aspirin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"calcium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium tablet","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. ( 2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. ( 7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of alendronate sodium and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of alendronate sodium. Therefore, instruct patients to wait at least one-half hour after taking alendronate sodium before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of alendronate greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs Alendronate sodium may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSA","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"monoamine","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"antibiotics","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"epinephrine","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"ergot-type","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"marcaine","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride and epinephrine bitartrate","ingredient2":"beta-adrenergic","severity":"severe","severity_confidence":0.9,"effect":"7 Drug Interactions 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with MARCAINE / MARCAINE WITH EPINEPHRINE cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2. 1), Warnings and Precautions (5. 2). 7. 2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants The administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors, or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. In situations when concurrent therapy is necessary, careful monitoring of the patients hemodynamic status is essential see Warnings and Precautions (5. 6). 7. 3 Ergot-Type Oxytocic Drugs Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebr","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"infliximab-dyyb","ingredient2":"ofloxacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"salicylate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"cytokines","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"folic","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"abatacept","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"inflectra","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"metronidazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"natu","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"ciprofloxacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"pea","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"infliximab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"sali","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"theophylline","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"folic acid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"salicylates","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"tocilizumab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"antibiotics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"methotrexate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"infliximab-dyyb","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Other Biological Products increased risk of serious infections (7. 1) 7. 1 Other Biological Products The combination of INFLECTRA with other biological products used to treat the same conditions as INFLECTRA is not recommended see Warnings and Precautions (5. 10). An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended see Warnings and Precautions (5. 10). The concomitant use of tocilizumab with biological DMARDs such as TNF antagonists, including INFLECTRA, should be avoided because of the possibility of increased immunosuppression and increased risk of infection. ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride for oral solution","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"iron","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"spironolactone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"potassium-sparing","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"renin-angiotensin-converting","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"aliskiren","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"raas","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"gla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"eplerenone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride for oral solution","ingredient2":"potassium i","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS. Potassium sparing diuretics: Avoid concomitant use ( 7. 1)  Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2)  Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Converting Enzyme Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the renin-angiotensin system. Closely monitor potassium in patients on concomita","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nitisinone","ingredient2":"table","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Nitisinone is a moderate CYP2C9 inhibitor, a weak CYP2E1 inducer and an inhibitor of OAT1/OAT3. Table 2 includes drugs with clinically important drug interactions when administered concomitantly with nitisinone capsules and instructions for preventing or managing them. TABLE 2: Clinically Relevant Interactions Affecting Co-Administered Drugs Sensitive CYP2C9 Substrates (e. G. , celecoxib, tolbutamide) or CYP2C9 Substrates with a Narrow Therapeutic Index (e. G. Phenytoin, warfarin) Clinical Impact Increased exposure of the co-administered drugs metabolized by CYP2C9. See Clinical Pharmacology (12. 3) Intervention Reduce the dosage of the co-administered drugs metabolized by CYP2C9 drug by half. Additional dosage adjustment may be needed to maintain therapeutic drug concentrations for narrow therapeutic index drugs. See prescribing information for those drugs. OAT1/OAT3 Substrates (e. G. , adefovir, ganciclovir, methotrexate) Clinical Impact Increased exposure of the ","recommendation":"Monitor for potential adverse reactions related to the co-administered drug.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"migalastat hydrochloride","ingredient2":"caf","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"caffeine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"iga","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"galafold","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"ala","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"migalastat hydrochloride","ingredient2":"caffein","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See Full Prescribing Information for clinically significant drug interactions. (7. 1) 7. 1 Effect of Other Drugs on GALAFOLD Co-administration of GALAFOLD with caffeine decreases migalastat AUC and Cmax see Clinical Pharmacology (12. 3) which may reduce GALAFOLD efficacy. Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2. 2).","recommendation":"Avoid co-administration of GALAFOLD with caffeine at least 2 hours before and 2 hours after taking GALAFOLD see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"relugolix, estradiol hemihydrate, and norethindrone acetate","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid use of MYFEMBREE with oral P-gp inhibitors. (7. 1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7. 1) 7. 1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix see Clinical Pharmacology (12. 3) and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions see Dosage and Administration (2. 4). Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone see Clinical Pharmacology (12. 3) and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P","recommendation":"Avoid use of MYFEMBREE with oral P-gp inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"relugolix, estradiol hemihydrate, and norethindrone acetate","ingredient2":"myfembree","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid use of MYFEMBREE with oral P-gp inhibitors. (7. 1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7. 1) 7. 1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix see Clinical Pharmacology (12. 3) and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions see Dosage and Administration (2. 4). Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone see Clinical Pharmacology (12. 3) and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P","recommendation":"Avoid use of MYFEMBREE with oral P-gp inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"relugolix, estradiol hemihydrate, and norethindrone acetate","ingredient2":"epa","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid use of MYFEMBREE with oral P-gp inhibitors. (7. 1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7. 1) 7. 1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix see Clinical Pharmacology (12. 3) and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions see Dosage and Administration (2. 4). Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone see Clinical Pharmacology (12. 3) and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P","recommendation":"Avoid use of MYFEMBREE with oral P-gp inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"relugolix, estradiol hemihydrate, and norethindrone acetate","ingredient2":"estradiol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid use of MYFEMBREE with oral P-gp inhibitors. (7. 1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7. 1) 7. 1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix see Clinical Pharmacology (12. 3) and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions see Dosage and Administration (2. 4). Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone see Clinical Pharmacology (12. 3) and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P","recommendation":"Avoid use of MYFEMBREE with oral P-gp inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"relugolix, estradiol hemihydrate, and norethindrone acetate","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid use of MYFEMBREE with oral P-gp inhibitors. (7. 1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7. 1) 7. 1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix see Clinical Pharmacology (12. 3) and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions see Dosage and Administration (2. 4). Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone see Clinical Pharmacology (12. 3) and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P","recommendation":"Avoid use of MYFEMBREE with oral P-gp inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"relugolix, estradiol hemihydrate, and norethindrone acetate","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Avoid use of MYFEMBREE with oral P-gp inhibitors. (7. 1) Avoid use with combined P-gp and strong CYP3A inducers, as the exposure of the components of MYFEMBREE may be decreased. (7. 1) 7. 1 Effect of Other Drugs on MYFEMBREE P-gp Inhibitors Co-administration of MYFEMBREE with P-gp inhibitors increases the AUC and maximum concentration (Cmax) of relugolix see Clinical Pharmacology (12. 3) and may increase the risk of adverse reactions associated with MYFEMBREE. Avoid use of MYFEMBREE with oral P-gp inhibitors. If use is unavoidable, take MYFEMBREE first, separate dosing by at least 6 hours, and monitor patients for adverse reactions see Dosage and Administration (2. 4). Combined P-gp and Strong CYP3A Inducers Use of MYFEMBREE with combined P-gp and strong CYP3A inducers decreases the AUC and Cmax of relugolix, estradiol, and/or norethindrone see Clinical Pharmacology (12. 3) and may decrease the therapeutic effects of MYFEMBREE. Avoid use of MYFEMBREE with combined P","recommendation":"Avoid use of MYFEMBREE with oral P-gp inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"diskus","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"salmeterol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"itraconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"thy","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"copd","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"monoamine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"clarithromycin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"ritonavir","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"beta-blockers","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"serevent","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"salmeterol xinafoate","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of salmeterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibitors of Cytochrome P450 3A4 Salmeterol is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with SEREVENT DISKUS is not recommended because increased cardiovascular adverse effects may occur. In a drug interaction trial in 20 hea","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone propionate","ingredient2":"diskus","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects. (7. 1) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone propionate is a substrate of CYP3A4. The use of strong CYP3A4 inhibitors (e. G. , ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin) with Fluticasone Propionate DISKUS is not recommended because increased systemic corticosteroid adverse effects may occur. Ritonavir A drug interaction trial with fluticasone propionate aqueous nasal spray in healthy subjects has shown that ritonavir (a strong CYP3A4 inhibitor) can significantly increase plasma fluticasone propionate exposure, resulting in significantly reduced serum cortisol concentrations see Clinical Pharmacology (12. 3). During postmarketing use, there have been reports of clinically significant drug interactions in patients receiving f","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pegloticase","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pegloticase","ingredient2":"pea","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pegloticase","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pegloticase","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pegloticase","ingredient2":"krystexxa","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pegloticase","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pegloticase","ingredient2":"methotrexate","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Methotrexate KRYSTEXXA 8 mg every 2 weeks has been studied in patients with chronic gout refractory to conventional therapy taking concomitant oral methotrexate 15 mg weekly see Clinical Studies (14). Co-administration of methotrexate with KRYSTEXXA may increase pegloticase concentration compared to KRYSTEXXA alone see Clinical Pharmacology (12. 3). 7. 2 PEGylated products Because anti-pegloticase antibodies appear to bind to the PEG portion of the drug, there may be potential for binding with other PEGylated products. The impact of anti-PEG antibodies on patients responses to other PEG-containing therapeutics is unknown.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"eru","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"testosterone","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"glucose","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"anticoagulant","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"but","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"tar","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"esterified estrogens and methyltestosterone","ingredient2":"anticoagulants","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions (Androgens) Anticoagulants: C-17 substituted derivatives of testosterone, such as methandrostenolone, have been reported to decrease the anticoagulant requirements of patients receiving oral anticoagulants. Patients receiving oral anticoagulant therapy require close monitoring, especially when androgens are started or stopped. Oxyphenbutazone: Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone. Insulin: In diabetic patients, the metabolic effects of androgens may decrease blood glucose and insulin requirements.","recommendation":"Monitoring, especially when androgens are started or stopped.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"apremilast","ingredient2":"otezla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Strong CYP450 Inducers Co-administration with strong CYP450 inducers (such as rifampin) decreases apremilast exposure and may result in loss of efficacy of OTEZLA/OTEZLA XR see Warnings and Precautions (5. 5) and Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"apremilast","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Strong CYP450 Inducers Co-administration with strong CYP450 inducers (such as rifampin) decreases apremilast exposure and may result in loss of efficacy of OTEZLA/OTEZLA XR see Warnings and Precautions (5. 5) and Clinical Pharmacology (12. 3).","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"econazole nitrate","ingredient2":"anticoagulant","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS - 7. 1 Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.","recommendation":"Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"econazole nitrate","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS - 7. 1 Warfarin Concomitant administration of econazole and warfarin has resulted in enhancement of anticoagulant effect. Most cases reported product application with use under occlusion, genital application, or application to a large body surface area which may increase the systemic absorption of econazole nitrate. Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.","recommendation":"Monitoring of International Normalized Ratio (INR) and/or prothrombin time may be indicated especially for patients who apply econazole to large body surface areas, in the genital area, or under occlusion.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"lenacapavir sodium","ingredient2":"rosuvastatin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"atorvastatin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"yeztugo","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"prop","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"pitavastatin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"famotidine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ros","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"mental","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"voriconazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"tenofovir alafenamide","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ala","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information for important drug interactions with YEZTUGO. (7, 12. 3) 7. 1 Effect of Other Drugs on YEZTUGO Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir, which may reduce the effectiveness of YEZTUGO. Therefore, dosage modifications (supplemental doses) of YEZTUGO are recommended when initiating strong or moderate CYP3A inducers see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of YEZTUGO. Concomitant administration of YEZTUGO with these inhibitors is not recommended. 7. 2 Effect of YEZTUGO on Other Drugs CYP3A and P-gp Substrates Lenacapavir is a moderate inhibitor of CYP3A and a P-gp inhibitor. The co-administ","recommendation":"Recommendations or appropriate monitoring of safety.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"diuretics","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"nsaids","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"beta blockers","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"vera","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"gre","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"glyce","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"anticoagulants","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"guanfacine","ingredient2":"sodi","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions The potential for increased sedation when guanfacine is given with other CNS-depressant drugs should be appreciated. The administration of guanfacine concomitantly with a known microsomal enzyme inducer (phenobarbital or phenytoin) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration. In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response. Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above). Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1-2 mg/day, for 4 weeks. No changes were observed in the degree of anticoagulation. In several well-controlled studies, guanfacine was administered together with diuretics with no drug interactions reported. In the long-term safety s","recommendation":"Should be appreciated.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rituximab-arrx","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"fludarabine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"rituximab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"cisplatin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"cyclophosphamide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rituximab-arrx","ingredient2":"methotrexate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Formal drug interaction studies have not been performed with rituximab products. In patients with CLL, rituximab did not alter systemic exposure to fludarabine or cyclophosphamide. In clinical trials of patients with RA, concomitant administration of methotrexate or cyclophosphamide did not alter the pharmacokinetics of rituximab. Renal toxicity when used in combination with cisplatin (5. 8).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"lenacapavir sodium","ingredient2":"rosuvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"fentanyl","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"efavirenz","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"tramadol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"corticosteroids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"tadalafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"pitavastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"hydrocortisone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"cobicistat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"dexamethasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"lovastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"darunavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ritonavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ergotamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"anticoagulants","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"hypericum","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"edoxaban","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"oxycodone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"vardenafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"famotidine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"sildenafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"oxcarbazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"rivaroxaban","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"simvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"pine o","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"tar","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"midazolam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"nevirapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"phenobarbital","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"ergotamin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"doac","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"iga","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"voriconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"tenofovir alafenamide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lenacapavir sodium","ingredient2":"sunlenca","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 7, 12. 3) 7. 1 Effect of Other Drugs on SUNLENCA Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A. Strong or Moderate CYP3A Inducers Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir see Clinical Pharmacology (12. 3), which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated see Contraindications (4). Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended. Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommend","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"testosterone undecanoate","ingredient2":"jatenzo","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Androgens may decrease blood glucose and therefore may decrease insulin requirements in diabetic patients (7. 1). Changes in anticoagulant activity may be seen with androgens. More frequent monitoring of International Normalized Ratio (INR) and prothrombin time is recommended in patients taking warfarin (7. 2). Use of testosterone with corticosteroids may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease (7. 3). Concomitant administration of medications that are known to increase blood pressure may lead to additional increases in blood pressure when used with JATENZO (7. 4). 7. 1 Insulin Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, may necessitate a decrease in the dose of anti-diabetic medication. 7. 2 Oral Vitamin K Antagonist Anticoagulants Chan","recommendation":"Monitoring of International Normalized Ratio (INR) and prothrombin time is recommended in patients taking warfarin (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bendamustine hydrochloride","ingredient2":"chlorid","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with bendamustine hydrochloride injection. (7. 1) 7. 1 Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of bendamustine hydrochloride injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with bendamustine hydrochloride injection see Clinical Pharmacology (12. 3). Consider alternative therapies that are not CYP1A2 inhibitors during treatment with bendamustine hydrochloride injection. CYP1A2 Inducers The coadministration of bendamustine hydrochloride injection with CYP1A2 inducers may decrease bendamustine plasma concentrations and may result in decreased efficacy of bendamustine hydrochloride injection see Clinical Pharmacology (12. 3). Consider alternative therapies that are not CYP1A2 inducers during treatment with bendamustine hydrochlori","recommendation":"Mustine hydrochloride injection.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bendamustine hydrochloride","ingredient2":"chloride","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with bendamustine hydrochloride injection. (7. 1) 7. 1 Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of bendamustine hydrochloride injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with bendamustine hydrochloride injection see Clinical Pharmacology (12. 3). Consider alternative therapies that are not CYP1A2 inhibitors during treatment with bendamustine hydrochloride injection. CYP1A2 Inducers The coadministration of bendamustine hydrochloride injection with CYP1A2 inducers may decrease bendamustine plasma concentrations and may result in decreased efficacy of bendamustine hydrochloride injection see Clinical Pharmacology (12. 3). Consider alternative therapies that are not CYP1A2 inducers during treatment with bendamustine hydrochlori","recommendation":"Mustine hydrochloride injection.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bendamustine hydrochloride","ingredient2":"bendamustine","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with bendamustine hydrochloride injection. (7. 1) 7. 1 Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of bendamustine hydrochloride injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with bendamustine hydrochloride injection see Clinical Pharmacology (12. 3). Consider alternative therapies that are not CYP1A2 inhibitors during treatment with bendamustine hydrochloride injection. CYP1A2 Inducers The coadministration of bendamustine hydrochloride injection with CYP1A2 inducers may decrease bendamustine plasma concentrations and may result in decreased efficacy of bendamustine hydrochloride injection see Clinical Pharmacology (12. 3). Consider alternative therapies that are not CYP1A2 inducers during treatment with bendamustine hydrochlori","recommendation":"Mustine hydrochloride injection.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"azelastine hydrochloride","ingredient2":"alcohol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5. 1).","recommendation":"Should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"azelastine hydrochloride","ingredient2":"chlorid","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5. 1).","recommendation":"Should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"azelastine hydrochloride","ingredient2":"elastin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5. 1).","recommendation":"Should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"azelastine hydrochloride","ingredient2":"chloride","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5. 1).","recommendation":"Should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"azelastine hydrochloride","ingredient2":"azelastine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5. 1).","recommendation":"Should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"azelastine hydrochloride","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Central Nervous System Depressants Concurrent use of azelastine hydrochloride nasal spray with alcohol or other central nervous system depressants should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5. 1).","recommendation":"Should be avoided because reductions in alertness and impairment of central nervous system performance may occur see Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moexipril hydrochloride","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"iron","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"hydrochlorothiazide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"triamterene","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"spironolactone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"potassium-sparing","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"anticoagulant","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"calcium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"ace inhibitor","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"electrolytes","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"glyce","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"cimetidine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"anticoagulants","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"amiloride","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"non-steroidal","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"ace inhibitors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"aliskiren","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"moexipril","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"warnings","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"renin-angiotensin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moexipril hydrochloride","ingredient2":"diuretic","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Diuretics Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. The possibility of hypotensive effects with moexipril hydrochloride can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with moexipril hydrochloride. If this is not possible, the starting dose of moexipril should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ). Potassium Supplements and Potassium-Sparing Diuretics Moexipril hydrochloride can increase serum potassium because it decreases aldosterone secretion. Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. Therefore, if concomitant use of such agents is indicated, they should be given with caution and the patients serum potassium should be monitored. Oral Anticoagulants Interaction","recommendation":"Should be reduced (see WARNINGS and DOSAGE AND ADMINISTRATION ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"leuprolide acetate","ingredient2":"lupron","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies have been conducted with LUPRON DEPOT 11. 25 mg.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"teduglutide","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Potential for Increased Absorption of Oral Medications Based upon the pharmacodynamic effect of GATTEX, there is a potential for increased absorption of concomitant oral medications. Altered mental status has been observed in patients taking GATTEX and benzodiazepines in the adult clinical studies see Warnings and Precautions (5. 5). Monitor patients on concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions related to the concomitant drug while on GATTEX. The concomitant drug may require a reduction in dosage.","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"teduglutide","ingredient2":"mental","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Potential for Increased Absorption of Oral Medications Based upon the pharmacodynamic effect of GATTEX, there is a potential for increased absorption of concomitant oral medications. Altered mental status has been observed in patients taking GATTEX and benzodiazepines in the adult clinical studies see Warnings and Precautions (5. 5). Monitor patients on concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions related to the concomitant drug while on GATTEX. The concomitant drug may require a reduction in dosage.","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"teduglutide","ingredient2":"gattex","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Potential for Increased Absorption of Oral Medications Based upon the pharmacodynamic effect of GATTEX, there is a potential for increased absorption of concomitant oral medications. Altered mental status has been observed in patients taking GATTEX and benzodiazepines in the adult clinical studies see Warnings and Precautions (5. 5). Monitor patients on concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions related to the concomitant drug while on GATTEX. The concomitant drug may require a reduction in dosage.","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"teduglutide","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Potential for Increased Absorption of Oral Medications Based upon the pharmacodynamic effect of GATTEX, there is a potential for increased absorption of concomitant oral medications. Altered mental status has been observed in patients taking GATTEX and benzodiazepines in the adult clinical studies see Warnings and Precautions (5. 5). Monitor patients on concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions related to the concomitant drug while on GATTEX. The concomitant drug may require a reduction in dosage.","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"teduglutide","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Potential for Increased Absorption of Oral Medications Based upon the pharmacodynamic effect of GATTEX, there is a potential for increased absorption of concomitant oral medications. Altered mental status has been observed in patients taking GATTEX and benzodiazepines in the adult clinical studies see Warnings and Precautions (5. 5). Monitor patients on concomitant oral drugs requiring titration or with a narrow therapeutic index for adverse reactions related to the concomitant drug while on GATTEX. The concomitant drug may require a reduction in dosage.","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"clorazepate dipotassium","ingredient2":"precautions","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"diazepam","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"thy","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"alcohol","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"gabaa","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"others","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"gaba","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"mental","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"warnings","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"chlordiazepoxide","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"milk","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"chlorpromazine","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clorazepate dipotassium","ingredient2":"ethyl alcohol","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation. If clorazepate dipotassium tablets is to be combined with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of the agents to be employed. Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase in","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tamoxifen citrate","ingredient2":"citrate","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions: When tamoxifen is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such coadministration exists, careful monitoring of the patients prothrombin time is recommended. In the NSABP P-1 trial, women who required coumarin-type anticoagulants for any reason were ineligible for participation in the trial (see CONTRAINDICATIONS ). There is an increased risk of thromboembolic events occurring when cytotoxic agents are used in combination with tamoxifen. Tamoxifen reduced letrozole plasma concentrations by 37%. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known. Tamoxifen and N-desmethyl tamoxifen plasma concentrations have been shown to be reduced when coadministered with rifampin or aminoglutethimide. Induction of CYP3A4-mediated metabolism is considered to be the mecha","recommendation":"Monitoring of the patients prothrombin time is recommended.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"abatacept","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"immune-modulating","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"sulfasalazine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"cyclophosphamide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etanercept","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Live vaccines  Avoid concurrent administration with Enbrel (5. 8, 7. 1) Anakinra  Increased risk of serious infection (5. 12, 7. 2) Abatacept  Increased risk of serious adverse events, including infections (5. 12, 7. 2) Cyclophosphamide  Not recommended for use with Enbrel. (7. 3) 7. 1 Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy a","recommendation":"Avoid concurrent administration with Enbrel (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deferoxamine mesylate","ingredient2":"deferoxamine","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Concurrent treatment with prochlorperazine may lead to temporary impairment of consciousness. (7. 1) Imaging results may be distorted due to rapid urinary excretion of deferoxamine mesylate bound gallium-67. Discontinue deferoxamine mesylate 48 hours prior to scintigraphy. (7. 2) 7. 1 Prochlorperazine Concurrent treatment with deferoxamine mesylate and prochlorperazine, a phenothiazine derivative, may lead to temporary impairment of consciousness. 7. 2 Gallium-67 Imaging results may be distorted because of the rapid urinary excretion of deferoxamine mesylate-bound gallium-67. Discontinue deferoxamine mesylate 48 hours prior to scintigraphy.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"meloxicam","ingredient2":"diuretics","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"furosemide","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"nsaids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"aspirin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"ace inhibitors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"warfarin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"rose","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"meloxicam","ingredient2":"diuretic","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. , warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis. Concomitant use of meloxicam and analgesic doses of aspirin is not generally recommended ( 7) ACE Inhibitors, Angiotensin Receptor Blockers (ARBs) or Beta-Blockers: Concomitant use with meloxicam may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with meloxicam in elderly, volume-depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) 1","recommendation":"Monitor patients for bleeding who are concomitantly taking meloxicam with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"imbruvica","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"grape","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"rutin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"grapefruit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"posaconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"voriconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ibrutinib","ingredient2":"orange","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Modify IMBRUVICA dose as described (2. 3, 7. 1). CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (7. 2). 7. 1 Effect of CYP3A Inhibitors on Ibrutinib The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations see Clinical Pharmacology ( 12. 3 ). Increased ibrutinib concentrations may increase the risk of drug-related toxicity. Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors see Dosage and Administration ( 2. 3 ). Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) see Dosage and Administration ( 2. 3 ). Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A. 7. 2 Effect of CYP3A Inducers on Ibrutinib The c","recommendation":"Avoid coadministration with strong CYP3A inducers (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amiodarone hydrochloride","ingredient2":"close","severity":"contraindicated","severity_confidence":1.0,"effect":"7 Drug Interactions 7. 1 Pharmacodynamic InteractionsDrugs Prolonging the QT IntervalCo-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes. In general, avoid concomitant use of drugs that prolong the QT interval see WARNINGS AND PRECAUTIONS (5. 4). Drugs That Slow Heart RateConcomitant use of drugs with depressant effects on the sinus and AV nodes (e. G. , digoxin, beta blockers, verapamil, diltiazem, ivabradine, clonidine) can potentiate the electrophysiologic and hemodynamic effects of amiodarone, resulting in bradycardia, sinus arrest, and AV block. Monitor heart rate in patients on amiodarone and concomitant drugs that slow heart rate. 7. 2 Pharmacokinetic InteractionsEffect of Other Drugs on AmiodaroneAmiodarone is metabolized to ","recommendation":"Avoid concomitant use of drugs that prolong the QT interval see WARNINGS AND PRECAUTIONS (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"xcopri","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"phenobarbital","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"thy","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"prop","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"lamotrigine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"carbamazepine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"alcohol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"methy","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cenobamate","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Gradually decrease phenytoin dosage by up to 50%. (7. 1) Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Lamotrigine, Carbamazepine: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2B6 and CYP3A Substrates: Increase dosage as needed when used concomitantly with XCOPRI. (7. 1) CYP2C19 Substrates: Reduce dosage as needed when used concomitantly with XCOPRI. (7. 1) Oral Contraceptives: Effectiveness of hormonal oral contraceptives may be reduced when administered concomitantly with XCOPRI. Women should use additional or alternative non-hormonal birth control. (7. 1) 7. 1 Effect of XCOPRI on Other Drugs Table 5 summarizes the effect of XCOPRI on other drugs see Clinical Pharmacology (12. 3). Table 5: Pharmacokinetic Drug Interactions Drug or Substrate Type Effect of XCOPRI on Drug or Substrate Clinical Recommendation Antiepileptic Drugs lamotrigine  plasma concentrations Because of a pot","recommendation":"Should use additional or alternative non-hormonal birth control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"koselugo","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"fluconazole","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"prop","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"vitami","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"vitamin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"mental","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"vita","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"vitamin e","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selumetinib","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong or Moderate CYP3A4 Inhibitors or Fluconazole: Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration cannot be avoided, reduce the dose of KOSELUGO. (2. 5, 7. 1)  Strong or Moderate CYP3A4 Inducers: Avoid concomitant use of strong and moderate CYP3A4 inducers. (7. 1) 7. 1 Effect of Other Drugs on KOSELUGO Strong or Moderate CYP3A4 Inhibitors or Fluconazole Clinical Impact Concomitant use of KOSELUGO with a strong or moderate CYP3A4 inhibitor or fluconazole increased selumetinib plasma concentrations see Clinical Pharmacology (12. 3), which may increase the risk of adverse reactions. Management Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO. If coadministration with strong or moderate CYP3A4 inhibitors or fluconazole cannot be avoided, reduce KOSELUGO dosage see Dosage and Administration (2. 4). Strong or Moderate CYP3A4 Inducers Clinical Impact Concomitant ","recommendation":"Avoid coadministration of strong or moderate CYP3A4 inhibitors or fluconazole with KOSELUGO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"benznidazole","ingredient2":"aldh","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"propylene glyc","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"prop","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"alcohol","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"propylene glyco","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"propylene gly","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"ethanol","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"glycol","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"propylene glycol","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"but","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"vit","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benznidazole","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Disulfiram Psychotic reactions have been reported in patients who are concurrently taking disulfiram and nitroimidazole agents (structurally related to benznidazole, but not with benznidazole). Benznidazole Tablets should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4. 2). 7. 2 Alcohol and Products Containing Propylene Glycol In vitro studies showed that benznidazole, at concentrations from 0. 03 Î¼M to 100 Î¼M, does not inhibit the enzymatic activity of human alcohol dehydrogenase (ALDH). Benznidazole Tablets are not expected to cause alcohol aversion or a disulfiram-like reaction as a result of ethanol ingestion.","recommendation":"Should not be given to patients who have taken disulfiram within the last two weeks see Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin","ingredient2":"vit","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dabigatran etexilate","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS P-gp inducers: Avoid coadministration with dabigatran etexilate capsules (5. 5) P-gp inhibitors in adult patients with CrCl 30-50 mL/min: Reduce dosage or avoid (7) P-gp inhibitors in adult patients with CrCl  30 mL/min: Not recommended (7) 7. 1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of dabigatran etexilate capsules with P-gp inducers (e. G. , rifampin) reduces exposure to dabigatran and should generally be avoided see Clinical Pharmacology (12. 3). P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran see Clinical Pharmacology (12. 3). Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dosage of dabigatran etexilate c","recommendation":"Avoid coadministration with dabigatran etexilate capsules (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dabigatran etexilate","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS P-gp inducers: Avoid coadministration with dabigatran etexilate capsules (5. 5) P-gp inhibitors in adult patients with CrCl 30-50 mL/min: Reduce dosage or avoid (7) P-gp inhibitors in adult patients with CrCl  30 mL/min: Not recommended (7) 7. 1 Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients The concomitant use of dabigatran etexilate capsules with P-gp inducers (e. G. , rifampin) reduces exposure to dabigatran and should generally be avoided see Clinical Pharmacology (12. 3). P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran see Clinical Pharmacology (12. 3). Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone. In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dosage of dabigatran etexilate c","recommendation":"Avoid coadministration with dabigatran etexilate capsules (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"maoi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"short-acting","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"itraconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"airsupra","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"desonide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"monoamine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"beta blockers","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"budesonide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"clarithromycin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"ritonavir","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"beta-blockers","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"corticosteroid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"albuterol sulfate and budesonide","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been performed with AIRSUPRA. Strong cytochrome P450 3A4 inhibitors (e. G. Ritonavir): Use with caution. May cause systemic corticosteroid effects. (7. 1) Other short-acting bronchodilators: Use judiciously with other short-acting beta agonists. (7. 2) Beta blockers: May decrease effectiveness of AIRSUPRA and produce severe bronchospasm. When there are no acceptable alternatives to the use of beta-adrenergic-blocking agents, consider cardioselective beta-blockers and use with caution. (7. 3) Diuretics, or non-potassium-sparing diuretics: May potentiate hypokalemia or ECG changes. Consider monitoring potassium levels with concomitant use. (7. 4) Digoxin: May decrease serum digoxin levels. Carefully evaluate digoxin levels with concomitant use. (7. 5) Monoamine oxidase inhibitors (MAOI) and tricyclic antidepressants: Use AIRSUPRA with extreme caution with concomitant use. (7. 6) 7. 1 Inhibitors of Cytochrome P450 3A4 The main ro","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gabapentin","ingredient2":"aluminium hydroxide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Concentrations increased by morphine; may need dose adjustment ( 5. 4, 7. 1) 7. 1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e. G. , morphine, hydrocodone, oxycodone, buprenorphine) see Warnings and Precautions ( 5. 8). Hydrocodone Coadministration of gabapentin with hydrocodone decreases hydrocodone exposure see Clinical Pharmacology ( 12. 3). The potential for alteration in hydrocodone exposure and effect should be considered when gabapentin is started or discontinued in a patient taking hydrocodone. Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression see Clinical Pharmacology ( 12. 3). 7. 2 Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sofpironium bromide","ingredient2":"sofdra","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7. 1). Strong Inhibitors of CYP2D6: Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6 ( 7. 2). 7. 1 Anticholinergics Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects See Warnings and Precautions (5. 2) and Adverse Reactions (6. 1). Avoid coadministration of SOFDRA with other anticholinergic-containing drugs. 7. 2 Strong Inhibitors of CYP2D6 Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6.","recommendation":"Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sofpironium bromide","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7. 1). Strong Inhibitors of CYP2D6: Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6 ( 7. 2). 7. 1 Anticholinergics Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects See Warnings and Precautions (5. 2) and Adverse Reactions (6. 1). Avoid coadministration of SOFDRA with other anticholinergic-containing drugs. 7. 2 Strong Inhibitors of CYP2D6 Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6.","recommendation":"Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sofpironium bromide","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7. 1). Strong Inhibitors of CYP2D6: Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6 ( 7. 2). 7. 1 Anticholinergics Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects See Warnings and Precautions (5. 2) and Adverse Reactions (6. 1). Avoid coadministration of SOFDRA with other anticholinergic-containing drugs. 7. 2 Strong Inhibitors of CYP2D6 Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6.","recommendation":"Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sofpironium bromide","ingredient2":"choline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects. Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7. 1). Strong Inhibitors of CYP2D6: Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6 ( 7. 2). 7. 1 Anticholinergics Coadministration of SOFDRA with anticholinergic medications may result in additive interaction leading to an increase in anticholinergic adverse effects See Warnings and Precautions (5. 2) and Adverse Reactions (6. 1). Avoid coadministration of SOFDRA with other anticholinergic-containing drugs. 7. 2 Strong Inhibitors of CYP2D6 Avoid co-administration of SOFDRA with drugs that are strong inhibitors of CYP2D6.","recommendation":"Avoid coadministration of SOFDRA with other anticholinergic-containing drugs ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"indomethacin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"beta-blocker","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"pea","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"calcium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"epinephrine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"chlorthalidone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"atenolol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"gla","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"warnings","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"amiodarone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"beta-blockers","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"reserpine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"olamine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atenolol and chlorthalidone tablet","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Atenolol and chlorthalidone may potentiate the action of other antihypertensive agents used concomitantly. Patients treated with atenolol and chlorthalidone plus a catecholamine depletor (e. G. , reserpine) should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol and chlorthalidone. (See WARNINGS. ) Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Thiazides may decrease arterial responsiveness to norepinephrine. This diminution is not sufficient to preclude the therapeutic effectiveness of norepinephrin","recommendation":"Should be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope or postural hypotension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"baclofen injection","ingredient2":"baclofen","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS There is inadequate systematic experience with the use of intrathecal baclofen in combination with other medications to predict specific drug-drug interactions. Interactions attributed to the combined use of GABLOFEN and epidural morphine include hypotension and dyspnea. Combined use with morphine: hypotension and dyspnea ( 7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"baclofen injection","ingredient2":"morphine","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS There is inadequate systematic experience with the use of intrathecal baclofen in combination with other medications to predict specific drug-drug interactions. Interactions attributed to the combined use of GABLOFEN and epidural morphine include hypotension and dyspnea. Combined use with morphine: hypotension and dyspnea ( 7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"baclofen injection","ingredient2":"but","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS There is inadequate systematic experience with the use of intrathecal baclofen in combination with other medications to predict specific drug-drug interactions. Interactions attributed to the combined use of GABLOFEN and epidural morphine include hypotension and dyspnea. Combined use with morphine: hypotension and dyspnea ( 7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"baclofen injection","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS There is inadequate systematic experience with the use of intrathecal baclofen in combination with other medications to predict specific drug-drug interactions. Interactions attributed to the combined use of GABLOFEN and epidural morphine include hypotension and dyspnea. Combined use with morphine: hypotension and dyspnea ( 7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"baclofen injection","ingredient2":"gablofen","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS There is inadequate systematic experience with the use of intrathecal baclofen in combination with other medications to predict specific drug-drug interactions. Interactions attributed to the combined use of GABLOFEN and epidural morphine include hypotension and dyspnea. Combined use with morphine: hypotension and dyspnea ( 7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clonidine hydrochloride","ingredient2":"chlorid","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS The following have been reported with other oral immediate release formulations of clonidine: Table 6 Clinically Important Drug Interactions Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Tricyclic antidepressants Increase blood pressure and may counteract clonidines hypotensive effects Monitor blood pressure and adjust as needed Antihypertensive drugs Potentiate clonidines hypotensive effects Monitor blood pressure and adjust as needed CNS depressants Potentiate sedating effects Avoid use Drugs that affect sinus node function or AV node conduction (e. G. , digitalis, calcium channel blockers, beta blockers) Potentiate bradycardia and risk of AV block Avoid use Sedating Drugs: Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. (7) Tricyclic Antidepressants: May reduce the hypotensive effect of clonidine. (7) Drugs Known to Affect Sinus Node Function or AV Nodal Conduction: Caution is ","recommendation":"Recommendation Tricyclic antidepressants Increase blood pressure and may counteract clonidines hypotensive effects Monitor blood pressure and adjust as needed Antihypertensive drugs Potentiate clonidines hypotensive effects Monitor blood pressure and adjust as needed CNS depressants Potentiate sedating effects Avoid use Drugs that affect sinus node function or AV node conduction (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clonidine hydrochloride","ingredient2":"chloride","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS The following have been reported with other oral immediate release formulations of clonidine: Table 6 Clinically Important Drug Interactions Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Tricyclic antidepressants Increase blood pressure and may counteract clonidines hypotensive effects Monitor blood pressure and adjust as needed Antihypertensive drugs Potentiate clonidines hypotensive effects Monitor blood pressure and adjust as needed CNS depressants Potentiate sedating effects Avoid use Drugs that affect sinus node function or AV node conduction (e. G. , digitalis, calcium channel blockers, beta blockers) Potentiate bradycardia and risk of AV block Avoid use Sedating Drugs: Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. (7) Tricyclic Antidepressants: May reduce the hypotensive effect of clonidine. (7) Drugs Known to Affect Sinus Node Function or AV Nodal Conduction: Caution is ","recommendation":"Recommendation Tricyclic antidepressants Increase blood pressure and may counteract clonidines hypotensive effects Monitor blood pressure and adjust as needed Antihypertensive drugs Potentiate clonidines hypotensive effects Monitor blood pressure and adjust as needed CNS depressants Potentiate sedating effects Avoid use Drugs that affect sinus node function or AV node conduction (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"clonidine hydrochloride","ingredient2":"cla","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS The following have been reported with other oral immediate release formulations of clonidine: Table 6 Clinically Important Drug Interactions Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Tricyclic antidepressants Increase blood pressure and may counteract clonidines hypotensive effects Monitor blood pressure and adjust as needed Antihypertensive drugs Potentiate clonidines hypotensive effects Monitor blood pressure and adjust as needed CNS depressants Potentiate sedating effects Avoid use Drugs that affect sinus node function or AV node conduction (e. G. , digitalis, calcium channel blockers, beta blockers) Potentiate bradycardia and risk of AV block Avoid use Sedating Drugs: Clonidine may potentiate the CNS-depressive effects of alcohol, barbiturates or other sedating drugs. (7) Tricyclic Antidepressants: May reduce the hypotensive effect of clonidine. (7) Drugs Known to Affect Sinus Node Function or AV Nodal Conduction: Caution is ","recommendation":"Recommendation Tricyclic antidepressants Increase blood pressure and may counteract clonidines hypotensive effects Monitor blood pressure and adjust as needed Antihypertensive drugs Potentiate clonidines hypotensive effects Monitor blood pressure and adjust as needed CNS depressants Potentiate sedating effects Avoid use Drugs that affect sinus node function or AV node conduction (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"pheniramine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"ephedrine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"chlorid","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"contraindications","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"chloride","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"brompheniramine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"pheniramine maleate","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"pseudoephedrine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"mao inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"choline","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"dextromethorphan hydrobromide","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride and dextromethorphan hydrobromide","ingredient2":"dextromethorphan","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Monoamine oxidase (MAO) inhibitors Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAO inhibitors and products containing dextromethorphan. In addition, MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide Oral Syrup and MAO inhibitors should be avoided (see CONTRAINDICATIONS). Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"diazepam","ingredient2":"valtoco","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP2C19 and CYP3A4 Inhibitors: Elimination of diazepam could be decreased with concurrent administration; therefore, adverse reactions with VALTOCO may be increased. (7. 3) Inducers of CYP2C19 and CYP3A4 Inducers: Exposure of diazepam with concurrent administration may be decreased; therefore, efficacy with VALTOCO may be decreased. (7. 3) 7. 1 Effect of Concomitant Use of Benzodiazepines and Opioids The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABA-A sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists see Warnings and Precautions (5. 1). Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respirator","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"zidovudine","ingredient2":"retrovir","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Avoid use with stavudine. (7. 1) Avoid use with doxorubicin. (7. 2) Bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (7. 3) 7. 1 Antiretroviral Agents Stavudine Concomitant use of zidovudine with stavudine should be avoided since an antagonistic relationship has been demonstrated in vitro. Nucleoside Analogues Affecting DNA Replication Some nucleoside analogues affecting DNA replication, such as ribavirin, antagonize the in vitro antiviral activity of RETROVIR against HIV-1; concomitant use of such drugs should be avoided. 7. 2 Doxorubicin Concomitant use of zidovudine with doxorubicin should be avoided since an antagonistic relationship has been demonstrated in vitro. 7. 3 Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration of ganciclovir, interferon alfa, ribavirin, and other bone marrow suppressive or cytotoxic agents may increase the hematologic toxicity of zidovudine.","recommendation":"Avoid use with stavudine.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"morphine sulfate","ingredient2":"mitigo","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with MITIGO. Table 1. Clinically Significant Drug Interactions with MITIGO  Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. The depressant effects of morphine are potentiated by the presence of other CNS depressants. Use of neuroleptics in conjunction with neuraxial morphine may increase the risk of respiratory depression see Warnings and Precautions (5. 4). Intervention: Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor patients closely for signs of respiratory depression and sedation see Warnings and Precautions (5. 4). Examp","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"amino acids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"clonazepam","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"epa","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"gaba","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"iga","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"vigafyde","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"amino acid","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"ala","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vigabatrin","ingredient2":"drug-laboratory","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Decreased phenytoin plasma levels: Dosage adjustment may be needed. (7. 1) 7. 1 Antiepileptic Drugs Phenytoin Although phenytoin dose adjustments are not routinely required, dose adjustment of phenytoin should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12. 3 ). Clonazepam VIGAFYDE may moderately increase the Cmax of clonazepam resulting in an increase of clonazepam-associated adverse reactions see Clinical Pharmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions VIGAFYDE decreases alanine transaminase (ALT) and aspartate transaminase (AST) plasma activity in up to 90% of patients. In some patients, these enzymes become undetectable. The suppression of ALT and AST activity by vigabatrin may preclude the use of these markers, especially ALT, to detect early hepatic injury. VIGAFYDE may increase the amount of amino acids in the urine, possibly leading to a false","recommendation":"Should be considered if clinically indicated, since VIGAFYDE may cause a moderate reduction in total phenytoin plasma levels see Clinical Pharmacology ( 12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"buprenorphine hydrochloride and naloxone hydrochloride dihydrate","ingredient2":"gabapentin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine and Naloxone Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine and Naloxone Sublingual Tablets Benzodiazepines or Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consid","recommendation":"Monitoring in a higher level of care for taper may be appropriate.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"buprenorphine hydrochloride and naloxone hydrochloride dihydrate","ingredient2":"gaba","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine and Naloxone Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine and Naloxone Sublingual Tablets Benzodiazepines or Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consid","recommendation":"Monitoring in a higher level of care for taper may be appropriate.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"zonisamide","ingredient2":"zonisade","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS ZONISADE should be used with caution if used in combination with alcohol or other CNS depressants (7. 1). Concomitant use of ZONISADE with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation (7. 2). 7. 1 CNS Depressants Concomitant use of ZONISADE with other CNS depressants, including alcohol, may increase the risk of CNS depression, as well as other cognitive and/or neuropsychiatric adverse events see Warnings and Precautions (5. 11). 7. 2 Other Carbonic Anhydrase Inhibitors Concomitant use of ZONISADE, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor, may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation see Warnings and Precautions (5. 8, 5. 15). Therefore, if ZONISADE is given concomitantly with another carbonic anhydrase inhibitor, monitor the patient for the appearance or worsening of metaboli","recommendation":"Should be used with caution if used in combination with alcohol or other CNS depressants (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"zonisamide","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS ZONISADE should be used with caution if used in combination with alcohol or other CNS depressants (7. 1). Concomitant use of ZONISADE with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation (7. 2). 7. 1 CNS Depressants Concomitant use of ZONISADE with other CNS depressants, including alcohol, may increase the risk of CNS depression, as well as other cognitive and/or neuropsychiatric adverse events see Warnings and Precautions (5. 11). 7. 2 Other Carbonic Anhydrase Inhibitors Concomitant use of ZONISADE, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor, may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation see Warnings and Precautions (5. 8, 5. 15). Therefore, if ZONISADE is given concomitantly with another carbonic anhydrase inhibitor, monitor the patient for the appearance or worsening of metaboli","recommendation":"Should be used with caution if used in combination with alcohol or other CNS depressants (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"mycophenolate mofetil","ingredient2":"myhibbin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce MYHIBBIN efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. ( 7. 1) MYHIBBIN may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. ( 7. 2) See FPI for other important drug interactions. ( 7) 7. 1 Effect of Other Drugs on MYHIBBIN Table 3 Drug Interactions with MYHIBBIN that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure see Clinical Pharmacology (12. 3), which may reduce MYHIBBIN efficacy. Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after MYHIBBIN. Proton Pump Inhibitors (PPIs) Clinical Impact Con","recommendation":"Monitor patients for alterations in efficacy when PPIs are co- administered with MYHIBBIN.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"triptorelin","ingredient2":"triptodur","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"pea","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"drug-drug","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"tar","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin","ingredient2":"drug-laboratory","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Drug-Drug Interactions Results of in vitro studies show that drug-drug interactions with triptorelin are unlikely see Clinical Pharmacology (12. 3). However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors. 7. 2 Drug-Laboratory Test Interactions Administration of TRIPTODUR results in suppression of the pituitary-gonadal system. The effect of TRIPTODUR on pituitary and gonadal function is expected to disappear within six to twelve months after treatment discontinuation. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment or after discontinuation of treatment may be affected.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with triptorelin since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"linezolid","ingredient2":"counseling","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Monoamine oxidase inhibitors and potential for interaction with adrenergic and serotonergic agents. ( 4. 2, 5. 3, 5. 6, 7, 12. 3) See 17 for PATIENT COUNSELING INFORMATION Revised: 10/2024 7. 1 Monoamine Oxidase Inhibitors Linezolid is a reversible, nonselective inhibitor of monoamine oxidase. See Contraindications ( 4. 2) and Clinical Pharmacology ( 12. 3). 7. 2 Adrenergic and Serotonergic Agents Linezolid has the potential for interaction with adrenergic and serotonergic agents. See Warnings and Precautions ( 5. 3, 5. 6) and Clinical Pharmacology ( 12. 3).","recommendation":"Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"halothane","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"lithium carbonate","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"magnesi","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"prop","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"carbamazepine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"lysi","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"propofol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"anis","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"sodium","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"magnesium salts","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"vancomycin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"bacitracin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"pine o","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"antibiotics","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"isoflurane","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"vera","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"gre","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"but","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"quinidine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"rocuronium bromide","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"tetracycline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"polymyxin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"magnesium","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"choline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"ala","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"sodi","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rocuronium","ingredient2":"succinylcholine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Antibiotics Drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as rocuronium bromide include certain antibiotics (e. G. , aminoglycosides; vancomycin; tetracyclines; bacitracin; polymyxins; colistin; and sodium colistimethate). If these antibiotics are used in conjunction with rocuronium bromide, prolongation of neuromuscular block may occur. 7. 2 Anticonvulsants In 2 of 4 patients receiving chronic anticonvulsant therapy, apparent resistance to the effects of rocuronium bromide was observed in the form of diminished magnitude of neuromuscular block, or shortened clinical duration. As with other nondepolarizing neuromuscular blocking drugs, if rocuronium bromide is administered to patients chronically receiving anticonvulsant agents such as carbamazepine or phenytoin, shorter durations of neuromuscular block may occur and infusion rates may be higher due to the development of resistance to nondepolarizing muscle relaxants. ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"venlafaxine","ingredient2":"diazepam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"tramadol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"vera","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"cimetidine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"proteins","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"fluoxetine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"metoprolol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"dextromethorphan","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"caf","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"nsaid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"protein","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"nsaids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"haloperidol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"linezolid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"caffein","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"risperidone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"iron","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"anis","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"aspirin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"pea","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"anticoagulant","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"clozapin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"buspirone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"tar","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"warfarin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"imipramine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"clozapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"alprazolam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"caffeine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"ethanol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"50 mg","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine","ingredient2":"drug-laboratory","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated ( 4). Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5. 2). Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in Haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"histrelin acetate","ingredient2":"dhea","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"supprelin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"eru","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"ros","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"tar","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"histrelin acetate","ingredient2":"drug-laboratory","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Overview: No formal drug-drug, drug-food, or drug-herb interaction studies were performed with SUPPRELIN LA. Drug-Laboratory Interactions: Therapy with SUPPRELIN LA results in suppression of the pituitary-gonadal system. Results of diagnostic tests of pituitary gonadotropic and gonadal functions conducted during and after SUPPRELIN LA therapy may be affected. SUPPRELIN LA decreased mean serum insulin like growth factor 1 (IGF 1) levels by approximately 11% in one study (Study 1). SUPPRELIN LA increased the serum concentration of dehydroepiandrosterone (DHEA) in 8 of 36 patients in another study (Study 2).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"bupivacaine hydrochloride","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INERACTIONS 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with Bupivacaine Hydrochloride in Dextrose Injection, USP cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2. 1), Warnings and Precautions (5. 3). 7. 2 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride in Dextrose Injection, USP are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics  see Warnings and Precautions (5. 5). Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents ","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride","ingredient2":"dextrose","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INERACTIONS 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with Bupivacaine Hydrochloride in Dextrose Injection, USP cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2. 1), Warnings and Precautions (5. 3). 7. 2 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride in Dextrose Injection, USP are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics  see Warnings and Precautions (5. 5). Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents ","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride","ingredient2":"ineractions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INERACTIONS 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with Bupivacaine Hydrochloride in Dextrose Injection, USP cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2. 1), Warnings and Precautions (5. 3). 7. 2 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride in Dextrose Injection, USP are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics  see Warnings and Precautions (5. 5). Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents ","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupivacaine hydrochloride","ingredient2":"rose","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INERACTIONS 7. 1 Local Anesthetics The toxic effects of local anesthetics are additive. If coadministration of other local anesthetics with Bupivacaine Hydrochloride in Dextrose Injection, USP cannot be avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2. 1), Warnings and Precautions (5. 3). 7. 2 Drugs Associated with Methemoglobinemia Patients who are administered Bupivacaine Hydrochloride in Dextrose Injection, USP are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics  see Warnings and Precautions (5. 5). Examples of Drugs Associated with Methemoglobinemia: Class Examples Nitrates/Nitrites nitric oxide, nitroglycerin, nitroprusside, nitrous oxide Local anesthetics articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine Antineoplastic agents ","recommendation":"Avoided, monitor patients for neurologic and cardiovascular effects related to local anesthetic systemic toxicity  see Dosage and Administration (2.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methylphenidate hydrochloride","ingredient2":"relexxii","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Antihypertensive Drugs: Monitor blood pressure. Adjust dosage of antihypertensive drug as needed (7. 1) 7. 1 Clinically Important Drug Interactions Table 6 presents clinically important drug interactions with RELEXXII. Table 6: Drugs Having Clinically Important Interactions with RELEXXII Monoamine Oxidase Inhibitors (MAOI) Clinical Impact: Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure see Contraindications ( 4). Intervention: Do not administer RELEXXII concomitantly with MAOIs or within 14 days after discontinuing MAOI treatment. Antihypertensive Drugs Clinical Impact: RELEXXII may decrease the effectiveness of drugs used to treat hypertension see Warnings and Precautions (5. 3). Intervention: Monitor blood pressure and adjust the dosage of the antihypertensive drug as needed. H","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nirsevimab","ingredient2":"protein","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Interference with RT-PCR or Rapid Antigen Detection RSV Diagnostic Assays Nirsevimab-alip does not interfere with reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen detection RSV diagnostic assays that employ commercially available antibodies targeting antigenic site I, II, or IV on the RSV fusion (F) protein. For immunological assay results which are negative when clinical observations are consistent with RSV infection, it is recommended to confirm using an RT-PCR-based assay.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nirsevimab","ingredient2":"tar","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Interference with RT-PCR or Rapid Antigen Detection RSV Diagnostic Assays Nirsevimab-alip does not interfere with reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen detection RSV diagnostic assays that employ commercially available antibodies targeting antigenic site I, II, or IV on the RSV fusion (F) protein. For immunological assay results which are negative when clinical observations are consistent with RSV infection, it is recommended to confirm using an RT-PCR-based assay.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nirsevimab","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Interference with RT-PCR or Rapid Antigen Detection RSV Diagnostic Assays Nirsevimab-alip does not interfere with reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen detection RSV diagnostic assays that employ commercially available antibodies targeting antigenic site I, II, or IV on the RSV fusion (F) protein. For immunological assay results which are negative when clinical observations are consistent with RSV infection, it is recommended to confirm using an RT-PCR-based assay.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nirsevimab","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Interference with RT-PCR or Rapid Antigen Detection RSV Diagnostic Assays Nirsevimab-alip does not interfere with reverse transcriptase polymerase chain reaction (RT-PCR) or rapid antigen detection RSV diagnostic assays that employ commercially available antibodies targeting antigenic site I, II, or IV on the RSV fusion (F) protein. For immunological assay results which are negative when clinical observations are consistent with RSV infection, it is recommended to confirm using an RT-PCR-based assay.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin ophthalmic","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin ophthalmic","ingredient2":"moxifloxacin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin ophthalmic","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin ophthalmic","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"moxifloxacin ophthalmic","ingredient2":"vit","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug-drug interaction studies have not been conducted with moxifloxacin ophthalmic solution. In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"perphenazine","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, Î²-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). Approximately 10% of the Caucasian population has reduced activity of this enzyme, so-called poor metabolizers. Among other populations the prevalence is not known. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events. The concomitant ","recommendation":"Monitoring is essential and dose reduction may become necessary to avoid toxicity.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine","ingredient2":"guar","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, Î²-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). Approximately 10% of the Caucasian population has reduced activity of this enzyme, so-called poor metabolizers. Among other populations the prevalence is not known. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events. The concomitant ","recommendation":"Monitoring is essential and dose reduction may become necessary to avoid toxicity.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Metabolism of a number of medications, including antipsychotics, antidepressants, Î²-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase). Approximately 10% of the Caucasian population has reduced activity of this enzyme, so-called poor metabolizers. Among other populations the prevalence is not known. Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects. In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge. Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events. The concomitant ","recommendation":"Monitoring is essential and dose reduction may become necessary to avoid toxicity.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dexrazoxane for injection","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No drug interactions have been identified see Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dexrazoxane for injection","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No drug interactions have been identified see Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"clonidine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"catecholamine-depleting","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"precautions","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"beta-blocker","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"calcium","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"epinephrine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"quinidine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"catecholamine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"reserpine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"olamine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"beta-adrenergic","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"timolol maleate ophthalmic gel forming solution","ingredient2":"timolol","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions Beta-Adrenergic Blocking Agents Patients who are receiving a beta-adrenergic blocking agent orally and timolol maleate ophthalmic gel forming solution should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. Calcium Antagonists Caution should be used in the coadministration of beta-adrenergic blocking agents, such as timolol maleate ophthalmic gel forming solution, and oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension. In patients with impaired cardiac function, coadministration should be avoided. Catecholamine-Depleting Drugs Close observation of the patient is recommended when a beta-blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of h","recommendation":"Should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"journavx","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"grape","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"anis","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"levonorgestrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"norgestrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"grapefruit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"ethinyl estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"suzetrigine","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A inhibitors: Concomitant use with strong CYP3A inhibitors is contraindicated. Reduce the JOURNAVX dose when used concomitantly with moderate CYP3A inhibitors. Avoid food or drink containing grapefruit. (2. 3, 7. 1, 12. 3) Strong and Moderate CYP3A inducers: Avoid JOURNAVX use with strong or moderate CYP3A inducers. (7. 1, 12. 3) CYP3A substrates: If JOURNAVX is used concomitantly with sensitive CYP3A substrates or CYP3A substrates where minimal concentration changes may lead to loss of efficacy, refer to the Prescribing Information for the CYP3A substrates for dosing instructions. Dosage modification of the concomitant CYP3A substrates may be required when initiating or discontinuing JOURNAVX. (7. 2, 12. 3) Hormonal contraceptives: JOURNAVX-treated patients using hormonal contraceptives containing progestins other than levonorgestrel and norethindrone should use an additional nonhormonal contraceptive method or an alternative hormonal contra","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atropine sulfate","ingredient2":"maoi","severity":"minor","severity_confidence":0.3,"effect":"7. DRUG INTERACTIONS The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis. (7) 7. 1 Monoamine Oxidase Inhibitors (MAOI) The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"atropine sulfate","ingredient2":"monoamine","severity":"minor","severity_confidence":0.3,"effect":"7. DRUG INTERACTIONS The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis. (7) 7. 1 Monoamine Oxidase Inhibitors (MAOI) The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"atropine sulfate","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"7. DRUG INTERACTIONS The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis. (7) 7. 1 Monoamine Oxidase Inhibitors (MAOI) The use of atropine and monoamine oxidase inhibitors (MAOI) is generally not recommended because of the potential to precipitate hypertensive crisis.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"amikacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"piperacillin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"lysi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"anis","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"bio-rad","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"probenecid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"gentamicin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"sodium chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"vancomycin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"heparin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"glucose","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"clinitest","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"vecuronium bromide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"tobramycin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"edta","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"anticoagulants","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"copper","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"methotrexate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"piperacillin and tazobactam and sodium chloride","ingredient2":"tazobactam","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Piperacillin and Tazobactam for Injection and Sodium Chloride Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7. 1) Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection and Sodium Chloride Injection unless the benefit outweighs the risk. (7. 2) Co-administration of Piperacillin and Tazobactam for Injection and Sodium Chloride Injection with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and vancomycin. (7. 3) Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and Sodium Chloride Injection and heparin or oral anticoagulants. (7. 4) Piperacillin and Tazobactam for Injection and Sodium Chloride In","recommendation":"Monitor tobramycin concentrations in these patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"pack","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"ribociclib","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"femara","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"letrozole and ribociclib","ingredient2":"kisqali","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Ribociclib CYP3A4 Inhibitors: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates with narrow therapeutic indices may need to be reduced when given concurrently with KISQALI FEMARA CO-PACK. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of a strong CYP3A4 inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhi","recommendation":"Avoid concomitant use of KISQALI FEMARA CO-PACK with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"halothane","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"fentanyl","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"diltiazem","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"erythromycin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"diazepam","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"itraconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"thy","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"pancuronium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"verapamil","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"hydroxyzine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"gabaa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"nifedipine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"morphine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"atropine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"gaba","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"thiopental","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"cimetidine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"ranitidine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"iga","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"midazolam","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"cetacaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"lidocaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"pan","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"choline","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"olamine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"midazolam in 0.8% sodium chloride","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Opioid Analgesics and Other Sedative Hypnotics: Risk of respiratory depression is increased (7. 1) Cytochrome P450-3A4 Inhibitors: May result in prolonged sedation due to decreased plasma clearance of midazolam. (7. 2) 7. 1 Opioid Analgesics and Other Sedative Hypnotics The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Monitor patients closely for respiratory depression and sedation. The sedative effect of intravenous midazolam is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly opioids (e. G. , morphine, meperidine and fentanyl) and also s","recommendation":"Monitor patients closely for respiratory depression and sedation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"anticoagulant","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"omega","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"omega-3","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"anticoagulants","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"omega-3-acid ethyl esters capsules","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Omega-3-acids may prolong bleeding time. Patients taking omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically. (7. 1) 7. 1 Anticoagulants or Other Drugs Affecting Coagulation Some trials with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these trials has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical trials have not been done to thoroughly examine the effect of omega-3-acid ethyl esters capsules and concomitant anticoagulants. Patients receiving treatment with omega-3-acid ethyl esters capsules and an anticoagulant or other drug affecting coagulation (e. G. , anti-platelet agents) should be monitored periodically.","recommendation":"Should be monitored periodically.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rifabutin","ingredient2":"cobicistat","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"darunavir","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"sofosbuvir","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"drugs","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"rilpivirine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"dolutegravir","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"bedaquiline","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"tar","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"doravirine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"protease","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"sulfamethoxazole-trimethoprim","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"antiretrovirals","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"vite","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"etravirine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"tenofovir alafenamide","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"emtricitabine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of rifabutin may need to be reduced when it is co-administered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity ","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"furosemide","ingredient2":"lasix","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions LASIX may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination. LASIX should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with LASIX, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites. There is a risk of ototoxic effects if cisplatin and LASIX are given concomitantly. In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if LASIX is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment. LASIX has a tendency to antagonize the skeletal muscle-relaxing effect of tubocurarine and may potentiate the action of succinylcholine. Lithium generally should not be given with diuretics becau","recommendation":"Avoid this combination.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"sertraline","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"sumatriptan","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"hgprt","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"propranolol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"ergotamin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"beta blockers","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"others","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"antibiotics","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"paroxetine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"contraindications","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"epinephrine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"fluoxetine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"warnings","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"ergotamine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"protease","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"milk","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"nicotine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dihydroergotamine mesylate","ingredient2":"dihydroergotamine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Vasoconstrictors Dihydroergotamine mesylate Nasal Spray should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure. Sumatriptan Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with dihydroergotamine mesylate nasal spray. Sumatriptan and dihydroergotamine mesylate nasal spray should not be taken within 24 hours of each other. (See CONTRAINDICATIONS) Beta Blockers Although the results of a clinical study did not indicate a safety problem associated with the administration of dihydroergotamine mesylate nasal spray to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine. Nicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy. CYP 3A4 Inhibitors (e. G.","recommendation":"Should not be used with peripheral vasoconstrictors because the combination may cause synergistic elevation of blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"benazepril hydrochloride and hydrochlorothiazide","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. Monitor potassium periodically. MTOR (mammalian target of rapamycin) inhibitor s: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e. G. , temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). Lithium: Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. Monitor lithium levels when used concomitantly with Lotensin HCT. Dual Blockade of the Renin-Angiotensin System (RAS): Dual Blockade of the RAS with angiotensin recept","recommendation":"Monitor potassium periodically.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"benazepril hydrochloride and hydrochlorothiazide","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. Monitor potassium periodically. MTOR (mammalian target of rapamycin) inhibitor s: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e. G. , temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). Lithium: Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. Monitor lithium levels when used concomitantly with Lotensin HCT. Dual Blockade of the Renin-Angiotensin System (RAS): Dual Blockade of the RAS with angiotensin recept","recommendation":"Monitor potassium periodically.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"benazepril hydrochloride and hydrochlorothiazide","ingredient2":"50 mg","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. Monitor potassium periodically. MTOR (mammalian target of rapamycin) inhibitor s: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e. G. , temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). Lithium: Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. Monitor lithium levels when used concomitantly with Lotensin HCT. Dual Blockade of the Renin-Angiotensin System (RAS): Dual Blockade of the RAS with angiotensin recept","recommendation":"Monitor potassium periodically.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"benazepril hydrochloride and hydrochlorothiazide","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema. Interactions Common for Both Benazepril and Hydrochlorothiazide Potassium Supplements and Potassium -Sparing Diuretics: Concomitant use with Lotensin HCT may effect potassium levels. Monitor potassium periodically. MTOR (mammalian target of rapamycin) inhibitor s: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e. G. , temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS ). Lithium: Renal clearance of lithium is reduced by thiazides and increase the risk of lithium toxicity. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. Monitor lithium levels when used concomitantly with Lotensin HCT. Dual Blockade of the Renin-Angiotensin System (RAS): Dual Blockade of the RAS with angiotensin recept","recommendation":"Monitor potassium periodically.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tizanidine hydrochloride","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Moderate or weak CYP1A2 inhibitors: avoid concomitant use; may cause hypotension, bradycardia, or excessive drowsiness; if concomitant use is necessary and adverse reactions occur, reduce tizanidine dosage or discontinue. ( 7. 2, 12. 3) 7. 1 Strong CYP1A2 Inhibitors Concomitant use of tizanidine with strong cytochrome P450 1A2 (CYP1A2) inhibitors (e. G. , fluvoxamine, ciprofloxacin) is contraindicated. Changes in pharmacokinetics of tizanidine when administered with a strong CYP1A2 inhibitor resulted in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment see Contraindications ( 4) and Clinical Pharmacology ( 12. 3). 7. 2 Moderate or Weak CYP1A2 Inhibitors Concomitant use of tizanidine with moderate or weak CYP1A2 inhibitors (e. G. , zileuton, antiarrhythmics amiodarone, mexiletine, propafenone, and verapamil, cimetidine, famotidine, oral contraceptives, acyclovir, and ticlopidine) should be avoided. If concomitant use i","recommendation":"Avoid concomitant use; may cause hypotension, bradycardia, or excessive drowsiness; if concomitant use is necessary and adverse reactions occur, reduce tizanidine dosage or discontinue.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nitroglycerin","ingredient2":"lysi","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"sodium","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"epa","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"sodium chloride","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"ros","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"glycerin","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"chlorid","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"heparin","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"anticoagulant","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"glycer","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"chloride","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"glyce","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"dextrose","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"lutin","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"glyceri","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"rose","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitroglycerin","ingredient2":"sodi","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions: The vasodilating effects of nitroglycerin may be additive with those of other vasodilators. Administration of nitroglycerin infusions through the same infusion set as blood can result in pseudoagglutination and hemolysis. More generally, nitroglycerin in 5% dextrose or sodium chloride 0. 9% should not be mixed with any other medication of any kind. Intravenous nitroglycerin interferes, at least in some patients, with the anticoagulant effect of heparin. In patients receiving intravenous nitroglycerin, concomitant heparin therapy should be guided by frequent measurement of the activated partial thromboplastin time.","recommendation":"Should not be mixed with any other medication of any kind.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"corticosteroid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"drug-laboratory","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4: Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release concomitantly or within 14 days after discontinuing MAOI see Contraindications (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine aspartate m","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brompheniramine maleate, pseudoephedrine hydrochloride, and dextromethorphan hydrobromide","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions: Monoamine oxidase inhibitors (MAOIs) Hyperpyrexia, hypotension, and death have been reported coincident with the coadministration of MAOIs and products containing dextromethorphan. In addition, MAOIs prolong and intensify the anticholinergic (drying) effects of antihistamines and may enhance the effect of pseudoephedrine. Concomitant administration of Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide Syrup and MAOIs should be avoided (see CONTRAINDICATIONS ). Central nervous system (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc. ). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs.","recommendation":"Should be avoided (see CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"insulin lispro","ingredient2":"admelog","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 2 presents clinically significant drug interactions with ADMELOG. Table 2: Clinically Significant Drug Interactions with ADMELOG Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e. G. , octreotide), and sulfonamide antibiotics. Intervention: Dose adjustment and increased frequency of glucose monitoring may be required when ADMELOG is concomitantly administered with these drugs. Drugs That May Decrease the Blood Glucose Lowering Effect of ADMELOG Drugs: Atypical antipsychotics (e. G. , olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e. G. , in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e. G. , albuterol, epine","recommendation":"Monitoring may be required when ADMELOG is concomitantly administered with these drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ruxolitinib","ingredient2":"opzelura","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug interaction studies with OPZELURA have not been conducted. Ruxolitinib is known to be a substrate for cytochrome P450 3A4 (CYP3A4). Inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations whereas inducers of CYP3A4 may decrease ruxolitinib systemic concentrations see Clinical Pharmacology (12. 3). Strong Inhibitors of CYP3A4 Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12. 3).","recommendation":"Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ruxolitinib","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug interaction studies with OPZELURA have not been conducted. Ruxolitinib is known to be a substrate for cytochrome P450 3A4 (CYP3A4). Inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations whereas inducers of CYP3A4 may decrease ruxolitinib systemic concentrations see Clinical Pharmacology (12. 3). Strong Inhibitors of CYP3A4 Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12. 3).","recommendation":"Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ruxolitinib","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug interaction studies with OPZELURA have not been conducted. Ruxolitinib is known to be a substrate for cytochrome P450 3A4 (CYP3A4). Inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations whereas inducers of CYP3A4 may decrease ruxolitinib systemic concentrations see Clinical Pharmacology (12. 3). Strong Inhibitors of CYP3A4 Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12. 3).","recommendation":"Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ruxolitinib","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug interaction studies with OPZELURA have not been conducted. Ruxolitinib is known to be a substrate for cytochrome P450 3A4 (CYP3A4). Inhibitors of CYP3A4 may increase ruxolitinib systemic concentrations whereas inducers of CYP3A4 may decrease ruxolitinib systemic concentrations see Clinical Pharmacology (12. 3). Strong Inhibitors of CYP3A4 Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12. 3).","recommendation":"Avoid concomitant use of OPZELURA with strong inhibitors of CYP3A4 as there is a potential to increase the systemic exposure of ruxolitinib and could increase the risk of OPZELURA adverse reactions see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"brimonidine tartrate","ingredient2":"alphagan","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Antihypertensives/cardiac glycosides may lower blood pressure. (7. 1) Use with CNS depressants may result in an additive or potentiating effect. (7. 2) Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine. (7. 3) Monoamine oxidase inhibitors may result in increased hypotension. (7. 4) 7. 1 Antihypertensives/Cardiac Glycosides Because ALPHAGAN P may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with ALPHAGAN P is advised. 7. 2 CNS Depressants Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. 7. 3 Tricyclic Antidepressants Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAG","recommendation":"Caution in using drugs such as antihypertensives and/or cardiac glycosides with ALPHAGAN P is advised.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"alcohol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"glyce","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"cimetidine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"maois","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxepin hydrochloride","ingredient2":"mao inhibitors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS MAO inhibitors: Doxepin should not be administered in patients on MAOIs within the past two weeks. ( 4. 2) Cimetidine: Increases exposure to doxepin. ( 7. 2) Alcohol: Sedative effects may be increased with doxepin. ( 7. 3, 5. 4) CNS Depressants and Sedating Antihistamines: Sedative effects may be increased with doxepin ( 7. 4, 5. 4) Tolazamide: A case of severe hypoglycemia has been reported. ( 7. 5) 7. 1 Cytochrome P450 Isozymes Doxepin is primarily metabolized by hepatic cytochrome P450 isozymes CYP2C19 and CYP2D6, and to a lesser extent, by CYP1A2 and CYP2C9. Inhibitors of these isozymes may increase the exposure of doxepin. Doxepin is not an inhibitor of any CYP isozymes at therapeutically relevant concentrations. The ability of doxepin to induce CYP isozymes is not known. 7. 2 Cimetidine Doxepin exposure is doubled with concomitant administration of cimetidine, a nonspecific inhibitor of CYP isozymes. A maximum dose of 3 mg is recommended in adults and elderly ","recommendation":"Should not be administered in patients on MAOIs within the past two weeks.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"palsonify","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"cyclosporine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"cyclosporin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"paltusotine","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Moderate CYP3A4 Inducers: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1). Proton Pump Inhibitors: may decrease paltusotine exposure. May require PALSONIFY dosage increase (2. 3, 7. 1) Cyclosporine: may decrease cyclosporine exposure. May require cyclosporine dosage adjustment (7. 2). 7. 1 Effect of Other Drugs on PALSONIFY Table 3. Clinically Significant Interactions Affecting PALSONIFY Strong CYP3A4 Inducers Intervention Concomitant use of PALSONIFY with strong CYP3A4 inducers may require an increased dosage of PALSONIFY, not to exceed three-fold the dose prior to concomitant use or 120 mg daily, whichever is less. Clinical Impact Concomitant use of PALSONIFY with strong CYP3A4 inducers reduced paltusotine exposure and may affect therapeutic response see Clinical Pharmacology (12. 3). Moderate CYP3A4 Inducers Interven","recommendation":"Should avoid concomitant use with proton pump inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bumetanide","ingredient2":"enbumyst","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Lithium may reduce renal clearance of bumetanide and add a high risk of lithium toxicity. (7) Probenecid reduces both the natriuresis and hyperreninemia. (7) Indomethacin blunts the increase in urine volume and sodium excretion. (7) Drugs with ototoxic potential: avoid parenteral bumetanide in patients receiving aminoglycoside antibiotics. (7) Drugs with nephrotoxic potential: the simultaneous administration of ENBUMYST with drugs of nephrotoxic potential should be avoided. (7) Antihypertensive effects may be potentiated by bumetanide. (7) 7. 1 Effects of Other Drugs on Bumetanide Lithium Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity. Probenecid Probenecid should not be administered concurrently with bumetanide. Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide. This antagonistic effect of probenecid on bumetan","recommendation":"Avoid parenteral bumetanide in patients receiving aminoglycoside antibiotics.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bumetanide","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Lithium may reduce renal clearance of bumetanide and add a high risk of lithium toxicity. (7) Probenecid reduces both the natriuresis and hyperreninemia. (7) Indomethacin blunts the increase in urine volume and sodium excretion. (7) Drugs with ototoxic potential: avoid parenteral bumetanide in patients receiving aminoglycoside antibiotics. (7) Drugs with nephrotoxic potential: the simultaneous administration of ENBUMYST with drugs of nephrotoxic potential should be avoided. (7) Antihypertensive effects may be potentiated by bumetanide. (7) 7. 1 Effects of Other Drugs on Bumetanide Lithium Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity. Probenecid Probenecid should not be administered concurrently with bumetanide. Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide. This antagonistic effect of probenecid on bumetan","recommendation":"Avoid parenteral bumetanide in patients receiving aminoglycoside antibiotics.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bumetanide","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Lithium may reduce renal clearance of bumetanide and add a high risk of lithium toxicity. (7) Probenecid reduces both the natriuresis and hyperreninemia. (7) Indomethacin blunts the increase in urine volume and sodium excretion. (7) Drugs with ototoxic potential: avoid parenteral bumetanide in patients receiving aminoglycoside antibiotics. (7) Drugs with nephrotoxic potential: the simultaneous administration of ENBUMYST with drugs of nephrotoxic potential should be avoided. (7) Antihypertensive effects may be potentiated by bumetanide. (7) 7. 1 Effects of Other Drugs on Bumetanide Lithium Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity. Probenecid Probenecid should not be administered concurrently with bumetanide. Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by bumetanide. This antagonistic effect of probenecid on bumetan","recommendation":"Avoid parenteral bumetanide in patients receiving aminoglycoside antibiotics.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"salicylic","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"rhapsido","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"salicylic a","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"sali","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"clopidogrel","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"rutin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"salicylic acid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"ibrutinib","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"anticoagulants","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"remibrutinib","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or Moderate CYP3A4 Inhibitors: Avoid concomitant use with RHAPSIDO. (7. 1) Strong or Moderate CYP3A4 Inducers: Avoid concomitant use with RHAPSIDO. (7. 1) P-gp Substrates: Exposure increases where minimal concentration changes may lead to serious adverse reactions: Monitor more frequently for adverse reactions when used concomitantly with RHAPSIDO. (7. 2) Antithrombotic Agents: Consider the risks and benefits of concomitant use of antithrombotic agents with RHAPSIDO. (7. 2) 7. 1 Effect of Other Drugs on RHAPSIDO Strong or Moderate CYP3A4 Inhibitors Avoid use of RHAPSIDO with strong or moderate CYP3A4 inhibitors. Remibrutinib is a CYP3A4 substrate. Concomitant use with a strong or moderate CYP3A4 inhibitor increases remibrutinib exposure see Clinical Pharmacology (12. 3), which may increase the risk of RHAPSIDO adverse reactions. Strong or Moderate CYP3A4 Inducers Avoid use of RHAPSIDO with strong or moderate CYP3A4 inducers. Remibrutinib is a CYP3A4 substrate","recommendation":"Avoid concomitant use with RHAPSIDO.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gabapentin","ingredient2":"neurontin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Concentrations increased by morphine; may need dose adjustment (5. 4, 7. 1) 7. 1 Opioids Respiratory depression and sedation, sometimes resulting in death, have been reported following coadministration of gabapentin with opioids (e. G. , morphine, hydrocodone, oxycodone, buprenorphine) see Warnings and Precautions (5. 7). Hydrocodone Coadministration of NEURONTIN with hydrocodone decreases hydrocodone exposure see Clinical Pharmacology (12. 3). The potential for alteration in hydrocodone exposure and effect should be considered when NEURONTIN is started or discontinued in a patient taking hydrocodone. Morphine When gabapentin is administered with morphine, patients should be observed for signs of CNS depression, such as somnolence, sedation and respiratory depression see Clinical Pharmacology (12. 3). 7. 2 Other Antiepileptic Drugs Gabapentin is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered antiepileptic drugs see C","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"goserelin","ingredient2":"bet","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs. None 7. 1 Drug/Laboratory Test Interactions Administration of ZOLADEX in therapeutic doses results in suppression of the pituitary-gonadal system. Because of this suppression, diagnostic tests of pituitary-gonadotropic and gonadal functions conducted during treatment and until the resumption of menses may show results which are misleading. Normal function is usually restored within 12 weeks after treatment is discontinued.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"goserelin","ingredient2":"tar","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs. None 7. 1 Drug/Laboratory Test Interactions Administration of ZOLADEX in therapeutic doses results in suppression of the pituitary-gonadal system. Because of this suppression, diagnostic tests of pituitary-gonadotropic and gonadal functions conducted during treatment and until the resumption of menses may show results which are misleading. Normal function is usually restored within 12 weeks after treatment is discontinued.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"goserelin","ingredient2":"zoladex","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs. None 7. 1 Drug/Laboratory Test Interactions Administration of ZOLADEX in therapeutic doses results in suppression of the pituitary-gonadal system. Because of this suppression, diagnostic tests of pituitary-gonadotropic and gonadal functions conducted during treatment and until the resumption of menses may show results which are misleading. Normal function is usually restored within 12 weeks after treatment is discontinued.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"goserelin","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs. None 7. 1 Drug/Laboratory Test Interactions Administration of ZOLADEX in therapeutic doses results in suppression of the pituitary-gonadal system. Because of this suppression, diagnostic tests of pituitary-gonadotropic and gonadal functions conducted during treatment and until the resumption of menses may show results which are misleading. Normal function is usually restored within 12 weeks after treatment is discontinued.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"goserelin","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs. None 7. 1 Drug/Laboratory Test Interactions Administration of ZOLADEX in therapeutic doses results in suppression of the pituitary-gonadal system. Because of this suppression, diagnostic tests of pituitary-gonadotropic and gonadal functions conducted during treatment and until the resumption of menses may show results which are misleading. Normal function is usually restored within 12 weeks after treatment is discontinued.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"buspirone hydrochloride","ingredient2":"precautions","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Psychotropic Agents MAO Inhibitors The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. The use of buspirone within 14 days of stopping an MAOI intended to treat depression is also contraindicated. Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND DOSAGE AND ADMINISTRATION). Amitriptyline After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (Cmax, AUC, and Cmin) of amitriptyline or its metabolite nortriptyline were observed. Diazepam After addition of buspirone to the diazepam dose reg","recommendation":"CONTRAINDICATIONS, WARNINGS, PRECAUTIONS AND DOSAGE AND ADMINISTRATION).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"precautions","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"phenobarbital","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"thy","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"magnesi","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vitamin d","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vitami","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"lysi","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"corticosteroids","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"epa","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"eru","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vitamin","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"calcium","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"cholestyramine","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"phosphate-binding","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"fat","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"but","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vita","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"iga","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vitamins","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vitamin d 3","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"warnings","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"magnesium","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"ketoconazole","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"calcitriol capsules 0.25 mcg","ingredient2":"calcitriol","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Cholestyramine Cholestyramine has been reported to reduce intestinal absorption of fat-soluble vitamins; as such it may impair intestinal absorption of calcitriol (see WARNINGS and PRECAUTIONS: General ). Phenytoin/Phenobarbital The coadministration of phenytoin or phenobarbital will not affect plasma concentrations of calcitriol, but may reduce endogenous plasma levels of 25(OH)D 3 by accelerating metabolism. Since blood level of calcitriol will be reduced, higher doses of calcitriol may be necessary if these drugs are administered simultaneously. Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. Some reports have shown that the concomitant administration of thiazides with calcitriol causes hypercalcemia. Therefore, precaution should be taken when coadministration is necessary. Digitalis Calcitriol dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients ","recommendation":"CAUTIONS: General ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxcarbazepine","ingredient2":"trileptal","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Phenytoin: Increased phenytoin levels. Reduced dose of phenytoin may be required (7. 1) Carbamazepine, Phenytoin, and Phenobarbital: Decreased plasma levels of MHD (the active metabolite). Dose adjustments may be necessary (7. 1) Oral Contraceptive: TRILEPTAL may decrease the effectiveness of hormonal contraceptives (7. 3) 7. 1 Effect of TRILEPTAL on Other Drugs Phenytoin levels have been shown to increase with concomitant use of TRILEPTAL at doses greater than 1200 mg/day see Clinical Pharmacology (12. 3). Therefore, it is recommended that the plasma levels of phenytoin be monitored during the period of TRILEPTAL titration and dosage modification. A decrease in the dose of phenytoin may be required. 7. 2 Effect of Other Drugs on TRILEPTAL Strong inducers of cytochrome P450 enzymes and/or inducers of UGT (e. G. , rifampin, carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma/serum levels of MHD, the active metabolite of TRILEPTAL (25% t","recommendation":"Monitored during the period of TRILEPTAL titration and dosage modification.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"mifepristone","ingredient2":"korlym","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Based on the long terminal half-life of mifepristone after reaching steady state, at least 2 weeks should elapse after cessation of KORLYM before initiating or increasing the dose of any interacting concomitant medication. Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with KORLYM (7. 1). CYP3A inhibitors: Caution should be used when KORLYM is used with strong CYP3A inhibitors. Limit mifepristone dose to 900 mg per day when used with strong CYP3A inhibitors (7. 2). CYP3A inducers: Do not use KORLYM with CYP3A inducers (7. 3). Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used with KORLYM (7. 4). Drugs metabolized by CYP2B6: Use of KORLYM should be done with caution with bupropion and efavirenz (7. 5). Hormonal contraceptives: Do not use with KORLYM (7. 6). 7. 1 Drugs Metabolized by CYP3A Because KORLYM is an inhibitor of CYP3A, concurrent use of KORLYM with a drug whose met","recommendation":"Should elapse after cessation of KORLYM before initiating or increasing the dose of any interacting concomitant medication.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"atomoxetine hydrochloride","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Monoamine Oxidase Inhibitors. (4. 2, 7. 1) CYP2D6 Inhibitors  Concomitant use may increase atomoxetine steadystate plasma concentrations in EMs. (7. 2) Antihypertensive Drugs and Pressor Agents  Possible effects on blood pressure. (7. 3) Albuterol (or other beta 2agonists)  Action of albuterol on cardiovascular system can be potentiated. (7. 4) 7. 1 Monoamine Oxidase Inhibitors With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Such reactions may occur when these drugs are given concurrently or in close proximity see Contraindications ( 4. 2). 7. 2 Effect of CYP2D6 Inhibitors","recommendation":"Contraindications ( 4.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"ofloxacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"caf","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"alyftrek","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"grape","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"anis","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"ciprofloxacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"grapefruit juice","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"grapefruit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"estradiol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"ethinyl estradiol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"bcrp","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vanzacaftor, tezacaftor, and deutivacaftor","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong or moderate CYP3A inducers: Concomitant use with ALYFTREK is not recommended. (5. 5, 7. 1) Strong or moderate CYP3A inhibitors: Reduce ALYFTREK dosage with concomitant use. Avoid food or drink containing grapefruit. (2. 3, 5. 6, 7. 1) 7. 1 Effect of Other Drugs and Grapefruit on ALYFTREK Strong or Moderate CYP3A Inducers Concomitant use of ALYFTREK with strong or moderate CYP3A inducers is not recommended. Vanzacaftor, tezacaftor, and deutivacaftor are substrates of CYP3A. Concomitant use of ALYFTREK with a strong or moderate CYP3A inducer decreases vanzacaftor, tezacaftor, and deutivacaftor exposure see Clinical Pharmacology (12. 3) which may reduce ALYFTREK effectiveness see Warnings and Precautions (5. 5). Strong or Moderate CYP3A Inhibitors Reduce the ALYFTREK dosage when used concomitantly with a strong or moderate CYP3A inhibitor see Dosage and Administration (2. 3). Vanzacaftor, tezacaftor, and deutivacaftor are CYP3A substrates. Concomitant use with a","recommendation":"Avoid food or drink containing grapefruit.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"testosterone undecanoate","ingredient2":"kyzatrex","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS - Insulin: In patients with diabetes, concomitant use with KYZATREX may decrease blood glucose and insulin requirements ( 7. 1). Oral Anticoagulants: Concomitant use with KYZATREX may cause changes in anticoagulant activity. Monitor International Normalized Ratio (INR) and prothrombin time (PT) frequently ( 7. 2). Corticosteroids: Concomitant use with KYZATREX may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease ( 7. 3). Drugs that May Also Increase Blood Pressure: Concomitant use with KYZATREX may lead to additional increases in blood pressure ( 7. 4). 7. 1 Insulin Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore necessitate a decrease in the dose of anti-diabetic medication. 7. 2 Oral Vitamin K Antagonist Anticoagulants Changes in anticoagulant activi","recommendation":"Monitor International Normalized Ratio (INR) and prothrombin time (PT) frequently ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"triptorelin pamoate","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"epa","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"tar","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"trelstar","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"triptorelin pamoate","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS No drug-drug interaction studies involving TRELSTAR have been conducted. Human pharmacokinetic data with triptorelin suggest that C-terminal fragments produced by tissue degradation are either degraded completely within tissues, are rapidly degraded further in plasma, or cleared by the kidneys. Therefore, hepatic microsomal enzymes are unlikely to be involved in triptorelin metabolism. However, in the absence of relevant data and as a precaution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","recommendation":"Caution, hyperprolactinemic drugs should not be used concomitantly with TRELSTAR since hyperprolactinemia reduces the number of pituitary GnRH receptors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"rivastigmine","ingredient2":"exelon","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Concomitant use with metoclopramide, beta-blockers, or cholinomimetics and anticholinergic medications is not recommended. (7. 1, 7. 2, 7. 3) 7. 1 Metoclopramide Due to the risk of additive extra-pyramidal adverse reactions, the concomitant use of metoclopramide and EXELON PATCH is not recommended. 7. 2 Cholinomimetic and Anticholinergic Medications EXELON PATCH may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e. G. , oxybutynin, tolterodine). Concomitant use of EXELON PATCH with medications having these pharmacologic effects is not recommended unless deemed clinically necessary see Warnings and Precautions ( 5. 5 ). 7. 3 Beta-Blockers Additive bradycardic effects resulting in syncope may occur when EXELON is used concomitantly with beta-blockers, especially cardioselective beta-blockers (including atenolol). Concomitant use is not recommended when signs of bradycardia, ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rivastigmine","ingredient2":"patch","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Concomitant use with metoclopramide, beta-blockers, or cholinomimetics and anticholinergic medications is not recommended. (7. 1, 7. 2, 7. 3) 7. 1 Metoclopramide Due to the risk of additive extra-pyramidal adverse reactions, the concomitant use of metoclopramide and EXELON PATCH is not recommended. 7. 2 Cholinomimetic and Anticholinergic Medications EXELON PATCH may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e. G. , oxybutynin, tolterodine). Concomitant use of EXELON PATCH with medications having these pharmacologic effects is not recommended unless deemed clinically necessary see Warnings and Precautions ( 5. 5 ). 7. 3 Beta-Blockers Additive bradycardic effects resulting in syncope may occur when EXELON is used concomitantly with beta-blockers, especially cardioselective beta-blockers (including atenolol). Concomitant use is not recommended when signs of bradycardia, ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"iron","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"sucralfate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"magnesi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"zinc","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"vitami","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"moxifloxacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"glucose","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"vitamin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"anticoagulant","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"multivitamins","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"sotalol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"alum","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"glyce","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"fat","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"vita","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"vitamins","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"pan","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"vitamins c","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"magnesium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"multivitamin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"moxifloxacin hydrochloride tablets, 400 mg","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Interacting Drug Interaction Multivalent cation-containing products including: antacids, sucralfate, multivitamins Decreased Moxifloxacin hydrochloride absorption. Take moxifloxacin tablet at least 4 hours before or 8 hours after these products. ( 2. 2, 7. 1, 12. 3) Warfarin Anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding. (6, 7. 2, 12. 3) Class IA and Class III antiarrhythmics: Proarrhythmic effect may be enhanced. Avoid concomitant use. ( 5. 6, 7. 5) Antidiabetic agents Carefully monitor blood glucose. ( 5. 11, 7. 3) 7. 1 Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations Fluoroquinolones, including moxifloxacin hydrochloride, form chelates with alkaline earth and transition metal cations. Oral administration of moxifloxacin hydrochloride with antacids containing aluminum or magnesium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations co","recommendation":"Monitor prothrombin time/INR, and bleeding.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bacillus calmette-guerin","ingredient2":"tice","severity":"severe","severity_confidence":0.9,"effect":"Drug Interaction Drug combinations containing immunosuppressants and/or bone marrow depressants and/or radiation interfere with the development of the immune response and should not be used in combination with TICE BCG. Antimicrobial therapy for other infections may interfere with the effectiveness of TICE BCG. There are no data to suggest that the acute, local urinary tract toxicity common with BCG is due to mycobacterial infection, and antituberculosis drugs (e. G. , isoniazid) should not be used to prevent or treat the local, irritative toxicities of TICE BCG.","recommendation":"Should not be used in combination with TICE BCG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"bacillus calmette-guerin","ingredient2":"isoniazid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interaction Drug combinations containing immunosuppressants and/or bone marrow depressants and/or radiation interfere with the development of the immune response and should not be used in combination with TICE BCG. Antimicrobial therapy for other infections may interfere with the effectiveness of TICE BCG. There are no data to suggest that the acute, local urinary tract toxicity common with BCG is due to mycobacterial infection, and antituberculosis drugs (e. G. , isoniazid) should not be used to prevent or treat the local, irritative toxicities of TICE BCG.","recommendation":"Should not be used in combination with TICE BCG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"atomoxetine","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Monoamine Oxidase Inhibitors. ( 4. 2, 7. 1) CYP2D6 Inhibitors - Concomitant use may increase atomoxetinesteady-state plasma concentrations in EMs. (7. 2) Antihypertensive Drugs and Pressor Agents - Possible effects on blood pressure. (7. 3) Albuterol (or other beta 2agonists) - Action of albuterol on cardiovascular system can be potentiated. (7. 4) 7. 1 Monoamine Oxidase Inhibitors With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal reactions (including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma) when taken in combination with an MAOI. Some cases presented with features resembling neuroleptic malignant syndrome. Such reactions may occur when these drugs are given concurrently or in close proximity see Contraindications (4. 2). 7. 2 Effect of CYP2D6 Inhibit","recommendation":"Contraindications (4.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"fos","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"ropivacaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"salicylic a","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"metoclopramide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"bupivacaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"glycer","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"articaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"ergot-type","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"nitroglycerin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"cyclophosphamide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"glyceri","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"beta-adrenergic","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"phenytoin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"salicylic","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"sodium valproate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"glycerin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"antibiotics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"quinine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"nitrofurantoin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"flutamide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"prilocaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"urea","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"benzocaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"glyce","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"lidocaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"mepivacaine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"phenobarbital","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"monoamine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"sali","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"oat","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"salicylic acid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"ifosfamide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"dapsone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lidocaine hydrochloride and epinephrine","ingredient2":"hydroxyurea","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. ( 7. 1) Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of Lidocaine Hydrochloride and Epinephrine Injection to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension Concurrent use of these agents should generally be avoided. ( 5. 5, 7. 2) Ergot-type Oxytocic drugs: Concurrent administration of Lidocaine Hydrochloride and Epinephrine Injection and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. ( 5. 5, 7. 3) Nonselective Beta-Adrenergic Antagonists: Administration of Lidocaine Hydrochloride and Epinephrine Injection in patients receiving nonselective beta-adrenergic antagonist may cause severe hypertension and bradycardia. Concurrent use of these agents s","recommendation":"Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sertraline","ingredient2":"thioridazine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Protein-bound drugs: Monitor for adverse reactions and reduce dosage of sertraline hydrochloride or other protein-bound drugs (e. G. , warfarin) as warranted. ( 7. 1, 12. 3) CYP2D6 substrates: Reduce dosage of drugs metabolized by CYP2D6. ( 7. 1, 12. 3) 7. 1 Clinically Significant Drug Interactions Table 5 includes clinically significant drug interactions with sertraline hydrochloride See Clinical Pharmacology ( 12. 3). Table 5. Clinically Significant Drug Interactions with Sertraline Hydrochloride Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: The concomitant use of SSRIs including sertraline hydrochloride and MAOIs increases the risk of serotonin syndrome. Intervention: Sertraline hydrochloride is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue See Dosage and Administration ( 2. 5), Contraindications ( 4), Warnings and Precautions ( 5. 2). Examples: selegiline, tranylcypromine, isocarboxazid, phenelz","recommendation":"Monitor for adverse reactions and reduce dosage of sertraline hydrochloride or other protein-bound drugs (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tivozanib","ingredient2":"pharmacology","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. ( 7. 1) 7. 1 Effect of Other Drugs on FOTIVDA Strong CYP3A Inducers Concomitant use of FOTIVDA with a strong CYP3A inducer decreases tivozanib exposure see CLINICAL PHARMACOLOGY (12. 3), which may reduce FOTIVDA anti-tumor activity. Avoid concomitant use of strong CYP3A inducers with FOTIVDA.","recommendation":"Avoid concomitant use of strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"tivozanib","ingredient2":"fotivda","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. ( 7. 1) 7. 1 Effect of Other Drugs on FOTIVDA Strong CYP3A Inducers Concomitant use of FOTIVDA with a strong CYP3A inducer decreases tivozanib exposure see CLINICAL PHARMACOLOGY (12. 3), which may reduce FOTIVDA anti-tumor activity. Avoid concomitant use of strong CYP3A inducers with FOTIVDA.","recommendation":"Avoid concomitant use of strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"tivozanib","ingredient2":"clinical","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. ( 7. 1) 7. 1 Effect of Other Drugs on FOTIVDA Strong CYP3A Inducers Concomitant use of FOTIVDA with a strong CYP3A inducer decreases tivozanib exposure see CLINICAL PHARMACOLOGY (12. 3), which may reduce FOTIVDA anti-tumor activity. Avoid concomitant use of strong CYP3A inducers with FOTIVDA.","recommendation":"Avoid concomitant use of strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"tivozanib","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. ( 7. 1) 7. 1 Effect of Other Drugs on FOTIVDA Strong CYP3A Inducers Concomitant use of FOTIVDA with a strong CYP3A inducer decreases tivozanib exposure see CLINICAL PHARMACOLOGY (12. 3), which may reduce FOTIVDA anti-tumor activity. Avoid concomitant use of strong CYP3A inducers with FOTIVDA.","recommendation":"Avoid concomitant use of strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"tivozanib","ingredient2":"vit","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS CYP3A Inducers: Avoid concomitant use of strong CYP3A inducers. ( 7. 1) 7. 1 Effect of Other Drugs on FOTIVDA Strong CYP3A Inducers Concomitant use of FOTIVDA with a strong CYP3A inducer decreases tivozanib exposure see CLINICAL PHARMACOLOGY (12. 3), which may reduce FOTIVDA anti-tumor activity. Avoid concomitant use of strong CYP3A inducers with FOTIVDA.","recommendation":"Avoid concomitant use of strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"polidocanol","ingredient2":"varithena","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No specific drug interaction studies have been performed. There are no known drug interactions with VARITHENA. There are no known drug interactions with VARITHENA. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"polidocanol","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No specific drug interaction studies have been performed. There are no known drug interactions with VARITHENA. There are no known drug interactions with VARITHENA. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"polidocanol","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No specific drug interaction studies have been performed. There are no known drug interactions with VARITHENA. There are no known drug interactions with VARITHENA. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"amitriptyline","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"sertraline","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"alcohol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"pine o","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"paroxetine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"atropine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"epinephrine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"cimetidine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"ssri","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"perphenazine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"topiramate","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"50 mg","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"fluoxetine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"propafenone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"choline","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"perphenazine and amitriptyline hydrochloride","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Topiramate Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patients clinical response and not on the basis of plasma levels. Drugs Metabolized by P450 2D6 The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA). In addition, certain drugs inhibit the","recommendation":"Should be made according to the patients clinical response and not on the basis of plasma levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"arsenic trioxide","ingredient2":"trisenox","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs That Can Prolong the QT/QTc Interval Concomitant use of these drugs and TRISENOX may increase the risk of serious QT/QTc interval prolongation see Warnings and Precautions (5. 1). Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while the patient is using TRISENOX. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use. Drugs That Can Lead to Electrolyte Abnormalities Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation see Warnings and Precautions (5. 1). Avoid concomitant use of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and TRISENOX. Drugs That Can Lead to Hepatotoxicity Concomitant use of these drugs and TRISENOX, particularly when given in combination with tretinoin, may increase the risk of serious hepatotoxicity see Warnings and Precautions (5. 4","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"arsenic trioxide","ingredient2":"tretinoin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs That Can Prolong the QT/QTc Interval Concomitant use of these drugs and TRISENOX may increase the risk of serious QT/QTc interval prolongation see Warnings and Precautions (5. 1). Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while the patient is using TRISENOX. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use. Drugs That Can Lead to Electrolyte Abnormalities Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation see Warnings and Precautions (5. 1). Avoid concomitant use of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and TRISENOX. Drugs That Can Lead to Hepatotoxicity Concomitant use of these drugs and TRISENOX, particularly when given in combination with tretinoin, may increase the risk of serious hepatotoxicity see Warnings and Precautions (5. 4","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide","ingredient2":"copd","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT HFA and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs (7. 1) 7. 1 Anticholinergic Agents There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of ATROVENT HFA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5).","recommendation":"Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ipratropium bromide","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. With the exception of albuterol, there are no formal studies fully evaluating the interaction effects of ATROVENT HFA and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs (7. 1) 7. 1 Anticholinergic Agents There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of ATROVENT HFA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5).","recommendation":"Avoid administration of ATROVENT HFA with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"liposom","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with DOXIL liposomal infusion.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"doxil","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with DOXIL liposomal infusion.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with DOXIL liposomal infusion.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with DOXIL liposomal infusion.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"levothyroxine sodium","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e. G. , absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets. (7) 7. 1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics and metabolism (e. G. , absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to Levothyroxine Sodium Tablets (Tables 5 to 8). Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of Levothyroxine Sodium Tablets by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders(e. G. , calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders m","recommendation":"Monitor patients treated concomitantly with orlistat and Levothyroxine Sodium Tablets for changes in thyroid function.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolvaptan","ingredient2":"samsca","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Avoid concomitant use with: Moderate CYP3A inhibitors (7. 1) Strong CYP3A inducers (7. 1) V2-receptor antagonists (7. 3) Monitor serum potassium during concomitant therapy with (7. 2): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7. 1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptans AUC was 5. 4 times as large and Cmax was 3. 5 times as large after co-administration of tolvaptan and 200 mg ketoconazole see Warnings and Precautions (5. 5) and Clinical Pharmacology (12. 3). Larger doses of the strong CYP3A inhibitor would be expected to produce larger increases in tolvaptan exposure. Concomitant use of tolvaptan with strong CYP3A inhibitors is contraindicated see Contraindications (4). Moderate CYP3A Inhibitors A substantial increase in the exposure to tolvaptan would be expected when SAMSCA is co-administered with moderate CYP3A inhibitors. Avoid co-administration of SAMSCA with moderate CYP3A inhi","recommendation":"Avoid concomitant use with: Moderate CYP3A inhibitors (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"fos","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"rifapentine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"atorvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"lamivudine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"phenobarbital","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"sofosbuvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"magnesi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"efavirenz","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"ledipasvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"metformin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"levonorgestrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"enzalutamide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"simethicone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"norgestrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"alum","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"oxcarbazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"midazolam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"magnesium hydroxide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"pantoprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"nevirapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"ritonavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"pan","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"ethinyl estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"magnesium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"pifeltro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"elbasvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"grazoprevir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doravirine","ingredient2":"dolutegravir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Consult the full prescribing information prior to and during treatment for important potential drug-drug interactions. (4, 5. 2, 7) 7. 1 Effect of Other Drugs on PIFELTRO Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy see Contraindications (4), Warnings and Precautions (5. 2), and Clinical Pharmacology (12. 3). Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine. Table 6 shows significant drug interactions with PIFELTRO. Table 6: Drug Interactions with PIFELTROThis table is not all inclusive. Concomitant Drug Class: Drug Name Effect on Concentration Clinical Comment   increase, decreaseAll other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. Androgen Receptors enzalutamide  doravirine Co-administration is contraindicated with enzalutamide. At least a 4-week","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"antipyrine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"zomacton","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"prednisone","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"eru","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"ros","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"gre","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"glyce","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"others","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 7 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZOMACTON and instructions for preventing or managing them. Table 7: Clinically Important Drug Interactions with ZOMACTON Glucocorticoids Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. ZOMACTON inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of ZOMACTON may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of ZOMACTONseeWarnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be affected more than others since c","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine sodium","ingredient2":"ermeza","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See full prescribing information for drugs that affect thyroid hormone pharmacokinetics (e. G. , absorption, synthesis, secretion, metabolism, protein binding, and target tissue response) and may alter the therapeutic response to ERMEZA. (7) 7. 1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics (e. G. , absorption, synthesis, secretion, metabolism, protein binding, and target tissue response) and may alter the therapeutic response to ERMEZA (Tables 5 to 8). Table 5. Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of ERMEZA by binding and delaying or preventing absorption, potentially resulting in hypothyroidism. Drug or Drug Class Effect Phosphate Binders (e. G. , calcium carbonate, ferrous sulfate, sevelamer, lanthanum) Phosphate binders may bind to levothyroxine. Administer ERMEZA at least 4 hours apart from these agents. Orlistat ","recommendation":"Monitor patients treated concomitantly with orlistat and ERMEZA for changes in thyroid function.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diltiazem hydrochloride","ingredient2":"betablockers","severity":"severe","severity_confidence":0.9,"effect":"Interactions Because of the potential for additive effects, slow titration is warranted inpatients receiving diltiazem hydrochloride concomitantly with other agents known to affect cardiac contractility and/or conduction see Warnings. Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using betablockers or digitalis concomitantly with diltiazem hydrochloride extendedrelease capsules see Warnings. Diltiazem is both a substrate and an inhibitor of the cytochrome P450 3A4 enzyme system. Other drugs that are specific substrates, inhibitors, orinducers of this enzyme system may have a significant impact on the efficacy and side effect profile of diltiazem. Patients taking other drugsthat are substrates of CYP450 3A4, especially patients with renal and/or hepatic impairment, may require dosage adjustment when starting orstopping concomitantly administered diltiazem in order to maintain optimum therapeutic blood levels. Anesthetics: The depressi","recommendation":"Should be based on clinical assessment.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"monoamine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"cla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"mao inhibitors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxymetazoline hydrochloride ophthalmic","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Anti-hypertensives/Cardiac Glycosides Alpha-adrenergic agonists, as a class, may impact blood pressure. Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised. Caution should also be exercised in patients receiving alpha adrenergic receptor antagonists such as in the treatment of cardiovascular disease, or benign prostatic hypertrophy. 7. 2 Monoamine Oxidase Inhibitors Caution is advised in patients taking MAO inhibitors which can affect the metabolism and uptake of circulating amines.","recommendation":"Caution in using drugs such as beta-blockers, anti-hypertensives, and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"corticosteroids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"mercaptopurine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"tar","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"azathioprine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"natalizumab","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"tyruko","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"cyclosporin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"natalizumab-sztn","ingredient2":"methotrexate","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Because of the potential for increased risk of PML and other infections, Crohns disease patients receiving natalizumab products should not be treated with concomitant immunosuppressants (e. G. , 6 mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-Î±, and corticosteroids should be tapered in those patients with Crohns disease who are on chronic corticosteroids when they start TYRUKO therapy see Indications and Usage (1. 2) and Warnings and Precautions (5. 1, 5. 6). Ordinarily, MS patients receiving chronic immunosuppressant or immunomodulatory therapy should not be treated with TYRUKO see Indications and Usage (1. 1) and Warnings and Precautions (5. 1, 5. 6).","recommendation":"Should not be treated with concomitant immunosuppressants (e.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"reslizumab","ingredient2":"cinqair","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal clinical drug interaction studies have been performed with CINQAIR.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"reslizumab","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal clinical drug interaction studies have been performed with CINQAIR.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"reslizumab","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal clinical drug interaction studies have been performed with CINQAIR.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"vonoprazan fumarate","ingredient2":"iron","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"itraconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"cilostazol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"amoxicillin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"co-administered","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"neuroendocrine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"pea","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"citalopram","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"dasatinib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"voquezna","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"clopidogrel","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"erlotinib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"rilpivirine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"nilotinib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"phenol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"clarithromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"iga","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"mycophenolate mofetil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"vonoprazan","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vonoprazan fumarate","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 9 and Table 10 include drugs with clinically important drug interactions and interaction with diagnostics when administered concomitantly with VOQUEZNA and instructions for preventing or managing them. These recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12. 3). Consult the labeling of concomitantly used drugs to obtain further information about interactions with vonoprazan. Table 9: Drug Interactions Affecting Drugs Co-Administered with VOQUEZNA and Interactions with Diagnostics Drugs Dependent on Gastric pH for Absorption Antiretrovirals Clinical Effect Vonoprazan reduces intragastric acidity see Clinical Pharmacology (12. 2), which may alter the absorption of antiretroviral drugs, leading to changes in the safety and/or effectiveness. Prevention or Management Rilpivirine-containing pro","recommendation":"Recommendations are based on either drug interaction trials or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cosyntropin","ingredient2":"iron","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: oAccuracy of the test results can be affected by concomitant medications. OGlucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing. (7) oEstrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before cosyntropin for injection testing. (7) 7. 1 Drug Effects on Plasma Cortisol Levels Accuracy of the test results can be affected by concomitant medications. Plasma cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels see Dosage and Administration (2. 1) and Warnings and Precautions (5. 2). Glucocortico","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cosyntropin","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: oAccuracy of the test results can be affected by concomitant medications. OGlucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing. (7) oEstrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before cosyntropin for injection testing. (7) 7. 1 Drug Effects on Plasma Cortisol Levels Accuracy of the test results can be affected by concomitant medications. Plasma cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels see Dosage and Administration (2. 1) and Warnings and Precautions (5. 2). Glucocortico","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cosyntropin","ingredient2":"spironolactone","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: oAccuracy of the test results can be affected by concomitant medications. OGlucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing. (7) oEstrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before cosyntropin for injection testing. (7) 7. 1 Drug Effects on Plasma Cortisol Levels Accuracy of the test results can be affected by concomitant medications. Plasma cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels see Dosage and Administration (2. 1) and Warnings and Precautions (5. 2). Glucocortico","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cosyntropin","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drug effects on plasma cortisol levels: oAccuracy of the test results can be affected by concomitant medications. OGlucocorticoids and spironolactone: May falsely elevate plasma cortisol levels. Stop these drugs on day of cosyntropin for injection testing. Long-acting glucocorticoids may need to be stopped for a longer period before cosyntropin for injection testing. (7) oEstrogen: May elevate plasma total cortisol levels. Stop estrogen containing drugs 4 to 6 weeks before cosyntropin for injection testing. (7) 7. 1 Drug Effects on Plasma Cortisol Levels Accuracy of the test results can be affected by concomitant medications. Plasma cortisol levels and subsequent diagnosis of adrenocortical insufficiency following cosyntropin for injection administration may be inaccurate if patients are on certain medications because of their effect on cortisol or cortisol binding globulin levels see Dosage and Administration (2. 1) and Warnings and Precautions (5. 2). Glucocortico","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"metoprolol","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"ofloxacin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"salicylic","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"salicylic a","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"hydrochlorothiazide","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"losartan","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"furosemide","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"omeprazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"digoxin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"ros","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"nifedipine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"ciprofloxacin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"pea","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"sali","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"pine o","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"salicylic acid","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"quinidine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"acetylsalicylic acid","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"levothyroxine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"doxycycline","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"warfarin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"rose","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"thyroxine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"ala","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"enalapril","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sucroferric oxyhydroxide","ingredient2":"calcitriol","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 1 Oral drugs that can be administered concomitantly with Velphoro Calcitriol Ciprofloxacin Digoxin Enalapril Furosemide HMG-CoA reductase inhibitors Hydrochlorothiazide Losartan Metoprolol Nifedipine Omeprazole Quinidine Warfarin Oral drugs that are to be separated from Velphoro Dosing Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro. Levothyroxine Take at least 4 hours before Velphoro Velphoro can be administered concomitantly with oral calcitriol, ciprofloxacin, digoxin, enalapril, furosemide, HMGCoA reductase inhibitors, hydrochlorothiazide, losartan, metoprolol, nifedipine, omeprazole, quinidine and warfarin. ( 7) Take acetylsalicylic acid, cephalexin and doxycycline at least 1 hour before Velphoro. ( 7) Take levothyroxine at least 4 hours before Velphoro. ( 7) For oral medications not listed above where a reduction of bioavailability would be clinically significant consider separation of the timing of admini","recommendation":"Recommendations Doxycycline Acetylsalicylic acid Cephalexin Take at least 1 hour before Velphoro.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibric acid","ingredient2":"statins","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 2 presents clinically important drug interactions with Trilipix. Table 2. Clinically Important Drug Interactions with Trilipix Statins Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins. Intervention: Consider if the benefit of using Trilipix concomitantly with statin therapy outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with Trilipix outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs an","recommendation":"Monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibric acid","ingredient2":"statin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 2 presents clinically important drug interactions with Trilipix. Table 2. Clinically Important Drug Interactions with Trilipix Statins Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with statins. Intervention: Consider if the benefit of using Trilipix concomitantly with statin therapy outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with fenofibrates. Intervention: Consider if the benefit of using colchicine concomitantly with Trilipix outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs an","recommendation":"Monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dosage titration of statin therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"palivizumab","ingredient2":"prop","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"palivizumab","ingredient2":"corticosteroids","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"palivizumab","ingredient2":"mental","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"palivizumab","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"palivizumab","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"palivizumab","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine, bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"methylprednisolone","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS The pharmacokinetic interactions listed below are potentially clinically important. Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; therefore, it is possible that adverse events associated with the individual use of either drug may be more apt to occur. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of methylprednisolone and may require increases in methylprednisolone dose to achieve the desired response. Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. Therefore, the dose of methylprednisolone should be titrated to avoid steroid toxicity. Methylprednisolone may increase the clearance of chronic high dose aspirin. This could lead to decreased salicylate serum levels or increase the risk of sali","recommendation":"Should be titrated to avoid steroid toxicity.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"ellipta","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"copd","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"monoamine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"oat","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"vilanterol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"fluticasone furoate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"trelegy","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"fluticasone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"beta-blockers","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"choline","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"corticosteroid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fluticasone furoate, umeclidinium bromide and vilanterol trifenatate","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong cytochrome P450 3A4 inhibitors (e. G. , ketoconazole): Use with caution. May cause systemic corticosteroid and cardiovascular effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of vilanterol on cardiovascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of TRELEGY ELLIPTA with other anticholinergic-containing drugs. (7. 5) 7. 1 Inhibitors of Cytochrome P450 3A4 Fluticasone furoate and vilanterol are substrates of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the system","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methylphenidate hydrochloride","ingredient2":"metadate","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 3 presents clinically important drug interactions with METADATE CD. Table 3: Clinically Important Drug Interactions with METADATE CD Monoamine Oxidase Inhibitors (MAOI) Clinical Impact: Concomitant use of MAOIs and CNS stimulants, including METADATE CD, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure see Contraindications ( 4). Intervention: Concomitant use of METADATE CD with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOI treatment is contraindicated. Antihypertensive Drugs Clinical Impact: METADATE CD may decrease the effectiveness of drugs used to treat hypertension see Warnings and Precautions ( 5. 3). Intervention: Adjust the dosage of the antihypertensive drug as needed. Halogenated Anesthetics Clinical Impact: Concomitant use of halogenated anesthetics and METADATE CD may increa","recommendation":"Contraindications ( 4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bupropion hydrochloride","ingredient2":"wellbutrin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS CYP2B6 inducers: Dose increase may be necessary if coadministered with CYP2B6 inducers (e. G. , ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin) based on clinical response, but should not exceed the maximum recommended dose. (7. 1) Drugs metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e. G. , venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e. G. , haloperidol, risperidone, thioridazine), beta-blockers (e. G. , metoprolol), and Type 1C antiarrhythmics (e. G. , propafenone, flecainide). Consider dose reduction when using with bupropion. (7. 2) Digoxin: May decrease plasma digoxin levels. Monitor digoxin levels. (7. 2) Drugs that lower seizure threshold: Dose WELLBUTRIN SR with caution. (5. 3, 7. 3) Dopaminergic drugs (levodopa and amantadine): CNS toxicity can occur when used concomitantly with WELLBUTRIN SR. (7. 4) MAOIs: Increa","recommendation":"Should not exceed the maximum recommended dose.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"liposom","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"doxorubicin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"chlorid","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"liposome","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"chloride","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride liposome","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"lumateperone","ingredient2":"caplyta","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"sert","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"ssri","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"pan","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"lumateperone","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS CYP3A4 inducers: Avoid concomitant use with CAPLYTA. (7. 1) Strong CYP3A4 inhibitors: Recommended dosage is 10. 5 mg once daily. (2. 2, 7. 1) Moderate CYP3A4 inhibitors: Recommended dosage is 21 mg once daily. (2. 2, 7. 1) 7. 1 Drugs Having Clinically Important Interactions with CAPLYTA Clinically important drug interactions with CAPLYTA are presented in Table 6. Table 6: Clinically Important Drug Interactions with CAPLYTA CYP3A4 Inducers Prevention or Management Avoid concomitant use of CAPLYTA with CYP3A4 inducers. Clinical Impact Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone see Clinical Pharmacology ( 12. 3 ). Moderate or Strong CYP3A4 Inhibitors Prevention or Management Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors see Dosage and Administration ( 2. 2 ). Clinical Impact Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure see Cl","recommendation":"Avoid concomitant use with CAPLYTA.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"cmax-maximum","severity":"contraindicated","severity_confidence":1.0,"effect":"DRUG INTERACTIONS Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of Rifabutin may need to be reduced when it is coadministered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity o","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"rifabutin","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"DRUG INTERACTIONS Effect of Rifabutin on the Pharmacokinetics of Other Drugs Rifabutin induces CYP3A enzymes and therefore may reduce the plasma concentrations of drugs metabolized by those enzymes. This effect may reduce the efficacy of standard doses of such drugs, which include itraconazole, clarithromycin, and saquinavir. Effect of Other Drugs on Rifabutin Pharmacokinetics Some drugs that inhibit CYP3A may significantly increase the plasma concentration of rifabutin. Therefore, carefully monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin. In some cases, the dosage of Rifabutin may need to be reduced when it is coadministered with CYP3A inhibitors. Table 2 summarizes the results and magnitude of the pertinent drug interactions assessed with rifabutin. The clinical relevance of these interactions and subsequent dose modifications should be judged in light of the population studied, severity o","recommendation":"Monitor for rifabutin associated adverse events in those patients also receiving CYP3A inhibitors, which include fluconazole and clarithromycin.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"tizanidine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"itraconazole","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"phenobarbital","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"carbamazepine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"isturisa","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"cla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"clarithromycin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"theophylline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"osilodrostat","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitor: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor (7. 1) CYP3A4 and CYP2B6 Inducers: An increase of ISTURISA dosage may be needed if ISTURISA is used concomitantly with strong CYP3A4 and CYP2B6 inducers. A reduction in ISTURISA dosage may be needed if strong CYP3A4 and CYP2B6 inducers are discontinued while using ISTURISA (7. 1) 7. 1 Effect of Other Drugs on ISTURISA The effect of other drugs on ISTURISA can be found in Table 3. Table 3: Effect of Other Drugs on ISTURISA CYP3A4 Inhibitors Clinical Impact: Concomitant use of ISTURISA with a strong CYP3A4 inhibitor (e. G. , itraconazole, clarithromycin) may cause an increase in osilodrostat concentration and may increase the risk of ISTURISA-related adverse reactions see Clinical Pharmacology (12. 3). Intervention: Reduce the dose of ISTURISA by half with concomitant use of a strong CYP3A4 inhibitor. CYP3A4 and CYP2B6 Inducers Clinical Impact: Concomitant use of IS","recommendation":"Monitor cortisol concentration and patients signs and symptoms.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"erythromycin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"itraconazole","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"phenobarbital","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"sage","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"carbamazepine","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"protein","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"verapamil","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"vera","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"fat","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"but","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"rifampicin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"ritonavir","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"amiodarone","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"gilotrif","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"tacrolimus","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"ketoconazole","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"cyclosporin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"afatinib","ingredient2":"phenytoin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS P-glycoprotein (P-gp) Inhibitors: Co-administration of P-gp inhibitors can increase afatinib exposure. Reduce GILOTRIF by 10 mg per day if not tolerated. (2. 5, 7) P-gp Inducers: Co-administration of chronic P-gp inducers orally can decrease afatinib exposure. Increase GILOTRIF by 10 mg per day as tolerated. (2. 5, 7) Effect of P-glycoprotein (P-gp) Inhibitors and Inducers Concomitant taking of P-gp inhibitors (including but not limited to ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir, and amiodarone) with GILOTRIF can increase exposure to afatinib see Clinical Pharmacology (12. 3). Reduce GILOTRIF daily dose as recommended see Dosage and Administration (2. 5). Concomitant taking of P-gp inducers (including but not limited to rifampicin, carbamazepine, phenytoin, phenobarbital, and St. Johns wort) with GILOTRIF can decrease exposure to afatinib see Clinical Pharmacology (12. 3). Increase","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tiotropium bromide","ingredient2":"spiriva","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs. (7. 2) 7. 1 Sympathomimetics, Methylxanthines, Steroids SPIRIVA HANDIHALER has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids without increases in adverse reactions. 7. 2 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5) and Adverse Reactions (6).","recommendation":"Avoid administration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"tiotropium bromide","ingredient2":"handihaler","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs. (7. 2) 7. 1 Sympathomimetics, Methylxanthines, Steroids SPIRIVA HANDIHALER has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids without increases in adverse reactions. 7. 2 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid coadministration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5) and Adverse Reactions (6).","recommendation":"Avoid administration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"corticosteroids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"protein","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"valproic acid","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"probenecid","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"haloperidol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"ravicti","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"midazolam","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"pagn","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"cyclosporin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glycerol phenylbutyrate","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Corticosteroids, valproic acid, or haloperidol: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May affect renal excretion of metabolites of RAVICTI, including phenylacetylglutamine (PAGN) and PAA. (7. 2) CYP3A4 Substrates with narrow therapeutic index (e. G. , alfentanil, quinidine, cyclosporine): RAVICTI may decrease exposure; monitor for decreased efficacy of the narrow therapeutic index drug. (7. 3) Midazolam: Decreased exposure; monitor for suboptimal effect of midazolam. (7. 3) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Monitor ammonia levels closely when corticosteroids and RAVICTI are used concomitantly. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor ammonia levels closely when use of valproic acid or haloperidol is necessary in patients with UC","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"fos","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"rosuvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"amitriptyline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"salmeterol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"fentanyl","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"uspi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"diazepam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"dronedarone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"tramadol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"corticosteroids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"tadalafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"lamotrigine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"desonide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ciclesonide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"venetoclax","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"eru","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"simeprevir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"dasatinib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"glycer","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"rutin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"vera","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"clarithromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"dexamethasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"lovastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"colchicine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"fluoxetine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"darunavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"adcirca","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"theophylline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"propafenone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"glyceri","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ergotamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"tacrolimus","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"timolol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"metoprolol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"hypericum","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"apalutamide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"atorvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"vardenafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"protein","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"prednisone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"abemaciclib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"nifedipine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"paroxetine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"non-nucleoside","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"budesonide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"mometasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"sildenafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"cisapride","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"trazodone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"quinine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ethosuximide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ethinyl estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"beclomethasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"triglyceride","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"thioridazine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"bosentan","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"calcium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"pimozide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"vincristine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"risperidone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"diltiazem","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"iron","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"rivaroxaban","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"itraconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"prop","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"clcr","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"lysi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"verapamil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"simvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"pea","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ranolazine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"anticoagulant","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"buspirone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"quetiapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"prednisolone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"bedaquiline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"glyce","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"tar","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"midazolam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"norvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"lidocaine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"warfarin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ibrutinib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"mometason","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"amiodarone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"methylprednisolone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"lurasidone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"protease","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"alfuzosin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"mttp","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"clonazepam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"bupropion","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ergotamin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"avanafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"nilotinib","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"50 mg","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"voriconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"fluticasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"triamcinolone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"betamethasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"beta-blockers","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"cyclosporin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"perphenazine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ritonavir","ingredient2":"sirolimus","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS When co-administering NORVIR with other protease inhibitors (atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir), see the full prescribing information for that protease inhibitor including important information for drug interactions. Co-administration of NORVIR can alter the concentrations of other drugs. The potential for drug-drug interactions must be considered prior to and during therapy (4, 5. 1, 7, 12. 3) 7. 1 Potential for NORVIR to Affect Other Drugs Ritonavir is an inhibitor of cytochrome P450 3A (CYP3A) and may increase plasma concentrations of agents that are primarily metabolized by CYP3A. Agents that are extensively metabolized by CYP3A and have high first pass metabolism appear to be the most susceptible to large increases in AUC (greater than 3-fold) when co-administered with ritonavir. Thus, co-administration of NORVIR with drugs highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with ser","recommendation":"Must be considered prior to and during therapy (4, 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"histamine","ingredient2":"whea","severity":"severe","severity_confidence":0.9,"effect":"(2) Drug Interactions: Certain medications may lessen the skin test wheal and erythema responses elicited by histamine for varying time periods. Conventional antihistamines should be discontinued at least 5 days before skin testing. Long acting antihistamines should be discontinued for at least 3 weeks prior to skin testing. 7 Topical steroids should be discontinued at the skin test site for at least 2-3 weeks before skin testing. 7, 8 Tricyclic antidepressants such as Doxepin should be withheld for at least 7 days before skin testing. 9 The physician must determine whether the risk of severe depression occurring in patients who discontinue their medication outweighs the benefits that could be obtained from skin testing. Topical local anesthetics may suppress the flare responses and should be avoided in skin test sites. 10","recommendation":"Should be discontinued at least 5 days before skin testing.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metronidazole","ingredient2":"carbamazepine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions  Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metronidazole","ingredient2":"uracil","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions  Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metronidazole","ingredient2":"amiodarone","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions  Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metronidazole","ingredient2":"fluorouracil","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions  Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metronidazole","ingredient2":"tacrolimus","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions  Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metronidazole","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions  Disulfiram Psychotic reactions and confusion have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Do not administer Metronidazole Injection to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, tachycardia and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy. Discontinue consumption of alcohol or products containing propylene glycol before, during and up to 72 hours after therapy with Metronidazole Injection (see CONTRAINDICATIONS). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time and increased risk of hemorrhages. When Metronidazole Injection is prescribed for patients on this ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"salicylate","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"alcohol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"anis","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"sali","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"anticoagulant","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"contraindications","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"cyclosporine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"salicylates","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"sulfur","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"anticoagulants","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"griseofulvin","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Griseofulvin has been reported in the literature to interfere with the metabolism of various compounds. Whether this is due to a P-450 mediated enzyme induction effects on sulfurtransferase and/or glucotransferase activity, or some other mechanism is unknown. Griseofulvin decreases the activity of warfarin-type anticoagulants, so that patients receiving these drugs concomitantly may require dosage adjustment of the anticoagulant during and after griseofulvin therapy. Griseofulvin may enhance the hepatic metabolism of estrogens, including the estrogen component of oral contraceptives, thereby reducing the effectiveness of contraception and causing menstrual irregularities. Therefore, an alternate or second form of birth control may be indicated during periods of concurrent use (see also CONTRAINDICATIONS ). Cyclosporine levels may be reduced when administered concomitantly with griseofulvin, resulting in a decrease in the pharmacologic effects of cyclosporine. Serum sa","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"budesonide and formoterol fumarate dihydrate","ingredient2":"formoterol fumarate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2-agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. No formal drug interaction studies have been performed with budesonide and formoterol fumarate dihydrate. Strong cytochrome P450 3A4 inhibitors (e. G. , ritonavir): Use with caution. May cause increased systemic corticosteroid effects. (7. 1) Monoamine oxidase inhibitors and tricyclic antidepressants: Use with extreme caution. May potentiate effect of formoterol on vascular system. (7. 2) Beta-blockers: Use with caution. May block bronchodilatory effects of beta-agonists and produce severe bronchospasm. (7. 3) Diuretics: Use with caution. Electrocardiographic changes and/or hypokalemia associated with non-potassium-sparing diuretics may worsen with concomitant beta-agonists. (7. 4) 7. 1 Inhibito","recommendation":"Caution.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"erythromycin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"pirfenidone","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"vegfr","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"ofev","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"carbamazepine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"protein","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"rifampicin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"anticoagulants","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"ketoconazole","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"bosentan","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"phenytoin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nintedanib","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Coadministration of P-gp and CYP3A4 inhibitors may increase nintedanib exposure. Monitor patients closely for tolerability of OFEV. (7. 1) 7. 1 P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4 see Clinical Pharmacology (12. 3). Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e. G. , erythromycin) with OFEV may increase exposure to nintedanib see Clinical Pharmacology (12. 3). In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV see Dosage and Administration (2. 4). Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e. G. , carbamazep","recommendation":"Monitor patients closely for tolerability of OFEV.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"fetzima","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"iron","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"itraconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"nsaids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"aspirin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"tranylcypromine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"anticoagulant","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"buspirone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"clarithromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"warfarin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"methylene blue","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"linezolid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levomilnacipran hydrochloride","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 inhibitors: Maximum recommended dosage is 80 mg once daily (7). 7. 1 Drugs Having Clinically Important Interactions with FETZIMA Table 5 includes clinically important drug interactions with FETZIMA. Table 5: Clinically Important Drug Interactions with FETZIMA Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact: Concomitant use of SSRIs and SNRIs including FETZIMA with MAOIs increases the risk of serotonin syndrome. Intervention: Concomitant use of FETZIMA is contraindicated: With an MAOI intended to treat psychiatric disorders or within 7 days of stopping treatment with FETZIMA. Within 14 days of stopping an MAOI intended to treat psychiatric disorders In a patient who is being treated with linezolid or intravenous methylene blue see Dosage and Administration ( 2. 5, 2. 6 ), Contraindications ( 4 ), and Warnings and Precautions ( 5. 2 ). Examples: selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue Other Serotonergic Drug","recommendation":"Contraindications ( 4 ), and Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ropinirole","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Inhibitors or inducers of CYP1A2: May alter the clearance of ropinirole hydrochloride; dose adjustment of ropinirole hydrochloride may be required. ( 7. 1, 12. 3) Hormone replacement therapy (HRT): Starting or stopping HRT may require dose adjustment of ropinirole hydrochloride. ( 7. 2, 12. 3) Dopamine antagonists (e. G. , neuroleptics, metoclopramide): May reduce efficacy of ropinirole hydrochloride. ( 7. 3) 7. 1 Cytochrome P450 1A2 inhibitors and inducers In vitrometabolism studies showed that CYP1A2 is the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with ropinirole hydrochloride, adjustment of the dose of ropinirole hydrochloride may be required. Coadministration of ciprofloxacin, an inhibitor of CYP1A2, increases the A","recommendation":"Dose adjustment of ropinirole hydrochloride may be required.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ropinirole","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Inhibitors or inducers of CYP1A2: May alter the clearance of ropinirole hydrochloride; dose adjustment of ropinirole hydrochloride may be required. ( 7. 1, 12. 3) Hormone replacement therapy (HRT): Starting or stopping HRT may require dose adjustment of ropinirole hydrochloride. ( 7. 2, 12. 3) Dopamine antagonists (e. G. , neuroleptics, metoclopramide): May reduce efficacy of ropinirole hydrochloride. ( 7. 3) 7. 1 Cytochrome P450 1A2 inhibitors and inducers In vitrometabolism studies showed that CYP1A2 is the major enzyme responsible for the metabolism of ropinirole. There is thus the potential for inducers or inhibitors of this enzyme to alter the clearance of ropinirole. Therefore, if therapy with a drug known to be a potent inducer or inhibitor of CYP1A2 is stopped or started during treatment with ropinirole hydrochloride, adjustment of the dose of ropinirole hydrochloride may be required. Coadministration of ciprofloxacin, an inhibitor of CYP1A2, increases the A","recommendation":"Dose adjustment of ropinirole hydrochloride may be required.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"busulfan","ingredient2":"busulfex","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs that decrease BUSULFEX clearance: Metronidazole, itraconazole, iron chelating agents, acetaminophen. (7. 1) Drugs that increase BUSULFEX clearance: Phenytoin. (7. 2) 7. 1 Drugs that Decrease BUSULFEX Clearance Itraconazole decreases busulfan clearance by up to 25%. Metronidazole decreases the clearance of busulfan to a greater extent than does itraconazole; metronidazole coadministration has been associated with increased busulfan toxicity. Fluconazole (200 mg) has been used with BUSULFEX. Decreased clearance of busulfan was observed with concomitant use with deferasirox. The mechanism of this interaction is not fully elucidated. Discontinue iron chelating agents well in advance of administration of BUSULFEX to avoid increased exposure to busulfan. Because busulfan is eliminated from the body via conjugation with glutathione, use of acetaminophen prior to (less than 72 hours) or concurrent with BUSULFEX may result in reduced busulfan clearance based upon the k","recommendation":"Avoid increased exposure to busulfan.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"magnesi","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"anis","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"probenecid","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"magnesium trisilicate","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"nitrofurantoin","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"sulfinpyrazone","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"magnesium","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitrofurantoin oral suspension","ingredient2":"silica","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Antacids containing magnesium trisilicate, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption. The mechanism for this interaction probably is adsorption of nitrofurantoin onto the surface of magnesium trisilicate. Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract antibacterial.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"oxycodone hydrochloride and acetaminophen","ingredient2":"chlorid","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Inhibitors of CYP3A4 and CYP2D6 The concomitant use of oxycodone hydrochloride and acetaminophen oral solution and CYP3A4 inhibitors, such as macrolide antibiotics (e. G. , erythromycin), azole-antifungal agents (e. G. Ketoconazole), and protease inhibitors (e. G. , ritonavir), can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of oxycodone hydrochloride and acetaminophen oral solution and CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of oxycodone hydrochloride and acetaminophen oral solution is achieved see WARNINGS. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease see CLINICAL PHARMACOLOGY, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oxycodone hydrochloride and acet","recommendation":"CAUTIONS; Information for Patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxycodone hydrochloride and acetaminophen","ingredient2":"chloride","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Inhibitors of CYP3A4 and CYP2D6 The concomitant use of oxycodone hydrochloride and acetaminophen oral solution and CYP3A4 inhibitors, such as macrolide antibiotics (e. G. , erythromycin), azole-antifungal agents (e. G. Ketoconazole), and protease inhibitors (e. G. , ritonavir), can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of oxycodone hydrochloride and acetaminophen oral solution and CYP3A4 and CYP2D6 inhibitors, particularly when an inhibitor is added after a stable dose of oxycodone hydrochloride and acetaminophen oral solution is achieved see WARNINGS. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease see CLINICAL PHARMACOLOGY, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to oxycodone hydrochloride and acet","recommendation":"CAUTIONS; Information for Patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capivasertib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce TRUQAP dose. (2. 5, 7. 1)  Moderate CYP3A Inhibitors: Reduce TRUQAP dose. (2. 5, 7. 1)  Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effects of Other Drugs on TRUQAP Table 6 describes drug interactions where concomitant use of another drug affects TRUQAP. Table 6: Drug Interactions with TRUQAP Strong CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Strong CYP3A inhibitors increase capivasertib exposure see Clinical Pharmacology (12. 3), which may increase the risk of TRUQAP adverse reactions. Prevention or Management Avoid concomitant use with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the dose of TRUQAP and monitor patients for adverse reactions see Dosage and Administration (2. 5). Moderate CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Moderate CYP3A inhibitors increase capivase","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capivasertib","ingredient2":"truqap","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce TRUQAP dose. (2. 5, 7. 1)  Moderate CYP3A Inhibitors: Reduce TRUQAP dose. (2. 5, 7. 1)  Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effects of Other Drugs on TRUQAP Table 6 describes drug interactions where concomitant use of another drug affects TRUQAP. Table 6: Drug Interactions with TRUQAP Strong CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Strong CYP3A inhibitors increase capivasertib exposure see Clinical Pharmacology (12. 3), which may increase the risk of TRUQAP adverse reactions. Prevention or Management Avoid concomitant use with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the dose of TRUQAP and monitor patients for adverse reactions see Dosage and Administration (2. 5). Moderate CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Moderate CYP3A inhibitors increase capivase","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capivasertib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce TRUQAP dose. (2. 5, 7. 1)  Moderate CYP3A Inhibitors: Reduce TRUQAP dose. (2. 5, 7. 1)  Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effects of Other Drugs on TRUQAP Table 6 describes drug interactions where concomitant use of another drug affects TRUQAP. Table 6: Drug Interactions with TRUQAP Strong CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Strong CYP3A inhibitors increase capivasertib exposure see Clinical Pharmacology (12. 3), which may increase the risk of TRUQAP adverse reactions. Prevention or Management Avoid concomitant use with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the dose of TRUQAP and monitor patients for adverse reactions see Dosage and Administration (2. 5). Moderate CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Moderate CYP3A inhibitors increase capivase","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capivasertib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS  Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use cannot be avoided, reduce TRUQAP dose. (2. 5, 7. 1)  Moderate CYP3A Inhibitors: Reduce TRUQAP dose. (2. 5, 7. 1)  Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effects of Other Drugs on TRUQAP Table 6 describes drug interactions where concomitant use of another drug affects TRUQAP. Table 6: Drug Interactions with TRUQAP Strong CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Strong CYP3A inhibitors increase capivasertib exposure see Clinical Pharmacology (12. 3), which may increase the risk of TRUQAP adverse reactions. Prevention or Management Avoid concomitant use with a strong CYP3A inhibitor. If concomitant use cannot be avoided, reduce the dose of TRUQAP and monitor patients for adverse reactions see Dosage and Administration (2. 5). Moderate CYP3A Inhibitors Clinical Impact Capivasertib is a CYP3A substrate. Moderate CYP3A inhibitors increase capivase","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selegiline hydrochloride","ingredient2":"chlorid","severity":"contraindicated","severity_confidence":1.0,"effect":"DRUG INTERACTIONS The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see CONTRAINDICATIONS ). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and selegiline hydrochloride capsules and selective serotonin reuptake inhibitors and selegiline hydrochloride capsules. (see WARNINGS for details. ) One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"selegiline hydrochloride","ingredient2":"chloride","severity":"contraindicated","severity_confidence":1.0,"effect":"DRUG INTERACTIONS The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see CONTRAINDICATIONS ). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and selegiline hydrochloride capsules and selective serotonin reuptake inhibitors and selegiline hydrochloride capsules. (see WARNINGS for details. ) One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"selegiline hydrochloride","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"DRUG INTERACTIONS The occurrence of stupor, muscular rigidity, severe agitation, and elevated temperature has been reported in some patients receiving the combination of selegiline and meperidine. Symptoms usually resolve over days when the combination is discontinued. This is typical of the interaction of meperidine and MAOIs. Other serious reactions (including severe agitation, hallucinations, and death) have been reported in patients receiving this combination (see CONTRAINDICATIONS ). Severe toxicity has also been reported in patients receiving the combination of tricyclic antidepressants and selegiline hydrochloride capsules and selective serotonin reuptake inhibitors and selegiline hydrochloride capsules. (see WARNINGS for details. ) One case of hypertensive crisis has been reported in a patient taking the recommended doses of selegiline and a sympathomimetic medication (ephedrine).","recommendation":"CONTRAINDICATIONS ).","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cetirizine hydrochloride","ingredient2":"chlorid","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect see Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cetirizine hydrochloride","ingredient2":"chloride","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect see Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cetirizine hydrochloride","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect see Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cetirizine hydrochloride","ingredient2":"quzyttir","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. There was a small decrease in the clearance of oral cetirizine hydrochloride caused by a 400-mg dose of theophylline; it is possible that larger theophylline doses could have a greater effect see Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"isopro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"diuretics","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"diclofenac sodium","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"furosemide","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"digoxin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"nsaids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"sodium","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"aspirin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"eru","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"ace inhibitors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"warfarin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"misoprostol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"rose","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"sodi","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium and misoprostol","ingredient2":"diuretic","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Drugs that Interfere with Hemostasis (e. G. Warfarin, aspirin, SSRIs/SNRIs): Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis. Concomitant use of diclofenac sodium and misoprostol and analgesic doses of aspirin is not generally recommended ( 7) ACE inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with diclofenac sodium and misoprostol may diminish the antihypertensive effect of these drugs. Monitor blood pressure ( 7) ACE Inhibitors and ARBs: Concomitant use with diclofenac sodium and misoprostol in elderly, volume depleted, or those with renal impairment may result in deterioration of renal function. In such high risk patients, monitor for signs of worsening renal function ( 7) Diuretics: NSAIDs can reduce natriuretic effect of furosemide and thiazide diuretics. Monitor patients to assure diuretic efficacy including antihypertensive effects ( 7) D","recommendation":"Monitor patients for bleeding who are concomitantly taking diclofenac sodium and misoprostol with drugs that interfere with hemostasis.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS Caution must be exercised in the administration of 0. 9% Sodium Chloride Injection, USP to patients receiving corticosteroids or corticotropin. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed with Sodium Chloride Injection, USP to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility. Pregnancy: Teratogenic Effects Pregnancy Category C Animal reproduction studies have not been conducted with Sodium Chloride Injection, USP. It is also not known whether Sodium Chloride Injection, USP can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium Chloride Injection, USP should be given to a pregnant woman only if clearly needed. Labor and Delivery Studies have not been conducted to evaluate the effects of Sodium Chloride Injection, USP on labor and delivery. Caution should be exercised when administering this drug during labor and delivery. Nursing Mothers It is not k","recommendation":"Caution must be exercised in the administration of 0.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"seroquel","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"itraconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"alcohol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"carbamazepine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"pine o","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"quetiapine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"dopamine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"ritonavir","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"choline","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"levodopa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"phenytoin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine extended-release","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one-sixth when co-administered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir). (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. , phenytoin, rifampin, St. Johns wort). (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5-fold within 7 to 14 days of discontinuation of CYP3A4 inducers. (2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor effects of ","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"salicylate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"indomethacin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"diclofenac sodium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"nabumetone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"anticoagulants","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"furosemide","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"propranolol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"aspirin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"diflunisal","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"meloxicam","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"sali","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"epinephrine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"ace inhibitors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"gla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"beta-blockers","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"rose","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"cyclosporine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"salicylates","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"methotrexate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"diuretic","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diclofenac sodium topical","ingredient2":"pemetrexed","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See Table 2for clinically significant drug interactions with diclofenac. Table 2: Clinically Significant Drug Interactions with Diclofenac Drugs That Interfere with Hemostasis Clinical Impact: Diclofenac and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of diclofenac and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e. G. , warfarin), antiplatelet agents (e. G. , aspirin), selective serotonin reuptake inhibitors (SSRIs), and serotonin norepinephrine reuptake inhibitors (SNRIs) for signs of bleeding se","recommendation":"Monitor patients with concomitant use of diclofenac sodium topical gel with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"lamivudine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"isotretinoin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"efavirenz","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"tretinoin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"viii","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"roctavian","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"corticosteroid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valoctocogene roxaparvovec-rvox","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Prior to ROCTAVIAN administration, the patients existing medications should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section. Concomitant medications should be monitored after ROCTAVIAN administration, and the need to change concomitant medications based on patients hepatic status and risk should be evaluated. When a new medication is started, close monitoring of ALT and factor VIII activity levels (e. G. , weekly to every 2 weeks for the first month) is recommended to assess potential effects on both levels. No in vivo interaction studies have been performed. 7. 1 Isotretinoin In one patient, decreased factor VIII activity without ALT elevation was detected after starting treatment with systemic isotretinoin following ROCTAVIAN infusion. Factor VIII activity was 75 IU/dL at Week 60 and transiently decreased to  3 IU/dL at Week 64, after initiating isotretinoin. After discontinuing isotretinoin at Week","recommendation":"Should be reviewed to determine if they should be modified to prevent anticipated interactions described in this section.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium","ingredient2":"fos","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. (2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of FOSAMAX and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of FOSAMAX. Therefore, instruct patients to wait at least one-half hour after taking FOSAMAX before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of FOSAMAX greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs FOSAMAX may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In a 3-year, controlled, clinical study (n20","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alendronate sodium","ingredient2":"fosamax","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Calcium supplements, antacids, or oral medications containing multivalent cations interfere with absorption of alendronate. (2. 6, 7. 1) Use caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation. (7. 2, 7. 3) 7. 1 Calcium Supplements/Antacids Co-administration of FOSAMAX and calcium, antacids, or oral medications containing multivalent cations will interfere with absorption of FOSAMAX. Therefore, instruct patients to wait at least one-half hour after taking FOSAMAX before taking any other oral medications. 7. 2 Aspirin In clinical studies, the incidence of upper gastrointestinal adverse events was increased in patients receiving concomitant therapy with daily doses of FOSAMAX greater than 10 mg and aspirin-containing products. 7. 3 Nonsteroidal Anti-Inflammatory Drugs FOSAMAX may be administered to patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). In a 3-year, controlled, clinical study (n20","recommendation":"Caution when co-prescribing aspirin/nonsteroidal anti-inflammatory drugs that may worsen gastrointestinal irritation.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"delandistrogene moxeparvovec-rokl","ingredient2":"gre","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Prior to initiating the corticosteroid regimen required before ELEVIDYS administration, consider the patients vaccination status. Patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines. Vaccinations should be completed at least 4 weeks prior to initiation of the corticosteroid regimen.","recommendation":"Should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"delandistrogene moxeparvovec-rokl","ingredient2":"elevidys","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Prior to initiating the corticosteroid regimen required before ELEVIDYS administration, consider the patients vaccination status. Patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines. Vaccinations should be completed at least 4 weeks prior to initiation of the corticosteroid regimen.","recommendation":"Should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"delandistrogene moxeparvovec-rokl","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Prior to initiating the corticosteroid regimen required before ELEVIDYS administration, consider the patients vaccination status. Patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines. Vaccinations should be completed at least 4 weeks prior to initiation of the corticosteroid regimen.","recommendation":"Should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"delandistrogene moxeparvovec-rokl","ingredient2":"corticosteroid","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Prior to initiating the corticosteroid regimen required before ELEVIDYS administration, consider the patients vaccination status. Patients should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines. Vaccinations should be completed at least 4 weeks prior to initiation of the corticosteroid regimen.","recommendation":"Should, if possible, be brought up to date with all immunizations in agreement with current immunization guidelines.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"etoposide phosphate","ingredient2":"etopophos","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Warfarin: Co-administration of ETOPOPHOS with warfarin can result in elevated international normalized ratio (INR). Measure INR frequently. Warfarin: Co-administration can result in elevated international normalized ratio (INR). Measure INR frequently. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etoposide phosphate","ingredient2":"warfarin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Warfarin: Co-administration of ETOPOPHOS with warfarin can result in elevated international normalized ratio (INR). Measure INR frequently. Warfarin: Co-administration can result in elevated international normalized ratio (INR). Measure INR frequently. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"etoposide phosphate","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Warfarin: Co-administration of ETOPOPHOS with warfarin can result in elevated international normalized ratio (INR). Measure INR frequently. Warfarin: Co-administration can result in elevated international normalized ratio (INR). Measure INR frequently. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sapropterin dihydrochloride","ingredient2":"kuvan","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 4 includes drugs with clinically important drug interactions when administered with sapropterin dihydrochloride and instructions for preventing or managing them. Table 4: Clinically Relevant Drug Interactions Levodopa Clinical Impact Sapropterin dihydrochloride may increase the availability of tyrosine, a precursor of levodopa. Neurologic events were reported postmarketing in patients receiving sapropterin and levodopa concomitantly for a non-PKU indication see Warnings and Precautions (5. 5). Intervention Monitor patients for a change in neurologic status. Inhibitors of Folate Synthesis (e. G. , methotrexate, valproic acid, phenobarbital, trimethoprim) Clinical Impact In vitro and in vivo nonclinical data suggest that drugs that inhibit folate synthesis may decrease the bioavailability of endogenous BH4 by inhibiting the enzyme dihydrofolate reductase, which is involved in the recycling (regeneration) of BH4. This reduction in net BH4 levels may increase Phe ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"coagulation factor viia recombinant human","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Clinical experience with pharmacologic use of FVIIa-containing products indicates an elevated risk of serious thrombotic events when used simultaneously with activated prothrombin complex concentrates. Clinical experience with pharmacologic use of FVIIa-containing products indicates an elevated risk of serious thrombotic events when used simultaneously with activated prothrombin complex concentrates (7).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"coagulation factor viia recombinant human","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Clinical experience with pharmacologic use of FVIIa-containing products indicates an elevated risk of serious thrombotic events when used simultaneously with activated prothrombin complex concentrates. Clinical experience with pharmacologic use of FVIIa-containing products indicates an elevated risk of serious thrombotic events when used simultaneously with activated prothrombin complex concentrates (7).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"tramadol hydrochloride","ingredient2":"pregabalin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 2 includes clinically significant drug interactions with tramadol hydrochloride extended-release tablets. Inhibitors of CYP2D6 Clinical Impact: The concomitant use of tramadol hydrochloride extended-release tablets and CYP2D6 inhibitors may result in an increase in the plasma concentration of tramadol and a decrease in the plasma concentration of M1, particularly when an inhibitor is added after a stable dose of tramadol hydrochloride extended-release tablets is achieved. Since M1 is a more potent Âµ-opioid agonist, decreased M1 exposure could result in decreased therapeutic effects, and may result in signs and symptoms of opioid withdrawal in patients who had developed physical dependence to tramadol. Increased tramadol exposure can result in increased or prolonged therapeutic effects and increased risk for serious adverse events including seizures and serotonin syndrome. After stopping a CYP2D6 inhibitor, as the effects of the inhibitor decline, the tramadol ","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"umeclidinium","ingredient2":"incruse","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs. (7. 1) 7. 1 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5).","recommendation":"Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"umeclidinium","ingredient2":"ellipta","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs. (7. 1) 7. 1 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5).","recommendation":"Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"umeclidinium","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs. (7. 1) 7. 1 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5).","recommendation":"Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"umeclidinium","ingredient2":"choline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs. (7. 1) 7. 1 Anticholinergics There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects see Warnings and Precautions (5. 4, 5. 5).","recommendation":"Avoid administration of INCRUSE ELLIPTA with other anticholinergic-containing drugs.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"leuprolide acetate","ingredient2":"drug-laboratory","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS 7. 1 Drug Interactions No pharmacokinetic-based drug-drug interaction studies have been conducted with LUPRON DEPOT-PED see C linical P harmacology ( 12. 3 ). 7. 2 Drug-Laboratory Test Interactions Administration of LUPRON DEPOT-PED in therapeutic doses results in suppression of the pituitary-gonadal system. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment and up to six months after discontinuation of LUPRON DEPOT-PED may be affected. Normal pituitary-gonadal function is usually restored within six months after treatment with LUPRON DEPOT-PED is discontinued.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"mumps","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"prednisone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"rubella","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"itvisma","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"onasemnogene abeparvovec-brve","ingredient2":"corticosteroid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection see Dosage and Administration (2. 1). Certain vaccines, such as measles, mumps, and rubella (MMR) and varicella, are contraindicated for patients on a substantially immunosuppressive steroid dose (i. E. , 2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent). Adjust patients vaccination schedule to accommodate concomitant corticosteroid administration prior to and following ITVISMA injection. (7)","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"doxorubicin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"chlorid","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"liposome","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"doxorubicin hydrochloride","ingredient2":"chloride","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No formal drug interaction studies have been conducted with doxorubicin hydrochloride liposome injection.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"losartan potassium and hydrochlorothiazide","ingredient2":"hyzaar","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing serum potassium: Risk of hyperkalemia. (7. 1) Lithium: Risk of lithium toxicity. (7. 2) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (7. 3) Dual inhibition of the renin-angiotensin system: increased risk of renal impairment, hypotension, syncope, and hyperkalemia. (7. 4) Antidiabetic drugs: dosage adjustment of antidiabetic may be required. (7. 5) Cholestyramine and colestipol: Reduced absorption of thiazides. (7. 5) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of angiotensin II receptor antagonists or thiazide diuretics. Monitor lithium levels in patients receiving HYZAAR and lithium. 7. 3 N","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"valproic acid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"probenecid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"pheburane","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"haloperidol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium phenylbutyrate","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Valproic Acid, Haloperidol, or Corticosteroids: May increase plasma ammonia level; monitor ammonia levels closely. (7. 1) Probenecid: May inhibit renal excretion of metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine; monitor for potential neurotoxicity. (7. 2) 7. 1 Potential for Other Drugs to Affect Ammonia Corticosteroids Use of corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels. Valproic Acid and Haloperidol Hyperammonemia may be induced by haloperidol and by valproic acid. Monitor plasma ammonia levels closely when corticosteroids, valproic acid, or haloperidol is used concomitantly with PHEBURANE. 7. 2 Potential for Other Drugs to Affect PHEBURANE Probenecid Probenecid may inhibit renal excretion of the metabolites of PHEBURANE including phenylacetate and phenylacetylglutamine. Monitor patients for potential neurotoxicity and measure plasma phenylacetate and phenylacetylglutamine levels when proben","recommendation":"Monitor ammonia levels closely.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"epcoritamab-bysp","ingredient2":"epkinly","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY. Epcoritamab-bysp causes release of cytokines see Clinical Pharmacology (12. 2) that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY and up to 14 days after the first 48 mg dose, and during and after CRS see Warnings and Precautions (5. 1).","recommendation":"Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"epcoritamab-bysp","ingredient2":"cytokines","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY. Epcoritamab-bysp causes release of cytokines see Clinical Pharmacology (12. 2) that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY and up to 14 days after the first 48 mg dose, and during and after CRS see Warnings and Precautions (5. 1).","recommendation":"Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"epcoritamab-bysp","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY. Epcoritamab-bysp causes release of cytokines see Clinical Pharmacology (12. 2) that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY and up to 14 days after the first 48 mg dose, and during and after CRS see Warnings and Precautions (5. 1).","recommendation":"Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"epcoritamab-bysp","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY. Epcoritamab-bysp causes release of cytokines see Clinical Pharmacology (12. 2) that may suppress activity of CYP enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of EPKINLY and up to 14 days after the first 48 mg dose, and during and after CRS see Warnings and Precautions (5. 1).","recommendation":"Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with EPKINLY.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"spironolactone","ingredient2":"aldactone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Agents increasing serum potassium: Concomitant administration can lead to hyperkalemia (5. 1, 7. 1). Lithium: Increased risk of lithium toxicity (7. 2). NSAIDs: May reduce the diuretic, natriuretic and antihypertensive effect of ALDACTONE (7. 3). Digoxin: ALDACTONE can interfere with radioimmunologic assays of digoxin exposure (7. 4). Cholestyramine: Hyperkalemic metabolic acidosis has been reported with concomitant use (7. 5). Acetylsalicylic Acid (ASA): ASA may reduce the efficacy of ALDACTONE (7. 6). Abiraterone: May increase prostate-specific antigen (PSA) levels (7. 7). Mitotane: Avoid concomitant use of ALDACTONE and mitotane (7. 8). 7. 1 Drugs and Supplements Increasing Serum Potassium Concomitant administration of ALDACTONE with potassium supplementation or drugs that can increase potassium may lead to severe hyperkalemia. In general, discontinue potassium supplementation in heart failure patients who start ALDACTONE see Warnings and Precautions (5. 1) and C","recommendation":"Avoid concomitant use of ALDACTONE and mitotane (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"diuretics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"vitamin d","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"corticosteroids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"vitami","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"sodium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"eru","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"vitamin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"calcium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"arginine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"ace inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"electrolytes","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"vita","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"potassium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"siadh","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"arginin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"sodi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, calcium chloride, and potassium chloride","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factors. Avoid use of Ringers Injection in patients receiving drugs that are associated with hyperkalemia (e. G. , potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antag","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"mycophenolate mofetil","ingredient2":"cellcept","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS See FPI for drugs that may interfere with systemic exposure and reduce CELLCEPT efficacy: antacids with magnesium or aluminum hydroxide, proton pump inhibitors, drugs that interfere with enterohepatic recirculation, telmisartan, calcium-free phosphate binders. (7. 1) CELLCEPT may reduce effectiveness of oral contraceptives. Use of additional barrier contraceptive methods is recommended. (7. 2) See FPI for other important drug interactions. (7) 7. 1 Effect of Other Drugs on CELLCEPT Table 7 Drug Interactions with CELLCEPT that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure see Clinical Pharmacology (12. 3), which may reduce CELLCEPT efficacy. Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after CELLCEPT administration. Proton Pump Inhibitors (PPIs) Clinica","recommendation":"Monitor patients for alterations in efficacy when PPIs are co-administered with CELLCEPT.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"stavudine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"lamivudine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"interferon-beta","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"zidovudine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"cilostazol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"nimodipine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"cumin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"interferon","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"nifedipine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"ribavirin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"curcumin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"rifampicin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"proteins","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"ritonavir","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"sulindac","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"dipyridamole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"bcrp","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"reserpine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cladribine","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Table 3 Drug Interactions with cladribine tablets 7. 1 Immunomodulatory, Immunosuppressive, or Myelosuppressive Drugs Clinical Impact Concomitant use of cladribine with immunomodulatory, immunosuppressive, or myelosuppressive drugs may increase the risk of adverse reactions because of the additive effects on the immune system see Warnings and Precautions (5. 4). Prevention or Management Concomitant use with myelosuppressive or other immunosuppressive drugs is not recommended. Acute short-term therapy with corticosteroids can be administered. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, the mode of action, and duration of effect of the other drugs prior to initiation of cladribine. 7. 2 Interferon-Beta Clinical Impact Concomitant use of cladribine with interferon-beta did not change the exposure of cladribine to a clinically significant effect; however, lymphopenia risk may be incre","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"precautions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4 Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules concomitantly or within 14 days after discontinuing MAOI see CONTRAINDICATIONS (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine asp","recommendation":"CONTRAINDICATIONS (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"contraindications","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4 Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules concomitantly or within 14 days after discontinuing MAOI see CONTRAINDICATIONS (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine asp","recommendation":"CONTRAINDICATIONS (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"overdosage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4 Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules concomitantly or within 14 days after discontinuing MAOI see CONTRAINDICATIONS (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine asp","recommendation":"CONTRAINDICATIONS (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate","ingredient2":"warnings","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Alkalinizing agents (GI antacids and urinary): These agents increase blood levels of amphetamine. (2. 7, 7. 1) Acidifying agents (GI and urinary): These agents reduce blood levels of amphetamine. (7. 1) 7. 1 Clinically Important Interactions with Amphetamines Table 4 Drugs Having Clinically Important Interactions with Amphetamines Monoamine Oxidase Inhibitors (MAOIs) Clinical Impact Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Intervention Do not administer dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate, amphetamine sulfate extended-release capsules concomitantly or within 14 days after discontinuing MAOI see CONTRAINDICATIONS (4). Serotonergic Drugs Clinical Impact The concomitant use of dextroamphetamine saccharate, amphetamine asp","recommendation":"CONTRAINDICATIONS (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"amphetamine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"lithium carbonate","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"methenamine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"precautions","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"norepinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"phenobarbital","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"prop","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"omeprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"haloperidol","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"contraindications","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"epinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"vera","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"overdosage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"meperidine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"dopamine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"ethosuximide","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"warnings","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"mao inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"chlorpromazine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"dextroamphetamine saccharate and amphetamine aspartate and dextroamphetamine sulfate and amphetamine sulfate","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions MAO Inhibitors Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Do not administer Mixed Salts of a Single Entity Amphetamine Product concomitantly or within 14 days after discontinuing MAOI (see CONTRAINDICATIONS and WARNINGS ). Serotonergic Drugs The concomitant use of Mixed Salts of a Single Entity Amphetamine Product and serotonergic drugs increases the risk of serotonin syndrome. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during Mixed Salts of a Single Entity Amphetamine Product initiation or dosage increase. If serotonin syndrome occurs, discontinue Mixed Salts of a Single Entity Amphetamine Product and the concomitant serotonergic drug(s) (see WARNINGS and PRECAUTIONS ). CYP2D6 Inhibitors The concomitant use of Mix","recommendation":"CONTRAINDICATIONS and WARNINGS ).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"acid-reducing","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"retevmo","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"bcrp","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"selpercatinib","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Acid-Reducing Agents: Avoid coadministration. If coadministration cannot be avoided, take RETEVMO with food (with PPI) or modify its administration time (with H2 receptor antagonist or locally-acting antacid). (2. 4, 7. 1) Strong and Moderate CYP3A Inhibitors: Avoid coadministration. If coadministration cannot be avoided, reduce the RETEVMO dose. (2. 6, 7. 1) Strong and Moderate CYP3A Inducers: Avoid coadministration. (7. 1) CYP2C8 and CYP3A Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) Certain P-gp and BCRP Substrates: Avoid coadministration. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling. (7. 2) 7. 1 Effects of Other Drugs on RETEVMO Acid-Reducing Agents Concomitant use of RETEVMO with acid-reducing agents decreases selpercatinib plasma concentrations see Clinical Pharmacology (12. 3), which may reduce R","recommendation":"Avoid coadministration.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"methylphenidate hydrochloride","ingredient2":"quillivant","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Antihypertensive Drugs: Monitor blood pressure. Adjust dosage of antihypertensive drug as needed. (7) 7. 1 Clinically Important Drug Interactions MAOI Inhibitors Do not administer QUILLIVANT XR concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOI treatment. Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Antihypertensive Drugs QUILLIVANT XR may decrease the effectiveness of drugs used to treat hypertension. Monitor blood pressure and adjust the dosage of the hypertensive drug as needed see Warnings and Precautions (5. 3). Halogenated Anesthetics Concomitant use of halogenated anesthetics and QUILLIVANT XR may increase the risk of sudden blood pressure and heart rate increase during surgery. Monitor blood pressure and avoid use of QUIL","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxycodone hydrochloride","ingredient2":"pregabalin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with Oxycodone Hydrochloride Oral Solution. Table 1: Clinically Significant Drug Interactions with Oxycodone Hydrochloride Oral Solution Inhibitors of CYP3A4 and CYP2D6 Clinical Impact: The concomitant use of Oxycodone Hydrochloride Oral Solution and CYP3A4 inhibitors can increase the plasma concentration of oxycodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Oxycodone Hydrochloride Oral Solution and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of Oxycodone Hydrochloride Oral Solution is achieved see Warnings and Precautions (5. 7). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the oxycodone plasma concentration will decrease see Clinical Pharmacology (12. 3), resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical d","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ranibizumab-nuna","ingredient2":"ranibizumab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with Photodynamic Therapy (PDT). Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days ( 2 days) after PDT.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ranibizumab-nuna","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with Photodynamic Therapy (PDT). Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days ( 2 days) after PDT.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ranibizumab-nuna","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with Photodynamic Therapy (PDT). Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days ( 2 days) after PDT.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ranibizumab-nuna","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with Photodynamic Therapy (PDT). Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days ( 2 days) after PDT.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ranibizumab-nuna","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drug interaction studies have not been conducted with ranibizumab products. Ranibizumab intravitreal injection has been used adjunctively with Photodynamic Therapy (PDT). Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days ( 2 days) after PDT.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sevoflurane","ingredient2":"adverse","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"pancuronium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"propofol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"anis","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"verapamil","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"calcium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"epinephrine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"mental","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"isoflurane","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"potassium hydroxide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"iga","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"pan","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"warnings","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"reactions","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"mao inhibitors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"choline","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"ala","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sevoflurane","ingredient2":"succinylcholine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions In clinical studies, no significant adverse reactions occurred with other drugs commonly used in the perioperative period, including central nervous system depressants, autonomic drugs, skeletal muscle relaxants, anti-infective agents, hormones and synthetic substitutes, blood derivatives, and cardiovascular drugs. Epinephrine Epinephrine administered with sevoflurane may increase the risk of ventricular arrhythmias. Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available. Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. Blood pressure should be closely monitored and emergency medications to treat hypotension should be readily available when calcium antagonists are used concomitantly with sevoflurane. In animals, impairment of atrioventricular conduction has been observed when verapamil and sevoflurane are administered concomitan","recommendation":"Monitor the electrocardiogram and blood pressure and ensure emergency medications to treat ventricular arrhythmias are readily available.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"fentanyl","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"pancuronium","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"beta blockers","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"calcium","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"mental","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"gre","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"adrenaline","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"pan","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"sevoflurane","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"mao inhibitors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"choline","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"ala","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"isoflurane","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Concomitant use of N 2O and/or opioids reduces the MAC of Isoflurane USP. Adjust dose accordingly. ( 7. 1, 7. 2)  Isoflurane USP decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. ( 7. 3) 7. 1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of isoflurane. Opioids such as fentanyl and its analogues, when combined with isoflurane, may lead to a synergistic fall in blood pressure and respiratory rate. 7. 2 Nitrous Oxide Nitrous oxide decreases the MAC of isoflurane see Dosage and Administration (2. 1). 7. 3 Neuromuscular Blocking Agents Isoflurane potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations isoflurane at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2O/opioid anesthesia. If adde","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"cytokines","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"corticosteroids","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"pea","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"vera","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"ustekinumab","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-srlf","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis, the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of ","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxaprozin","ingredient2":"clinical","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See TABLE 2 for clinically significant drug interactions with oxaprozin see CLINICAL PHARMACOLOGY (12. 3). Table 2: Clinically Significant Drug Interactions with Oxaprozin Drugs That Interfere with Hemostasis Clinical Impact: Oxaprozin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of oxaprozin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e. G. , warfarin), antiplatelet drugs (e. G. , aspirin), SSRIs, and SNRIs for signs of bleeding see WARNINGS AND PRECAUTIONS (5. 12). Aspirin Clinical Impact: Controlle","recommendation":"Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxaprozin","ingredient2":"capsules","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See TABLE 2 for clinically significant drug interactions with oxaprozin see CLINICAL PHARMACOLOGY (12. 3). Table 2: Clinically Significant Drug Interactions with Oxaprozin Drugs That Interfere with Hemostasis Clinical Impact: Oxaprozin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of oxaprozin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e. G. , warfarin), antiplatelet drugs (e. G. , aspirin), SSRIs, and SNRIs for signs of bleeding see WARNINGS AND PRECAUTIONS (5. 12). Aspirin Clinical Impact: Controlle","recommendation":"Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxaprozin","ingredient2":"precautions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See TABLE 2 for clinically significant drug interactions with oxaprozin see CLINICAL PHARMACOLOGY (12. 3). Table 2: Clinically Significant Drug Interactions with Oxaprozin Drugs That Interfere with Hemostasis Clinical Impact: Oxaprozin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of oxaprozin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e. G. , warfarin), antiplatelet drugs (e. G. , aspirin), SSRIs, and SNRIs for signs of bleeding see WARNINGS AND PRECAUTIONS (5. 12). Aspirin Clinical Impact: Controlle","recommendation":"Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxaprozin","ingredient2":"pharmacology","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See TABLE 2 for clinically significant drug interactions with oxaprozin see CLINICAL PHARMACOLOGY (12. 3). Table 2: Clinically Significant Drug Interactions with Oxaprozin Drugs That Interfere with Hemostasis Clinical Impact: Oxaprozin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of oxaprozin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e. G. , warfarin), antiplatelet drugs (e. G. , aspirin), SSRIs, and SNRIs for signs of bleeding see WARNINGS AND PRECAUTIONS (5. 12). Aspirin Clinical Impact: Controlle","recommendation":"Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"oxaprozin","ingredient2":"table","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS See TABLE 2 for clinically significant drug interactions with oxaprozin see CLINICAL PHARMACOLOGY (12. 3). Table 2: Clinically Significant Drug Interactions with Oxaprozin Drugs That Interfere with Hemostasis Clinical Impact: Oxaprozin and anticoagulants such as warfarin have a synergistic effect on bleeding. The concomitant use of oxaprozin and anticoagulants have an increased risk of serious bleeding compared to the use of either drug alone. Serotonin release by platelets plays an important role in hemostasis. Case-control and cohort epidemiological studies showed that concomitant use of drugs that interfere with serotonin reuptake and an NSAID may potentiate the risk of bleeding more than an NSAID alone. Intervention: Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e. G. , warfarin), antiplatelet drugs (e. G. , aspirin), SSRIs, and SNRIs for signs of bleeding see WARNINGS AND PRECAUTIONS (5. 12). Aspirin Clinical Impact: Controlle","recommendation":"Monitor patients with concomitant use of OXAPROZIN CAPSULES with anticoagulants (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"cytokines","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"abatacept","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"hadlima","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"dmards","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"rituximab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"theophylline","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"adalimumab","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"methotrexate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab-bwwd","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS  Abatacept: Increased risk of serious infection (5. 1, 5. 11, 7. 2)  Anakinra: Increased risk of serious infection (5. 1, 5. 7, 7. 2)  Live vaccines: Avoid use with HADLIMA (5. 10, 7. 3) 7. 1 Methotrexate Adalimumab has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HADLIMA or MTX see Clinical Pharmacology (12. 3). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HADLIMA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions (5. 7, 5. 11). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocke","recommendation":"Avoid use with HADLIMA (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ustekinumab-aekn","ingredient2":"selarsdi","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of ustekinumab products in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of ustekinumab. In trials in subjects with Crohns disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohns disease and ulcerative colitis subjects, respectively. Use of these concomitant therapies did not appear to influence the overall safety or efficacy of ustekinumab. 7. 2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e. G. , IL-1, IL-6, TNFÎ±, IFN) during chronic inflammation. Thus, use of ustekinumab products, antagonists of I","recommendation":"Monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"doxylamine succinate and pyridoxine hydrochloride","ingredient2":"diclegis","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Severe drowsiness can occur when used in combination with alcohol or other sedating medications. (7) 7. 1 Drug Interactions Use of DICLEGIS is contraindicated in women who are taking monoamine oxidase inhibitors (MAOIs), which prolong and intensify the anticholinergic (drying) effects of antihistamines. Concurrent use of alcohol and other CNS depressants (such as hypnotic sedatives and tranquilizers) with DICLEGIS is not recommended. 7. 2 Drug-Food Interactions A food-effect study demonstrated that the delay in the onset of action of DICLEGIS may be further delayed, and a reduction in absorption may occur when tablets are taken with food see Dosage and Administration (2), Clinical Pharmacology (12. 3). Therefore, DICLEGIS should be taken on an empty stomach with a glass of water  see Dosage and Administration (2). 7. 3 False Positive Urine Tests for Methadone, Opiates and PCP False positive drug screens for methadone, opiates, and PCP can occur with doxylamine succi","recommendation":"Should be taken on an empty stomach with a glass of water  see Dosage and Administration (2).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"diuretics","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"thy","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"monoamine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"respimat","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"but","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"potassium","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"methy","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"choline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ipratropium bromide and albuterol","ingredient2":"combivent","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS COMBIVENT RESPIMAT has been used concomitantly with other drugs, including beta-adrenergic bronchodilators, methylxanthines, and oral and inhaled steroids, commonly used in the treatment of chronic obstructive pulmonary disease. There are no formal studies fully evaluating the interaction effects of COMBIVENT RESPIMAT and these drugs with respect to safety and effectiveness. Anticholinergics: May interact additively with concomitantly used anticholinergic medications. Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7. 1) Beta-adrenergic agonists: May increase the risk of adverse cardiovascular effects. Avoid coadministration of COMBIVENT RESPIMAT and other sympathomimetic agents (7. 2) Beta-blockers: Inhibit the effect of albuterol. Consider alternative therapy in patients with hyperreactive airways (7. 3) Diuretics: Electrocardiographic changes and/or hypokalemia associated with diuretics may worsen with concomitant use of be","recommendation":"Avoid administration of COMBIVENT RESPIMAT with other anticholinergic-containing drugs (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fludeoxyglucose f 18","ingredient2":"glucose","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS The interactions of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"fludeoxyglucose f 18","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS The interactions of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"fludeoxyglucose f 18","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS The interactions of Fludeoxyglucose F 18 Injection with other drugs taken by patients undergoing PET imaging has not been studied.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ergocalciferol","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"DRUG INTERACTIONS Mineral oil interferes with the absorption of fat-soluble vitamins, including vitamin D preparations. Administration of thiazide diuretics to hypoparathyroid patients who are concurrently being treated with ergocalciferol may cause hypercalcemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cyclosporine","ingredient2":"hplc","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions (See PRECAUTIONS, Drug Interactions) When diclofenac or methotrexate was coadministered with cyclosporine in rheumatoid arthritis patients, the AUC of diclofenac and methotrexate, each was significantly increased (see PRECAUTIONS, Drug Interactions). No clinically significant pharmacokinetic interactions occurred between cyclosporine and aspirin, ketoprofen, piroxicam, or indomethacin. Specific Populations Renal Impairment In a study performed in 4 subjects with end-stage renal disease (creatinine clearance  5 mL/min), an intravenous infusion of 3. 5 mg/kg of cyclosporine over 4 hours administered at the end of a hemodialysis session resulted in a mean volume of distribution (Vdss) of 3. 49 L/kg and systemic clearance (CL) of 0. 369 L/hr/kg. This systemic CL (0. 369 L/hr/kg) was approximately two thirds of the mean systemic CL (0. 56 L/hr/kg) of cyclosporine in historical control subjects with normal renal function. In 5 liver transplant patients, the mean clearance o","recommendation":"CAUTIONS, Drug Interactions) When diclofenac or methotrexate was coadministered with cyclosporine in rheumatoid arthritis patients, the AUC of diclofenac and methotrexate, each was significantly increased (see PRECAUTIONS, Drug Interactions).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"uracil","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"000","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"ixempra","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"fluorouracil","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ixabepilone","ingredient2":"capecitabine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Avoid strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). Strong CYP3A4 Inducers: Avoid strong CYP3A4 inducers. If coadministration cannot be avoided, reduce the dosage of IXEMPRA ( 2. 5, 7. 1). 7. 1 Effect of Other Drugs on IXEMPRA Strong CYP3A4 Inhibitors The coadministration of IXEMPRA with a strong CYP3A4 inhibitor increased ixabepilone plasma concentration, which may increase the incidence and severity of adverse reactions of IXEMPRA. Avoid coadministration of IXEMPRA with strong CYP3A4 inhibitors. If the coadministration of IXEMPRA with strong CYP3A4 cannot be avoided, reduce the dose of IXEMPRA see Dosage and Administration ( 2. 5), Clinical Pharmacology ( 12. 3. Moderate or Weak CYP3A4 Inhibitors The coadministration of IXEMPRA with moderate or weak CYP3A4 inhibitors may increase the incidence and severity of adverse reactions of IXEMPRA. Monitor for adverse reactions and redu","recommendation":"Avoid strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"metoprolol","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"clonidine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"diltiazem","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"beta-blocker","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"prop","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"verapamil","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"paroxetine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"calcium","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"vera","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"fluoxetine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"propafenone","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"catecholamine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"beta-blockers","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"reserpine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"olamine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"metoprolol succinate er tablets","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS  Catecholamine-depleting drugs may have an additive effect when given with beta-blocking agents. ( 7. 1)  CYP2D6 Inhibitors are likely to increase metoprolol concentration. ( 7. 2)  Beta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the withdrawal of clonidine. ( 7. 3) 7. 1 Catecholamine Depleting Drugs Catecholamine depleting drugs (e. G. , reserpine, monoamine oxidase (MAO) inhibitors) may have an additive effect when given with beta-blocking agents. Observe patients treated with metoprolol succinate extended-release tablets plus a catecholamine depletor for evidence of hypotension or marked bradycardia, which may produce vertigo, syncope, or postural hypotension. 7. 2 CYP2D6 Inhibitors Drugs that are strong inhibitors of CYP2D6 such as quinidine, fluoxetine, paroxetine, and propafenone were shown to double metoprolol concentrations. While there is no information about moderate or weak inhibitors, these too are likely to in","recommendation":"Monitor patients closely when the combination cannot be avoided.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"enfortumab vedotin","ingredient2":"padcev","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"enfortumab vedotin","ingredient2":"thy","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"enfortumab vedotin","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"enfortumab vedotin","ingredient2":"mmae","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"enfortumab vedotin","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"enfortumab vedotin","ingredient2":"methy","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"enfortumab vedotin","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of dual P-gp and strong CYP3A4 inhibitors with PADCEV may increase the exposure to monomethyl auristatin E (MMAE). (7. 1) 7. 1 Effects of Other Drugs on PADCEV Dual P-gp and Strong CYP3A4 Inhibitors Concomitant use with dual P-gp and strong CYP3A4 inhibitors may increase unconjugated MMAE exposure see Clinical Pharmacology (12. 3), which may increase the incidence or severity of PADCEV toxicities. Closely monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","recommendation":"Monitor patients for signs of toxicity when PADCEV is given concomitantly with dual P-gp and strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"losartan","ingredient2":"lisinopril","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"nsaid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"type 2","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"nsaids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"eru","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"non-steroidal","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"nephron","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"ace inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"aliskiren","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"electrolytes","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"potassium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"renin-angiotensin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"losartan potassium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"diuretic","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"losartan","ingredient2":"potassium i","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Agents increasing Serum Potassium: Risk of hyperkalemia. ( 7. 1) Lithium: Risk of lithium toxicity. ( 7. 2) NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. ( 7. 3) Dual inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. ( 7. 4) 7. 1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7. 2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use. 7. 3 Non-Steroidal Anti-inflammatory Drugs (NSAIDS) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therap","recommendation":"Monitor serum potassium in such patients.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"diuretics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"vitamin d","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"vitami","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"corticosteroids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"sodium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"eru","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"vitamin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"arginine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"ace inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"electrolytes","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"vita","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"potassium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"siadh","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"arginin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"sodi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sodium chloride, sodium lactate, potassium chloride, and calcium chloride","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Drugs that Affect Electrolyte and/or Fluid Balance: Avoid concomitant use. If concomitant use cannot be avoided, closely monitor electrolyte concentrations and fluid balance. (7. 1) Lithium: Avoid concomitant use. If concomitant use is unavoidable monitor serum lithium concentrations more frequently. (7. 2) Digoxin: Consider reducing the volume or rate of Lactated Ringers Injection due to the increased risk of digoxin toxicity with calcium-containing solutions. (7. 3) Drugs with pH-Dependent Renal Elimination: Renal clearance of acidic drugs may be increased. In contrast, renal clearance of alkaline drugs may be decreased. (7. 4) 7. 1 Drugs that Affect Electrolyte and/or Fluid Balance Hyperkalemia Administration of Lactated Ringers Injection to patients concomitantly treated or recently treated with drugs that are associated with hyperkalemia increases the risk of severe and potentially fatal hyperkalemia, especially in the presence of other hyperkalemia risk factor","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"eculizumab-aeeb","ingredient2":"bkemv","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.","recommendation":"Monitor for reduced effectiveness of BKEMV.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aeeb","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.","recommendation":"Monitor for reduced effectiveness of BKEMV.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aeeb","ingredient2":"eru","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.","recommendation":"Monitor for reduced effectiveness of BKEMV.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aeeb","ingredient2":"mental","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.","recommendation":"Monitor for reduced effectiveness of BKEMV.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aeeb","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.","recommendation":"Monitor for reduced effectiveness of BKEMV.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aeeb","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.","recommendation":"Monitor for reduced effectiveness of BKEMV.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"technetium tc 99m pyrophosphate","ingredient2":"iron","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m pyrophosphate","ingredient2":"calcium","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m pyrophosphate","ingredient2":"alum","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m pyrophosphate","ingredient2":"but","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"technetium tc 99m pyrophosphate","ingredient2":"warnings","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions The biodistribution of technetium Tc 99m pyrophosphate may be altered in the presence of high levels of certain cations (iron, calcium, and aluminum). This may result in reduced uptake of radionuclide in the skeleton and increased extraosseal uptake, which may potentially degrade imaging quality. In patients with high levels of these cations caused by concomitant medications, particularly patients receiving iron infusions, consider performing an imaging study with technetium Tc 99m pyrophosphate injection once the cation levels have normalized (e. G. , after 3 to 5 half-lives of the cation). (See WARNINGS. )","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"olanzapin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"olanzapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"lybalvi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"diazepam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"prop","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"pine o","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"tar","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"dopamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"choline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"levodopa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"olanzapine and samidorphan l-malate","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Strong CYP3A4 Inducers: Not recommended. (7. 1) Strong CYP1A2 Inhibitors: Consider dosage reduction of olanzapine component of LYBALVI. (7. 1) CYP1A2 Inducer: Consider dosage increase of the olanzapine component of LYBALVI. (7. 1) CNS Acting Drugs: May potentiate orthostatic hypotension. (7. 1) Anticholinergic Drugs: Can increase risk for severe gastrointestinal adverse reactions. (7. 1) Antihypertensive Agents: Monitor blood pressure. (7. 2) Levodopa and Dopamine Agonists: Not recommended. (7. 2) 7. 1 Effects of Other Drugs on LYBALVI Table 4 describes clinically significant drug interactions where the concomitant use of other drugs affects LYBALVI. Table 4: Effects of Other Drugs on LYBALVI Strong CYP3A4 Inducer Clinical Implication: Coadministration of LYBALVI with a strong CYP3A4 inducer decreases AUCinf of olanzapine and samidorphan see Clinical Pharmacology (12. 3), which may reduce LYBALVI efficacy. Prevention or Management: Concomitant use of LYBALVI with st","recommendation":"Monitor blood pressure.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"fenofibrate","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"thy","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"simvastatin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"bempedoic acid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"cholestyramine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"pravastatin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"nexlizet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"ezetimibe","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"cyclosporine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid and ezetimibe","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No specific pharmacokinetic drug interaction studies with NEXLIZET have been conducted. Table 4 lists drug interactions with NEXLIZET that have been identified in studies with bempedoic acid or ezetimibe. Table 4. Clinically Important Drug Interactions with NEXLIZET Simvastatin Clinical Impact: Concomitant use of NEXLIZET with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLIZET with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLIZET with pravastatin greater than 40 mg. Cyclosporine Clinical Impact: Concomitant use of NEXLIZET and cyclosporine increases ezetimibe and cyclosporine c","recommendation":"Avoid concomitant use of NEXLIZET with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"adalimumab","ingredient2":"humira","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Abatacept: Increased risk of serious infection. (5. 1, 5. 11, 7. 2) Anakinra: Increased risk of serious infection. (5. 1, 5. 7, 7. 2) Live vaccines: Avoid use with HUMIRA. (5. 10, 7. 3) 7. 1 Methotrexate HUMIRA has been studied in rheumatoid arthritis (RA) patients taking concomitant methotrexate (MTX). Although MTX reduced the apparent adalimumab clearance, the data do not suggest the need for dose adjustment of either HUMIRA or MTX see Clinical Pharmacology ( 12. 3 ). 7. 2 Biological Products In clinical studies in patients with RA, an increased risk of serious infections has been observed with the combination of TNF blockers with anakinra or abatacept, with no added benefit; therefore, use of HUMIRA with abatacept or anakinra is not recommended in patients with RA see Warnings and Precautions ( 5. 7, 5. 11 ). A higher rate of serious infections has also been observed in patients with RA treated with rituximab who received subsequent treatment with a TNF blocker. ","recommendation":"Avoid use with HUMIRA.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"hexaminolevulinate hydrochloride","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No specific drug interaction studies have been performed.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"hexaminolevulinate hydrochloride","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS No specific drug interaction studies have been performed.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"diltiazem hydrochloride","ingredient2":"protein","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Beta-blockers, digitalis, and other agents known to impair cardiac contractility and conduction may increase risk for hypotension, bradycardia, and heart failure. (7. 1) CYP450 3A4: Diltiazem is both a substrate and inhibitor of CYP450 3A4. CYP450 3A4 substrates may require dosage adjustment. (7. 2) 7. 1 Agents Known to Impair Cardiac Contractility and Conduction Using other agents known to affect cardiac conduction or contractility with diltiazem may increase the risk of bradycardia, AV block, and heart failure see Warnings and Precautions (5. 1, 5. 2 ). Ivabradine: Concurrent use of diltiazem increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Avoid concomitant use of ivabradine and diltiazem. 7. 2 P-glycoprotein (P-gp) and Cytochrome P450 3A4 Mediated Drug Interactions Diltiazem is both a substrate and an inhibitor of the Pg-p and cytochrome P450 3A4 enzyme system which may affect exposure to diltiazem and concomitant drug","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diltiazem hydrochloride","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Beta-blockers, digitalis, and other agents known to impair cardiac contractility and conduction may increase risk for hypotension, bradycardia, and heart failure. (7. 1) CYP450 3A4: Diltiazem is both a substrate and inhibitor of CYP450 3A4. CYP450 3A4 substrates may require dosage adjustment. (7. 2) 7. 1 Agents Known to Impair Cardiac Contractility and Conduction Using other agents known to affect cardiac conduction or contractility with diltiazem may increase the risk of bradycardia, AV block, and heart failure see Warnings and Precautions (5. 1, 5. 2 ). Ivabradine: Concurrent use of diltiazem increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Avoid concomitant use of ivabradine and diltiazem. 7. 2 P-glycoprotein (P-gp) and Cytochrome P450 3A4 Mediated Drug Interactions Diltiazem is both a substrate and an inhibitor of the Pg-p and cytochrome P450 3A4 enzyme system which may affect exposure to diltiazem and concomitant drug","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diltiazem hydrochloride","ingredient2":"ivabradine","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Beta-blockers, digitalis, and other agents known to impair cardiac contractility and conduction may increase risk for hypotension, bradycardia, and heart failure. (7. 1) CYP450 3A4: Diltiazem is both a substrate and inhibitor of CYP450 3A4. CYP450 3A4 substrates may require dosage adjustment. (7. 2) 7. 1 Agents Known to Impair Cardiac Contractility and Conduction Using other agents known to affect cardiac conduction or contractility with diltiazem may increase the risk of bradycardia, AV block, and heart failure see Warnings and Precautions (5. 1, 5. 2 ). Ivabradine: Concurrent use of diltiazem increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Avoid concomitant use of ivabradine and diltiazem. 7. 2 P-glycoprotein (P-gp) and Cytochrome P450 3A4 Mediated Drug Interactions Diltiazem is both a substrate and an inhibitor of the Pg-p and cytochrome P450 3A4 enzyme system which may affect exposure to diltiazem and concomitant drug","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"cinacalcet hydrochloride","ingredient2":"phosphorus","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Co-administration with a strong CYP3A4 inhibitor may increase serum levels of cinacalcet. Dose adjustment and monitoring of iPTH serum phosphorus and serum calcium may be required. (7. 1) Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6. (7. 2) 7. 1 Strong CYP3A4 Inhibitors Cinacalcet is partially metabolized by CYP3A4. Dose adjustment of Sensipar may be required if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e. G. , ketoconazole, itraconazole). The iPTH and serum calcium concentrations should be closely monitored in these patients see Clinical Pharmacology ( 12. 3 ). 7. 2 CYP2D6 Substrates Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e. G. , desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic ","recommendation":"Monitoring of iPTH serum phosphorus and serum calcium may be required.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"ofloxacin","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"caf","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"caffeine","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"eru","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"anticoagulant","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"warfarin","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"theophylline","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"cyclosporin","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ofloxacin ophthalmic solution usp, 0.3%","ingredient2":"caffein","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Specific drug interaction studies have not been conducted with ofloxacin ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"bempedoic acid","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them. Table 3. Clinically Important Drug Interactions with NEXLETOL Simvastatin Clinical Impact: Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7) Pravastatin: Avoid concomitant use of NEXLETOL with prava","recommendation":"Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid","ingredient2":"simvastatin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them. Table 3. Clinically Important Drug Interactions with NEXLETOL Simvastatin Clinical Impact: Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7) Pravastatin: Avoid concomitant use of NEXLETOL with prava","recommendation":"Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid","ingredient2":"pravastatin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them. Table 3. Clinically Important Drug Interactions with NEXLETOL Simvastatin Clinical Impact: Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7) Pravastatin: Avoid concomitant use of NEXLETOL with prava","recommendation":"Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid","ingredient2":"gre","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them. Table 3. Clinically Important Drug Interactions with NEXLETOL Simvastatin Clinical Impact: Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7) Pravastatin: Avoid concomitant use of NEXLETOL with prava","recommendation":"Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them. Table 3. Clinically Important Drug Interactions with NEXLETOL Simvastatin Clinical Impact: Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7) Pravastatin: Avoid concomitant use of NEXLETOL with prava","recommendation":"Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"bempedoic acid","ingredient2":"nexletol","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with NEXLETOL and instructions for preventing or managing them. Table 3. Clinically Important Drug Interactions with NEXLETOL Simvastatin Clinical Impact: Concomitant use of NEXLETOL with simvastatin causes an increase in simvastatin concentration and may increase the risk of simvastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. Pravastatin Clinical Impact: Concomitant use of NEXLETOL with pravastatin causes an increase in pravastatin concentration and may increase the risk of pravastatin-related myopathy see Clinical Pharmacology (12. 3). Intervention: Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg. Simvastatin: Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg. (7) Pravastatin: Avoid concomitant use of NEXLETOL with prava","recommendation":"Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brimonidine tartrate","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade (7. 1). Use with CNS depressants may result in an additive or potentiating effect (7. 2). Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine (7. 3). Monoamine oxidase inhibitors may result in increased hypotension (7. 4). 7. 1 Anti-hypertensives / Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug interaction studies have not been conducted with brimonidine tartrate ophthalmic solution, 0. 15%, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. 7. 3 Tricyclic Antidepressants Tricyclic antidepressants have been reported to blunt the hypotensive ef","recommendation":"Caution in using drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brimonidine tartrate","ingredient2":"cla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade (7. 1). Use with CNS depressants may result in an additive or potentiating effect (7. 2). Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine (7. 3). Monoamine oxidase inhibitors may result in increased hypotension (7. 4). 7. 1 Anti-hypertensives / Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug interaction studies have not been conducted with brimonidine tartrate ophthalmic solution, 0. 15%, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. 7. 3 Tricyclic Antidepressants Tricyclic antidepressants have been reported to blunt the hypotensive ef","recommendation":"Caution in using drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"brimonidine tartrate","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Concomitant use with systemic beta-blockers may potentiate systemic beta-blockade (7. 1). Use with CNS depressants may result in an additive or potentiating effect (7. 2). Tricyclic antidepressants may potentially blunt the hypotensive effect of systemic clonidine (7. 3). Monoamine oxidase inhibitors may result in increased hypotension (7. 4). 7. 1 Anti-hypertensives / Cardiac Glycosides Alpha-2 agonists, as a class, may reduce blood pressure. Caution in using drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised. 7. 2 CNS Depressants Although specific drug interaction studies have not been conducted with brimonidine tartrate ophthalmic solution, 0. 15%, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. 7. 3 Tricyclic Antidepressants Tricyclic antidepressants have been reported to blunt the hypotensive ef","recommendation":"Caution in using drugs such as beta-blockers (ophthalmic and systemic), anti-hypertensives and/or cardiac glycosides is advised.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"phenylephrine hydrochloride","ingredient2":"ala","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Atropine-like drugs: May exaggerate the adrenergic pressor response ( 7. 1) Potent inhalation anesthetic agents: May potentiate cardiovascular depressant effects ( 7. 1) 7. 1 Agents That May Exaggerate Pressor Response Concomitant use of phenylephrine and atropine may enhance the pressor effects and induce tachycardia in some patients. Phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic agents.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"sulbactam","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"probenecid","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"oat","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sulbactam and durlobactam","ingredient2":"xacduro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Organic Anion Transporter 1 (OAT1) Inhibitors: Concomitant administration with OAT1 inhibitors may increase plasma concentrations of XACDURO. Concomitant administration is not recommended. (7. 1) 7. 1 Organic Anion Transporter 1 (OAT1) Inhibitors Concomitant administration with OAT1 inhibitors may increase plasma concentrations of sulbactam. Concomitant administration of OAT1 inhibitors (e. G. , probenecid) with XACDURO is not recommended. See Clinical Pharmacology (12. 3).","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"thy","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"vitami","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"epa","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"eru","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"pea","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"vitamin","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"anticoagulant","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"cholestyramine","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"glyce","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"vita","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"tar","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"levothyroxine","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"gla","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"thyroxine","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"anticoagulants","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"vit","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"vitamin k","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"esmolol hydrochloride in sodium chloride","ingredient2":"beta blockers","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injections effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below). Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited","recommendation":"Should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approximate 10% to 20% increase of digoxin blood levels at some time points.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"esmolol hydrochloride in sodium chloride","ingredient2":"beta blocker","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Concomitant use of esmolol hydrochloride in sodium chloride injection with other drugs that can lower blood pressure, reduce myocardial contractility, or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate esmolol hydrochloride in sodium chloride injections effects on blood pressure, contractility, and impulse propagation. Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest. In addition, with some drugs, beta blockade may precipitate increased withdrawal effects. (See clonidine, guanfacine, and moxonidine below). Esmolol hydrochloride in sodium chloride injection should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited","recommendation":"Should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions, including but not limited to: Digitalis glycosides: Concomitant administration of digoxin and esmolol hydrochloride in sodium chloride injection leads to an approximate 10% to 20% increase of digoxin blood levels at some time points.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolmetin sodium","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors. Aspirin: As with other NSAIDs, concomitant administration of TOLECTIN sodium and aspirin is not generally recommended because of the potential of increased adverse effects. Diuretics: Clinical studies, as well as post-marketing observations have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decr","recommendation":"Should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolmetin sodium","ingredient2":"tolectin","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors. Aspirin: As with other NSAIDs, concomitant administration of TOLECTIN sodium and aspirin is not generally recommended because of the potential of increased adverse effects. Diuretics: Clinical studies, as well as post-marketing observations have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decr","recommendation":"Should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tolmetin sodium","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"DRUG INTERACTIONS ACE Inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE Inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors. Aspirin: As with other NSAIDs, concomitant administration of TOLECTIN sodium and aspirin is not generally recommended because of the potential of increased adverse effects. Diuretics: Clinical studies, as well as post-marketing observations have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure, as well as to assure diuretic efficacy. Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decr","recommendation":"Should be given consideration in patients taking NSAIDs concomitantly with ACE Inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"valganciclovir","ingredient2":"valcyte","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS In vivo drug-drug interaction studies were not conducted with valganciclovir. However, because valganciclovir is rapidly and extensively converted to ganciclovir, drug-drug interactions associated with ganciclovir will be expected for VALCYTE. Drug-drug interaction studies with ganciclovir were conducted in patients with normal renal function. Following concomitant administration of VALCYTE and other renally excreted drugs, patients with impaired renal function may have increased concentrations of ganciclovir and the coadministered drug. Therefore, these patients should be closely monitored for toxicity of ganciclovir and the coadministered drug. Established and other potentially significant drug interactions conducted with ganciclovir are listed in Table 9. Table 9 Established and Other Potentially Significant Drug Interactions with Ganciclovir Name of the Concomitant Drug Change in the Concentration of Ganciclovir or Concomitant Drug Clinical Comment Imipenem-cila","recommendation":"Should be closely monitored for toxicity of ganciclovir and the coadministered drug.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"norepinephrine bitartrate","ingredient2":"sodium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7. 1) Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7. 4) 7. 1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e. G. , linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7. 2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If adminis","recommendation":"Avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"norepinephrine bitartrate","ingredient2":"sodium chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7. 1) Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7. 4) 7. 1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e. G. , linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7. 2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If adminis","recommendation":"Avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"norepinephrine bitartrate","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7. 1) Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7. 4) 7. 1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e. G. , linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7. 2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If adminis","recommendation":"Avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"norepinephrine bitartrate","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7. 1) Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7. 4) 7. 1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e. G. , linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7. 2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If adminis","recommendation":"Avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"norepinephrine bitartrate","ingredient2":"sodi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types may result in hypertension. (7. 1) Cyclopropane and halothane anesthetics increase cardiac autonomic irritability. (7. 4) 7. 1 MAO-Inhibiting Drugs Co-administration of Norepinephrine in Sodium Chloride Injection with monoamine oxidase (MAO) inhibitors or other drugs with MAO-inhibiting properties (e. G. , linezolid) can cause severe, prolonged hypertension. If administration of Norepinephrine in Sodium Chloride Injection cannot be avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension. 7. 2 Tricyclic Antidepressants Co-administration of Norepinephrine in Sodium Chloride Injection with tricyclic antidepressants (including amitriptyline, nortriptyline, protriptyline, clomipramine, desipramine, imipramine) can cause severe, prolonged hypertension. If adminis","recommendation":"Avoided in patients who recently have received any of these drugs and in whom, after discontinuation, MAO activity has not yet sufficiently recovered, monitor for hypertension.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glyburide","ingredient2":"ros","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral ","recommendation":"Should be observed closely for hypoglycemia.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glyburide","ingredient2":"milk","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral ","recommendation":"Should be observed closely for hypoglycemia.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glyburide","ingredient2":"precautions","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral ","recommendation":"Should be observed closely for hypoglycemia.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glyburide","ingredient2":"dosage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral ","recommendation":"Should be observed closely for hypoglycemia.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glyburide","ingredient2":"others","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral ","recommendation":"Should be observed closely for hypoglycemia.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glyburide","ingredient2":"administration","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide tablets, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide tablets, the patient should be observed closely for loss of control. An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore, concomitant administration of glyburide tablets and bosentan is contraindicated. Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral ","recommendation":"Should be observed closely for hypoglycemia.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"sage","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"dosage","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"mumps","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"rubella","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"mmrv","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"epa","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"administration","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"human botulinum neurotoxin a/b immune globulin","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Admixtures of BabyBIG with other drugs have not been evaluated. It is recommended that BabyBIG be administered separately from other drugs or medications that the patient may be receiving see DOSAGE AND ADMINISTRATION (2). Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as polio, measles, mumps, and rubella; therefore, vaccination with live virus vaccines such as MMR (measles, mumps, and rubella), MMRV (measles, mumps, rubella, and varicella), and monovalent varicella vaccines should be deferred until six months after administration of BabyBIG. This interval may be shortened if exposure to measles is likely. If such vaccinations were given shortly before or after BabyBIG administration, revaccination may be necessary. 21 The passive transfer of antibodies may interfere with the response to live viral vaccines (7).","recommendation":"Should be deferred until six months after administration of BabyBIG.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"levothyroxine, liothyronine","ingredient2":"ros","severity":"moderate","severity_confidence":0.5,"effect":"Drug Interactions Oral Anticoagulants Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. If oral anticoagulants are also being given, compensatory increases in clotting factor synthesis are impaired. Patients stabilized on oral anticoagulants who are found to require thyroid replacement therapy should be watched very closely when thyroid is started. If a patient is truly hypothyroid, it is likely that a reduction in anticoagulant dosage will be required. No special precautions appear to be necessary when oral anticoagulant therapy is begun in a patient already stabilized on maintenance thyroid replacement therapy. Insulin or Oral Hypoglycemics Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. The effects seen are poorly understood and depend upon a variety of factors such as dose and type of thyroid preparations and endocrine status of the patient. Patients receiving insulin or oral hypoglycemic","recommendation":"Should be watched very closely when thyroid is started.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"fos","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"fluconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"ledipasvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"norgestimate","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"eru","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"simeprevir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"lansoprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"metformin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"cimetidine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"dexlansoprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"clarithromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"dexamethasone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"magnesium hydroxide","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"odefsey","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"pan","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"bee","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"valacyclovir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"bcrp","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"hypericum","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"atorvastatin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"erythromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"calcium carbonat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"sofosbuvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"magnesi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"esomeprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"protein","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"nsaids","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"famotidine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"atp","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"antibiotics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"sildenafil","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"alum","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"velpatasvir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"oxcarbazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"calcium carbonate","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"ethinyl estradiol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"calcium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"itraconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"nizatidine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"pine o","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"voxilaprevir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"acyclovir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"cla","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"chlorzoxazone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"midazolam","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"azithromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"phenobarbital","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"omeprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"gentamicin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"valganciclovir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"oat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"pantoprazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"posaconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"voriconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"ganciclovir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"magnesium","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"emtricitabine, rilpivirine hydrochloride, and tenofovir alafenamide","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS ODEFSEY is a complete regimen for the treatment of HIV-1 infection; therefore, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. (7. 1) Consult the Full Prescribing Information prior to and during treatment for important drug interactions. (4, 5. 6, 7) 7. 1 Not Recommended with Other Antiretroviral Medications Because ODEFSEY is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. 7. 2 Drugs Inducing or Inhibiting CYP3A Enzymes RPV is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of RPV see Clinical Pharmacology (12. 3). Coadministration of RPV and drugs that induce CYP3A may result in decreased plasma concentrations of RPV and loss of virologic response and possible resistance to RPV or to the class of NNRTIs see Contraindications (4), Warnings and Precautions (5. 6), and Table","recommendation":"Contraindications (4), Warnings and Precautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"bran","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"quinacrine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"duloxetine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"tizanidine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"precautions","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"adverse","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"digoxin","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"epa","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"primaquine","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"contraindications","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"bet","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"overdosage","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"iga","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"theophylline","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"reactions","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"methemoglobinemia-inducing","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"ala","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"primaquine phosphate","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"Drug Interactions Pharmacodynamics Interactions Quinacrine Concurrent use of quinacrine (mepacrine) and primaquine are contraindicated. Increased toxicity was seen when quinacrine was used with pamaquine, another 8-aminoquinoline (see CONTRAINDICATIONS). Hemolytic Agents and Methemoglobinemia-Inducing Drugs The concurrent administration of hemolytic agents or methemoglobinemia-inducing drugs and primaquine should be avoided (see PRECAUTIONS). If the concurrent administration cannot be avoided, close blood monitoring is required. QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between primaquine and other drugs that effect cardiac conduction is unknown. If primaquine is used concomitantly with other drugs that prolong the QT interval, close and frequent electrocardiogram monitoring is advised (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE). Effects of Other Drugs on the Pharmacokinetics of Primaquine Potent ","recommendation":"CONTRAINDICATIONS).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"eculizumab-aagh","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.","recommendation":"Monitor for reduced effectiveness of EPYSQLI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aagh","ingredient2":"eru","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.","recommendation":"Monitor for reduced effectiveness of EPYSQLI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aagh","ingredient2":"mental","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.","recommendation":"Monitor for reduced effectiveness of EPYSQLI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aagh","ingredient2":"epysqli","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.","recommendation":"Monitor for reduced effectiveness of EPYSQLI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aagh","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.","recommendation":"Monitor for reduced effectiveness of EPYSQLI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"eculizumab-aagh","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS 7. 1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI see Dosage and Administration (2. 5). 7. 2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.","recommendation":"Monitor for reduced effectiveness of EPYSQLI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"fenofibrate","ingredient2":"clinical","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"pan","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"milk","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"cla","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"pharmacology","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"mrhd","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"mental","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"50 mg","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"fenofibrate","ingredient2":"others","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES. THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS. FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED. HMG-CoA reductase inhibitors The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination (see WARNINGS). Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take fenofibrate capsules at least 1 hour before or 4 to 6 hours after a bile acid binding resin to avoid impeding its absorption. Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinin","recommendation":"CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH FENOFIBRATE CAPSULES.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"diltiazem","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"fluconazole","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"grape","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"efavirenz","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"pancuronium","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"carbamazepine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"corticosteroids","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"verapamil","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"vera","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"grapefruit juice","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"cla","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"grapefruit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"clarithromycin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"pan","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"phenytoin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of deflazacort ( 7. 1) Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7. 1) Additional pediatric use information is approved for PTC Therapeutics, Inc. S Emflaza (deflazacort) tablets. However, due to PTC Therapeutics, Inc. S marketing exclusivity rights, this drug product is not labeled with that information. 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology ( 12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of deflazacort when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with deflazaco","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with deflazacort, as they may reduce efficacy ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"non-replacement","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 8 includes a list of drugs with clinically important drug interactions when administered concomitantly with HUMATROPE and instructions for preventing or managing them. Table 8: Clinically Important Drug Interactions with HUMATROPE Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. HUMATROPE inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of HUMATROPE may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of HUMATROPE see Warnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be effec","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"somatropin","ingredient2":"humatrope","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Table 8 includes a list of drugs with clinically important drug interactions when administered concomitantly with HUMATROPE and instructions for preventing or managing them. Table 8: Clinically Important Drug Interactions with HUMATROPE Replacement Glucocorticoid Treatment Clinical Impact: Microsomal enzyme 11Î²-hydroxysteroid dehydrogenase type 1 (11Î²HSD-1) is required for conversion of cortisone to its active metabolite, cortisol, in hepatic and adipose tissue. HUMATROPE inhibits 11Î²HSD-1. Consequently, individuals with untreated GH deficiency have relative increases in 11Î²HSD-1 and serum cortisol. Initiation of HUMATROPE may result in inhibition of 11Î²HSD-1 and reduced serum cortisol concentrations. Intervention: Patients treated with glucocorticoid replacement for hypoadrenalism may require an increase in their maintenance or stress doses following initiation of HUMATROPE see Warnings and Precautions (5. 8). Examples: Cortisone acetate and prednisone may be effec","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trametinib","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib. Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"trametinib","ingredient2":"mekinist","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS MEKINIST is indicated for use in combination with dabrafenib. Refer to the dabrafenib prescribing information for additional risk information that applies to combination use treatment.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ponesimod","ingredient2":"diltiazem","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"anti-neoplastic","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"beta-blocker","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"prop","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"ponvory","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"digoxin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"verapamil","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"interferon","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"immune-modulating","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"calcium","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"sotalol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"vera","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"bet","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"cla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"tar","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"gla","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"bee","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"amiodarone","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"anti-arrhythmic","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"beta-blockers","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ponesimod","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Vaccines: Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY. (7. 4) 7. 1 Anti-Neoplastic, Immune-Modulating, or Immunosuppressive Therapies PONVORY has not been studied in combination with anti-neoplastic, immune-modulating, or immunosuppressive therapies. Caution should be used during concomitant administration because of the risk of additive immune effects during such therapy and in the weeks following administration see Warnings and Precautions (5. 1). When switching from drugs with prolonged immune effects, the half-life and mode of action of these drugs must be considered in order to avoid unintended additive effects on the immune system see Warnings and Precautions (5. 10). Because of the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with PONVORY after alemtuzumab is not recommended. PONVORY can generally be started immediately after discontinuation of beta interferon or gl","recommendation":"Avoid live attenuated vaccines during and for up to 1-2 weeks after treatment with PONVORY.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"epinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"mao inhibitors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"corticosteroid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amphetamine","ingredient2":"vit","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Acidifying and Alkalinizing Agents: Agents that alter urinary pH can alter blood levels of amphetamine. Acidifying agents can decrease amphetamine blood levels, while alkalinizing agents can increase amphetamine blood levels. Adjust amphetamine extended-release orally disintegrating tablets dosage accordingly. (7. 1) 7. 1 Drugs Having Clinically Important Interactions with Amphetamines Table 5: Drugs having clinically important interactions with amphetamines. MAO Inhibitors (MAOI) Clinical Impact MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Intervention Do not administer amphetamine extended-release orally disintegrating tablets during or within 14 days following the administration of MAOI see Cont","recommendation":"Contraindications (4).","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydrochlorothiazide","ingredient2":"drugs-in","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics. Alcohol, barbiturates or narcotics-potentiation of orthostatic hypotension may occur. Antidiabetic drugs-(oral agents and insulin)- dosage adjustment of the antidiabetic drug may be required. Other antihypertensive drugs-additive effect or potentiation. Cholestyramine and colestipol resins-Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively. Corticosteroids, ACTH-intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e. G. , norepinephrine)-possible decreased response to pressor amines but not sufficient to preclude their use. Skeletal muscle relaxants, nondepolarizing (e. G. , tubocurarine)-possible increased responsiveness to the muscle relaxa","recommendation":"Should not be given with diuretics.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"asenapine maleate","ingredient2":"saphris","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Antihypertensive Drugs: SAPHRIS may cause hypotension. (5. 7, 7. 1, 12. 3) Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with SAPHRIS. (7. 1, 12. 3) 7. 1 Drugs Having Clinically Important Drug Interactions with SAPHRIS Table 12: Clinically Important Drug Interactions with SAPHRIS Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its Î±1-adrenergic antagonism with potential for inducing hypotension, SAPHRIS may enhance the effects of certain antihypertensive agents see Warnings and Precautions ( 5. 7 ). Monitor blood pressure and adjust dosage of antihypertensive drug accordingly. Strong CYP1A2 Inhibitors (e. G. , Fluvoxamine) SAPHRIS is metabolized by CYP1A2. Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily  see Clinical Pharmacology ( 12. 3 ). However, the tested fluvoxamine dose ","recommendation":"Recommendation Antihypertensive Drugs Because of its Î±1-adrenergic antagonism with potential for inducing hypotension, SAPHRIS may enhance the effects of certain antihypertensive agents see Warnings and Precautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"ampicillin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"mefloquine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"digoxin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"eru","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"glyce","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"cimetidine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"fat","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"rifampicin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"chloroquine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"kaolin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"praziquantel","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"interactions","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"cyclosporine","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"ala","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"cyclosporin","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"methotrexate","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"hydroxychloroquine","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. ( 7. 1) See FPI for more important drug interactions. ( 7) 7. 1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic see Warnings and Precautions (5. 1). 7. 2 Insulin or Other Antidiabetic Drugs Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary see Warnings and Precautions (5. 10). 7. 3 Drugs that Lower the Seizure Threshold Hydroxychloroquine sulfate can lower the seiz","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"venlafaxine hydrochloride","ingredient2":"odesmethylvenlafaxine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS MAOIs: concomitant use contraindicated. ( 4) Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine. ( 5. 2) Cimetidine: Caution in patients with pre-existing hypertension, in elderly patients and patients with hepatic dysfunction. ( 7. 2) Haloperidol: Increase in haloperidol AUC and C max. ( 7. 4) Ketoconazole: Increase in venlafaxine and O-desmethylvenlafaxine AUC and C max. Caution when using venlafaxine with substances that inhibit both CYP2D6 and CYP3A4. ( 7. 7) Metoprolol: Possibly reduced blood pressure lowering effect despite increased metoprolol plasma levels. Caution should be exercised with co-administration of venlafaxine and metoprolol. ( 7. 8) CNS-active drugs: Caution when using venlafaxine with such drugs. ( 7. 10) Serotonergic drugs (e. G. , triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. Johns Wort): Potential for serotonin syndrome. Careful patient observation advised. ( 7. 10) Tryptophan supplemen","recommendation":"Avoid MAOIs 14 days before starting venlafaxine and 7 days after stopping venlafaxine.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"foscarnet sodium","ingredient2":"foscavir","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions A possible drug interaction of FOSCAVIR and intravenous pentamidine has been described. Concomitant treatment of four patients in the United Kingdom with FOSCAVIR and intravenous pentamidine may have caused hypocalcemia; one patient died with severe hypocalcemia. Toxicity associated with concomitant use of aerosolized pentamidine has not been reported. Because FOSCAVIR can reduce serum levels of ionized calcium, extreme caution is advised when used concurrently with other drugs known to influence serum calcium levels (e. G. , intravenous pentamidine). Renal impairment and symptomatic hypocalcemia have been observed during concurrent treatment with FOSCAVIR and intravenous pentamidine. Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B, cyclosporine, acyclovir, methotrexate, tacrolimus and intravenous pentamidine (see above) unless the ","recommendation":"Caution is advised when used concurrently with other drugs known to influence serum calcium levels (e.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"fluconazole","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"alcohol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"acetazolamide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"metformin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"cimetidine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"nicotinic","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"but","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"proteins","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"rose","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"metformin hydrochloride","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"nicotinic acid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"milk","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"phenytoin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"salicylate","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"thy","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"probenecid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"nifedipine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"mate","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"zonisamide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"salicylates","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"calcium","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"dolutegravir","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"colesevelam","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"propranolol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"urea","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"chlorid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"pea","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"glucose","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"ranolazine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"glyce","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"tar","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"lactic acid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"glipizide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"precautions","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"furosemide","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"mrhd","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"sali","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"chloramphenicol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"000","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"chloride","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"topiramate","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"ibuprofen","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"50 mg","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"warnings","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"others","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"isoniazid","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"glipizide and metformin hcl","ingredient2":"miconazole","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions Glipizide and Metformin HCl Tablets Certain drugs tend to produce hyperglycemia and may lead to loss of blood glucose control. These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving Glipizide and Metformin HCl Tablets, the patient should be closely observed for loss of blood glucose control. When such drugs are withdrawn from a patient receiving Glipizide and Metformin HCl Tablets, the patient should be observed closely for hypoglycemia. Metformin is negligibly bound to plasma proteins and is, therefore, less likely to interact with highly protein-bound drugs such as salicylates, sulfonamides, chloramphenicol, and probenecid as compared to sulfonylureas, which are extensively bound to serum proteins. Glipizide The hypoglycemic action of sulfonyl","recommendation":"Should be closely observed for loss of blood glucose control.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one sixth when coadministered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir) (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. Phenytoin, rifampin, St. Johns wort) (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5 fold within 7 to 14 days of discontinuation of CYP3A4 inducers ((2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release tablet in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release tablet, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor ef","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine","ingredient2":"pharmacology","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one sixth when coadministered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir) (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. Phenytoin, rifampin, St. Johns wort) (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5 fold within 7 to 14 days of discontinuation of CYP3A4 inducers ((2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release tablet in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release tablet, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor ef","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one sixth when coadministered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir) (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. Phenytoin, rifampin, St. Johns wort) (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5 fold within 7 to 14 days of discontinuation of CYP3A4 inducers ((2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release tablet in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release tablet, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor ef","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"quetiapine","ingredient2":"clinical","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one sixth when coadministered with strong CYP3A4 inhibitors (e. G. , ketoconazole, ritonavir) (2. 5, 7. 1, 12. 3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e. G. Phenytoin, rifampin, St. Johns wort) (2. 6, 7. 1, 12. 3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5 fold within 7 to 14 days of discontinuation of CYP3A4 inducers ((2. 6, 7. 1, 12. 3) 7. 1 Effect of Other Drugs on Quetiapine The risks of using quetiapine extended-release tablet in combination with other drugs have not been extensively evaluated in systematic studies. Given the primary CNS effects of quetiapine extended-release tablet, caution should be used when it is taken in combination with other centrally acting drugs. Quetiapine potentiated the cognitive and motor ef","recommendation":"Caution should be used when it is taken in combination with other centrally acting drugs.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"diazepam","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"corticosteroids","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"ephedrine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"atenolol","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"phenylephrine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"vera","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"but","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"phenylephrine hydrochloride","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"pan","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"bee","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"choline","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"pheniramine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"erythromycin","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"thy","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"met","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"antibiotics","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"administration","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"bet","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"ors","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"pro","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"diuretics","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"sulfamethoxazole","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"allopurinol","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"sage","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"prop","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"hydrochlorothiazide","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"phenylpropanolamine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"propranolol","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"aspirin","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"verapamil","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"epa","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"chlorid","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"pea","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"glyce","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"cla","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"pseudoephedrine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"captopril","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"indomethacin","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"chlorpheniramine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"dosage","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"prazosin","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"trimethoprim","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"chloride","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"ibuprofen","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"50 mg","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"codeine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"methy","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"olamine","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"terazosin","ingredient2":"vit","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions In controlled trials, terazosin has been added to diuretics, and several beta-adrenergic blockers; no unexpected interactions were observed. Terazosin has also been used in patients on a variety of concomitant therapies; while these were not formal interaction studies, no interactions were observed. Terazosin has been used concomitantly in at least 50 patients on the following drugs or drug classes: 1) analgesic/anti-inflammatory (e. G. , acetaminophen, aspirin, codeine, ibuprofen, indomethacin); 2) antibiotics (e. G. , erythromycin, trimethoprim and sulfamethoxazole); 3) anticholinergic/sympathomimetics (e. G. , phenylephrine hydrochloride, phenylpropanolamine hydrochloride, pseudoephedrine hydrochloride); 4) antigout (e. G. , allopurinol); 5) antihistamines (e. G. , chlorpheniramine); 6) cardiovascular agents (e. G. , atenolol, hydrochlorothiazide, methyclothiazide, propranolol); 7) corticosteroids; 8) gastrointestinal agents (e. G. , antacids); 9) hypoglycemics; 10","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"potassium chloride oral","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"iron","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"spironolactone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"renin-angiotensin-aldosterone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"potassium-sparing","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"aliskiren","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"raas","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"gla","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"eplerenone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"potassium chloride oral","ingredient2":"potassium i","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Potassium sparing diuretics: Avoid concomitant use ( 7. 1) Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia ( 7. 2) Nonsteroidal Anti-Inflammatory drugs: Monitor for hyperkalemia ( 7. 3) 7. 1 Potassium-Sparing Diuretics Use with potassium-sparing diuretics can produce severe hyperkalemia. Avoid concomitant use. 7. 2 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. Closely monitor potassium in patients receiving concomitant RAAS therapy. 7. 3 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) NSAIDs may produce potassium retention by reducing renal synthesis of prostaglandin E and impairing the reninangiotensin system. Closely monitor potassium in patients on concomitant NSAIDs.","recommendation":"Avoid concomitant use ( 7.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"digoxin","ingredient2":"salbutamol","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (7. 1) There are numerous drug interactions associated with digoxin. The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information for a complete listing of pharmacokinetic (7. 2) (12. 3) and pharmacodynamic interactions (7. 3). 7. 1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate for P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion. Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics. 7. 2 Pharmacokinetic Drug Interactions on Serum Digoxin Levels in Adults Digoxin concentrations increased  50% Digoxin Serum Concentration Increase Digoxin AUC Increase Recommendations Amiodarone 70% NA Measure serum digoxin concentrations before initiating concomitant drugs. Reduce ","recommendation":"Must be considered prior to and during drug therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"digoxin","ingredient2":"moricizine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (7. 1) There are numerous drug interactions associated with digoxin. The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information for a complete listing of pharmacokinetic (7. 2) (12. 3) and pharmacodynamic interactions (7. 3). 7. 1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate for P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion. Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics. 7. 2 Pharmacokinetic Drug Interactions on Serum Digoxin Levels in Adults Digoxin concentrations increased  50% Digoxin Serum Concentration Increase Digoxin AUC Increase Recommendations Amiodarone 70% NA Measure serum digoxin concentrations before initiating concomitant drugs. Reduce ","recommendation":"Must be considered prior to and during drug therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"digoxin","ingredient2":"nitrendipine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS PGP Inducers/Inhibitors: Drugs that induce or inhibit PGP have the potential to alter digoxin pharmacokinetics. (7. 1) There are numerous drug interactions associated with digoxin. The potential for drug-drug interactions must be considered prior to and during drug therapy. See full prescribing information for a complete listing of pharmacokinetic (7. 2) (12. 3) and pharmacodynamic interactions (7. 3). 7. 1 P-Glycoprotein (PGP) Inducers/Inhibitors Digoxin is a substrate for P-glycoprotein, at the level of intestinal absorption, renal tubular section and biliary-intestinal secretion. Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin pharmacokinetics. 7. 2 Pharmacokinetic Drug Interactions on Serum Digoxin Levels in Adults Digoxin concentrations increased  50% Digoxin Serum Concentration Increase Digoxin AUC Increase Recommendations Amiodarone 70% NA Measure serum digoxin concentrations before initiating concomitant drugs. Reduce ","recommendation":"Must be considered prior to and during drug therapy.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trimethobenzamide hydrochloride","ingredient2":"alcohol","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Alcohol: May cause drowsiness; avoid concomitant use. ( 7. 1) Other Drugs that Cause CNS Depression or EPS: Either trimethobenzamide hydrochloride capsules or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. ( 7. 2) 7. 1 Alcohol Alcohol may increase the CNS depressant effects of trimethobenzamide hydrochloride capsules and may cause drowsiness see Warnings and Precautions ( 5. 3, 5. 5). Avoid concomitant use of trimethobenzamide hydrochloride capsules with alcohol. 7. 2 Other Drugs that Cause CNS Depression or EPS The concurrent use of trimethobenzamide hydrochloride capsules with other drugs that cause CNS depression or EPS (e. G. , sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics, may potentiate the effects of trimethobenzamide hydrochloride capsules see Warnings and Precautions ( 5. 1, 5. 2, 5. 3, 5","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trimethobenzamide hydrochloride","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Alcohol: May cause drowsiness; avoid concomitant use. ( 7. 1) Other Drugs that Cause CNS Depression or EPS: Either trimethobenzamide hydrochloride capsules or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. ( 7. 2) 7. 1 Alcohol Alcohol may increase the CNS depressant effects of trimethobenzamide hydrochloride capsules and may cause drowsiness see Warnings and Precautions ( 5. 3, 5. 5). Avoid concomitant use of trimethobenzamide hydrochloride capsules with alcohol. 7. 2 Other Drugs that Cause CNS Depression or EPS The concurrent use of trimethobenzamide hydrochloride capsules with other drugs that cause CNS depression or EPS (e. G. , sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics, may potentiate the effects of trimethobenzamide hydrochloride capsules see Warnings and Precautions ( 5. 1, 5. 2, 5. 3, 5","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trimethobenzamide hydrochloride","ingredient2":"chlorid","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Alcohol: May cause drowsiness; avoid concomitant use. ( 7. 1) Other Drugs that Cause CNS Depression or EPS: Either trimethobenzamide hydrochloride capsules or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. ( 7. 2) 7. 1 Alcohol Alcohol may increase the CNS depressant effects of trimethobenzamide hydrochloride capsules and may cause drowsiness see Warnings and Precautions ( 5. 3, 5. 5). Avoid concomitant use of trimethobenzamide hydrochloride capsules with alcohol. 7. 2 Other Drugs that Cause CNS Depression or EPS The concurrent use of trimethobenzamide hydrochloride capsules with other drugs that cause CNS depression or EPS (e. G. , sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics, may potentiate the effects of trimethobenzamide hydrochloride capsules see Warnings and Precautions ( 5. 1, 5. 2, 5. 3, 5","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trimethobenzamide hydrochloride","ingredient2":"chloride","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Alcohol: May cause drowsiness; avoid concomitant use. ( 7. 1) Other Drugs that Cause CNS Depression or EPS: Either trimethobenzamide hydrochloride capsules or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. ( 7. 2) 7. 1 Alcohol Alcohol may increase the CNS depressant effects of trimethobenzamide hydrochloride capsules and may cause drowsiness see Warnings and Precautions ( 5. 3, 5. 5). Avoid concomitant use of trimethobenzamide hydrochloride capsules with alcohol. 7. 2 Other Drugs that Cause CNS Depression or EPS The concurrent use of trimethobenzamide hydrochloride capsules with other drugs that cause CNS depression or EPS (e. G. , sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics, may potentiate the effects of trimethobenzamide hydrochloride capsules see Warnings and Precautions ( 5. 1, 5. 2, 5. 3, 5","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trimethobenzamide hydrochloride","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Alcohol: May cause drowsiness; avoid concomitant use. ( 7. 1) Other Drugs that Cause CNS Depression or EPS: Either trimethobenzamide hydrochloride capsules or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. ( 7. 2) 7. 1 Alcohol Alcohol may increase the CNS depressant effects of trimethobenzamide hydrochloride capsules and may cause drowsiness see Warnings and Precautions ( 5. 3, 5. 5). Avoid concomitant use of trimethobenzamide hydrochloride capsules with alcohol. 7. 2 Other Drugs that Cause CNS Depression or EPS The concurrent use of trimethobenzamide hydrochloride capsules with other drugs that cause CNS depression or EPS (e. G. , sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics, may potentiate the effects of trimethobenzamide hydrochloride capsules see Warnings and Precautions ( 5. 1, 5. 2, 5. 3, 5","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"trimethobenzamide hydrochloride","ingredient2":"choline","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Alcohol: May cause drowsiness; avoid concomitant use. ( 7. 1) Other Drugs that Cause CNS Depression or EPS: Either trimethobenzamide hydrochloride capsules or the other interacting drug should be chosen, depending on the importance of the drug to the patient. If CNS-acting drugs cannot be avoided, monitor patients for CNS adverse reactions. ( 7. 2) 7. 1 Alcohol Alcohol may increase the CNS depressant effects of trimethobenzamide hydrochloride capsules and may cause drowsiness see Warnings and Precautions ( 5. 3, 5. 5). Avoid concomitant use of trimethobenzamide hydrochloride capsules with alcohol. 7. 2 Other Drugs that Cause CNS Depression or EPS The concurrent use of trimethobenzamide hydrochloride capsules with other drugs that cause CNS depression or EPS (e. G. , sedatives, hypnotics, opiates, anxiolytics, antipsychotics, and anticholinergics, may potentiate the effects of trimethobenzamide hydrochloride capsules see Warnings and Precautions ( 5. 1, 5. 2, 5. 3, 5","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deferasirox","ingredient2":"jadenu","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Do not take JADENU with aluminum-containing antacid preparations. (7. 1) Deferasirox increases the exposure of repaglinide. Consider repaglinide dose reduction and monitor blood glucose levels. (7. 3) Avoid the use of JADENU with theophylline as theophylline levels could be increased. (7. 4) Deferasirox increases exposure of busulfan. Monitor plasma concentrations of busulfan when coadministered with deferasirox to allow dose adjustment of busulfan, as needed. (7. 7) 7. 1 Aluminum-Containing Antacid Preparations The concomitant administration of JADENU and aluminum-containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminum than for iron, do not take JADENU with aluminum-containing antacid preparations. 7. 2 Agents Metabolized by CYP3A4 Deferasirox may induce CYP3A4 resulting in a decrease in CYP3A4 substrate concentration when these drugs are coadministered. Closely monitor patients for signs of reduced effe","recommendation":"Monitor blood glucose levels.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"morphine sulfate","ingredient2":"pine o","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with morphine sulfate extended-release capsules. Table 1: Clinically Significant Drug Interactions with Morphine Sulfate Extended-Release Capsules Alcohol Clinical Impact: Concomitant use of alcohol with morphine sulfate extended-release capsules can result in an increase of morphine plasma levels and potentially fatal overdose of morphine. Intervention: Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol while on morphine sulfate extended-release capsules therapy see Clinical Pharmacology (12. 3). Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effect, the concomitant use of benzodiazepine or other CNS depressants, including alcohol, can increase the risk of hypotension, respiratory depression, profound sedation, coma, and death. Intervention: Reserve concomitant prescribing ","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"deflazacort","ingredient2":"emflaza","severity":"major","severity_confidence":0.7,"effect":"7 DRUG INTERACTIONS Moderate or strong CYP3A4 inhibitors: Give one third of the recommended dosage of EMFLAZA (7. 1) Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy (7. 1) 7. 1 CYP3A4 Inhibitors and Inducers Moderate or Strong CYP3A4 Inhibitors The active metabolite of deflazacort, 21-desDFZ, is a substrate of CYP3A4 see Clinical Pharmacology (12. 3). Co-administration of deflazacort with clarithromycin, a strong CYP3A4 inhibitor, increased total exposure to 21-desDFZ by about 3-fold. Therefore, give one third the recommended dosage of EMFLAZA when moderate or strong CYP3A4 inhibitors (e. G. , clarithromycin, fluconazole, diltiazem, verapamil, grapefruit juice) are used concomitantly with EMFLAZA see Dosage and Administration (2. 5) and Clinical Pharmacology (12. 3). Moderate or Strong CYP3A4 Inducers Co-administration of deflazacort with rifampin, a strong CYP3A4 inducer, significantly decreased the exposure of 21-desDFZ. Avoid concomitant use","recommendation":"Avoid use of moderate or strong CYP3A4 inducers with EMFLAZA, as they may reduce efficacy (7.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"secukinumab","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Certain CYP450 Substrates Increased concentrations of cytokines (e. G. , IL-17) during chronic inflammation associated with certain diseases including PsO, PsA, AS, nr-axSpA, ERA, and HS may suppress the formation of CYP enzymes. Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those where minimal decreases in the concentration may reduce CYP substrate effectiveness or minimal increases in the concentration may increase CYP substrate adverse reactions, consider monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12. 3).","recommendation":"Monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"secukinumab","ingredient2":"cytokines","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Certain CYP450 Substrates Increased concentrations of cytokines (e. G. , IL-17) during chronic inflammation associated with certain diseases including PsO, PsA, AS, nr-axSpA, ERA, and HS may suppress the formation of CYP enzymes. Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those where minimal decreases in the concentration may reduce CYP substrate effectiveness or minimal increases in the concentration may increase CYP substrate adverse reactions, consider monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12. 3).","recommendation":"Monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"secukinumab","ingredient2":"cosentyx","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Certain CYP450 Substrates Increased concentrations of cytokines (e. G. , IL-17) during chronic inflammation associated with certain diseases including PsO, PsA, AS, nr-axSpA, ERA, and HS may suppress the formation of CYP enzymes. Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those where minimal decreases in the concentration may reduce CYP substrate effectiveness or minimal increases in the concentration may increase CYP substrate adverse reactions, consider monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12. 3).","recommendation":"Monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"secukinumab","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Certain CYP450 Substrates Increased concentrations of cytokines (e. G. , IL-17) during chronic inflammation associated with certain diseases including PsO, PsA, AS, nr-axSpA, ERA, and HS may suppress the formation of CYP enzymes. Upon initiation or discontinuation of COSENTYX in patients who are receiving concomitant CYP450 substrates, particularly those where minimal decreases in the concentration may reduce CYP substrate effectiveness or minimal increases in the concentration may increase CYP substrate adverse reactions, consider monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12. 3).","recommendation":"Monitoring for therapeutic effect or concentration of the CYP substrate and consider dosage adjustment of the CYP substrate as needed see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"pirtobrutinib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pirtobrutinib","ingredient2":"jaypirca","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pirtobrutinib","ingredient2":"rutin","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pirtobrutinib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pirtobrutinib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pirtobrutinib","ingredient2":"bcrp","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"pirtobrutinib","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS Strong CYP3A Inhibitors: Avoid concomitant use. If concomitant use is unavoidable, reduce the JAYPIRCA dose. (2. 4, 7. 1) Strong or Moderate CYP3A Inducers: Avoid concomitant use. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dose. (2. 5, 7. 1) Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates: For substrates where minimal concentration changes may increase the risk of adverse reactions, follow recommendations for co-administration with CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP inhibitors provided in their approved product labeling. (7. 2) 7. 1 Effect of Other Drugs on JAYPIRCA Strong CYP3A Inhibitors Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure see Clinical Pharmacology (12. 3), which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant us","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"heparin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"pine o","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"rifampicin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"tacrolimus","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"potassium i","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"non-steroidal","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"ace inhibitors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"aliskiren","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"renin-angiotensin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"cyclosporine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine valsartan and hydrochlorothiazide","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge HCT and other drugs, although studies have been conducted with the individual components. A pharmacokinetic drug-drug interaction study has been conducted to address the potential for pharmacokinetic interaction between the triple combination, Exforge HCT, and the corresponding 3 double combinations. No clinically relevant interaction was observed. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministere","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"basil","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"dosage","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"corticosteroids","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"pharmacology","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"igg","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"ros","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"others","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"administration","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"clinical","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"vera","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"phenol","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"iga","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"mycophenolate mofetil","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"azathioprine","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"olus","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"modified","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"milk","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"basiliximab","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"Drug Interactions No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens, including cyclosporine, corticosteroids, and either azathioprine or mycophenolate mofetil. Three clinical trials have investigated Simulect use in combination with triple-therapy regimens. Pharmacokinetics were assessed in two of these trials. Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids. Nonetheless, the range of individual Simulect clearance values in the presence of azathioprine (12-57 mL/h) or mycophenolate mofetil (7-54 mL/h) did not extend outside the range observed with dual therapy (10-78 mL/h). The following medications have been administered in clinical trials with Simulect with no increase in adverse reactions: ATG/ALG, azathioprine, corticosteroids, cyclosporine, mycophenolate mofetil, and muromo","recommendation":"Should only be used in pregnant women when the potential benefit justifies the potential risk to the fetus.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"nitric oxide","ingredient2":"prilocaine","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"sodium","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"sodium nitroprusside","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"glycerin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"glycer","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"glyce","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"nitroglycerin","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"glycerine","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"glyceri","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"nitric oxide","ingredient2":"sodi","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Nitric oxide donor compounds may increase the risk of developing methemoglobinemia (7). 7. 1 Nitric Oxide Donor Agents Nitric oxide donor agents such as prilocaine, sodium nitroprusside and nitroglycerine may increase the risk of developing methemoglobinemia.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"ros","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"epinephrine","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"fat","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"but","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"ors","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"albuterol sulfate","ingredient2":"ala","severity":"minor","severity_confidence":0.3,"effect":"Drug Interactions Other short-acting sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol sulfate inhalation solution.","recommendation":"Should not be used concomitantly with albuterol sulfate inhalation solution.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"diazepam","ingredient2":"anis","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions There have been no clinical studies or reports in literature to evaluate the interaction of rectally administered diazepam with other drugs. As with all drugs, the potential for interaction by a variety of mechanisms is a possibility. Effect of Concomitant Use of Benzodiazepines and Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation. Other Psychotropic Agents or Other CNS Depressants: If diazepam rectal gel is to be combined with other psychotropic agents","recommendation":"Should be given to the pharmacology of the agents to be employed particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diazepam","ingredient2":"sms","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions There have been no clinical studies or reports in literature to evaluate the interaction of rectally administered diazepam with other drugs. As with all drugs, the potential for interaction by a variety of mechanisms is a possibility. Effect of Concomitant Use of Benzodiazepines and Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation. Other Psychotropic Agents or Other CNS Depressants: If diazepam rectal gel is to be combined with other psychotropic agents","recommendation":"Should be given to the pharmacology of the agents to be employed particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"diazepam","ingredient2":"but","severity":"major","severity_confidence":0.7,"effect":"Drug Interactions There have been no clinical studies or reports in literature to evaluate the interaction of rectally administered diazepam with other drugs. As with all drugs, the potential for interaction by a variety of mechanisms is a possibility. Effect of Concomitant Use of Benzodiazepines and Opioids: The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation. Other Psychotropic Agents or Other CNS Depressants: If diazepam rectal gel is to be combined with other psychotropic agents","recommendation":"Should be given to the pharmacology of the agents to be employed particularly with known compounds which may potentiate the action of diazepam, such as phenothiazines, narcotics, barbiturates, MAO inhibitors and other antidepressants.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"ros","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"locametz","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"tar","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"bee","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"kit for the preparation of gallium ga 68 gozetotide","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Androgen Deprivation Therapy and Other Therapies Targeting the Androgen Pathway Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, can result in changes in uptake of gallium Ga 68 gozetotide in prostate cancer. The effect of these therapies on performance of LOCAMETZ PET has not been established.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"asfotase alfa","ingredient2":"alkaline","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug Interference with Laboratory Tests: Alkaline Phosphatase (ALP) is used as a detection reagent in many laboratory tests and the presence of asfotase alfa in clinical laboratory samples could result in erroneous test results. Inform laboratory personnel and discuss use of an alternative testing platform for patients on treatment. (7. 1) Serum Alkaline Phosphatase: Serum ALP measurements are expected to be elevated during treatment and may be unreliable for clinical decision making. (7. 1) 7. 1 Drug Interference with Laboratory Tests Laboratory Tests Utilizing Alkaline Phosphatase as a Detection Reagent Studies have shown that there is analytical interference between asfotase alfa and laboratory tests that utilize an alkaline phosphatase (ALP)-conjugated test system, rendering erroneous test results in patients treated with STRENSIQ. ALP-conjugated test systems are utilized to measure substances such as hormones, bacterial antigens and antibodies. Therefore, it is","recommendation":"Avoid erroneous test results for patients treated with STRENSIQ, inform laboratory personnel that the patient is being treated with STRENSIQ and discuss the use of a testing platform which does not utilize an ALP-conjugated test system.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"asfotase alfa","ingredient2":"eru","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug Interference with Laboratory Tests: Alkaline Phosphatase (ALP) is used as a detection reagent in many laboratory tests and the presence of asfotase alfa in clinical laboratory samples could result in erroneous test results. Inform laboratory personnel and discuss use of an alternative testing platform for patients on treatment. (7. 1) Serum Alkaline Phosphatase: Serum ALP measurements are expected to be elevated during treatment and may be unreliable for clinical decision making. (7. 1) 7. 1 Drug Interference with Laboratory Tests Laboratory Tests Utilizing Alkaline Phosphatase as a Detection Reagent Studies have shown that there is analytical interference between asfotase alfa and laboratory tests that utilize an alkaline phosphatase (ALP)-conjugated test system, rendering erroneous test results in patients treated with STRENSIQ. ALP-conjugated test systems are utilized to measure substances such as hormones, bacterial antigens and antibodies. Therefore, it is","recommendation":"Avoid erroneous test results for patients treated with STRENSIQ, inform laboratory personnel that the patient is being treated with STRENSIQ and discuss the use of a testing platform which does not utilize an ALP-conjugated test system.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"asfotase alfa","ingredient2":"strensiq","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug Interference with Laboratory Tests: Alkaline Phosphatase (ALP) is used as a detection reagent in many laboratory tests and the presence of asfotase alfa in clinical laboratory samples could result in erroneous test results. Inform laboratory personnel and discuss use of an alternative testing platform for patients on treatment. (7. 1) Serum Alkaline Phosphatase: Serum ALP measurements are expected to be elevated during treatment and may be unreliable for clinical decision making. (7. 1) 7. 1 Drug Interference with Laboratory Tests Laboratory Tests Utilizing Alkaline Phosphatase as a Detection Reagent Studies have shown that there is analytical interference between asfotase alfa and laboratory tests that utilize an alkaline phosphatase (ALP)-conjugated test system, rendering erroneous test results in patients treated with STRENSIQ. ALP-conjugated test systems are utilized to measure substances such as hormones, bacterial antigens and antibodies. Therefore, it is","recommendation":"Avoid erroneous test results for patients treated with STRENSIQ, inform laboratory personnel that the patient is being treated with STRENSIQ and discuss the use of a testing platform which does not utilize an ALP-conjugated test system.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"asfotase alfa","ingredient2":"bet","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug Interference with Laboratory Tests: Alkaline Phosphatase (ALP) is used as a detection reagent in many laboratory tests and the presence of asfotase alfa in clinical laboratory samples could result in erroneous test results. Inform laboratory personnel and discuss use of an alternative testing platform for patients on treatment. (7. 1) Serum Alkaline Phosphatase: Serum ALP measurements are expected to be elevated during treatment and may be unreliable for clinical decision making. (7. 1) 7. 1 Drug Interference with Laboratory Tests Laboratory Tests Utilizing Alkaline Phosphatase as a Detection Reagent Studies have shown that there is analytical interference between asfotase alfa and laboratory tests that utilize an alkaline phosphatase (ALP)-conjugated test system, rendering erroneous test results in patients treated with STRENSIQ. ALP-conjugated test systems are utilized to measure substances such as hormones, bacterial antigens and antibodies. Therefore, it is","recommendation":"Avoid erroneous test results for patients treated with STRENSIQ, inform laboratory personnel that the patient is being treated with STRENSIQ and discuss the use of a testing platform which does not utilize an ALP-conjugated test system.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"asfotase alfa","ingredient2":"interactions","severity":"minor","severity_confidence":0.3,"effect":"7 DRUG INTERACTIONS Drug Interference with Laboratory Tests: Alkaline Phosphatase (ALP) is used as a detection reagent in many laboratory tests and the presence of asfotase alfa in clinical laboratory samples could result in erroneous test results. Inform laboratory personnel and discuss use of an alternative testing platform for patients on treatment. (7. 1) Serum Alkaline Phosphatase: Serum ALP measurements are expected to be elevated during treatment and may be unreliable for clinical decision making. (7. 1) 7. 1 Drug Interference with Laboratory Tests Laboratory Tests Utilizing Alkaline Phosphatase as a Detection Reagent Studies have shown that there is analytical interference between asfotase alfa and laboratory tests that utilize an alkaline phosphatase (ALP)-conjugated test system, rendering erroneous test results in patients treated with STRENSIQ. ALP-conjugated test systems are utilized to measure substances such as hormones, bacterial antigens and antibodies. Therefore, it is","recommendation":"Avoid erroneous test results for patients treated with STRENSIQ, inform laboratory personnel that the patient is being treated with STRENSIQ and discuss the use of a testing platform which does not utilize an ALP-conjugated test system.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"vancomycin hydrochloride","ingredient2":"counseling","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing see Warnings and Precautions (5. 1) and Use in Specific Populations (8. 4). Anesthetic Agents: Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing. ( 2. 1, 7. 1) Piperacillin/Tazobactam: Increased incidence of acute kidney injury in patients receiving concomitant piperacillin/tazobactam and vancomycin as compared to vancomycin alone. Monitor kidney function in patients ( 7. 2) See 17 for PATIENT COUNSELING INFORMATION. 7. 1 Anesthetic Agents Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing see Warnings and Precautions (5. 1) and Use in Specific Populations (8. 4). 7. 2 Piperacillin-Tazobactam Studies have detected an increased incidence of acute kidney injury in patients administered concomitant p","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"bcrp","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"tabrecta","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"vit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"capmatinib","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Strong and Moderate CYP3A Inducers: Avoid concomitant use. (7. 1) 7. 1 Effect of Other Drugs on TABRECTA Strong CYP3A Inhibitors Coadministration of TABRECTA with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of TABRECTA see Clinical Pharmacology (12. 3). Closely monitor patients for adverse reactions during coadministration of TABRECTA with strong CYP3A inhibitors. Strong and Moderate CYP3A Inducers Coadministration of TABRECTA with a strong CYP3A inducer decreased capmatinib exposure. Coadministration of TABRECTA with a moderate CYP3A inducer may also decrease capmatinib exposure. Decreases in capmatinib exposure may decrease TABRECTA anti-tumor activity see Clinical Pharmacology (12. 3). Avoid coadministration of TABRECTA with strong and moderate CYP3A inducers. 7. 2 Effect of TABRECTA on Other Drugs CYP1A2 Substrates Coadministration of TABRECTA increased the exposure of a CYP1A2 substr","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sacituzumab govitecan","ingredient2":"trodelvy","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS UGT1A1 inhibitors or inducers: Avoid concomitant use. (7) 7. 1 Effect of Other Drugs on TRODELVY UGT1A1 Inhibitors Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38 see Warning and Precaution (5. 5) and Clinical Pharmacology (12. 3, 12. 5). Avoid administering UGT1A1 inhibitors with TRODELVY. UGT1A1 Inducers Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers see Warning and Precaution (5. 5) and Clinical Pharmacology (12. 3, 12. 5). Avoid administering UGT1A1 inducers with TRODELVY.","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sacituzumab govitecan","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS UGT1A1 inhibitors or inducers: Avoid concomitant use. (7) 7. 1 Effect of Other Drugs on TRODELVY UGT1A1 Inhibitors Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38 see Warning and Precaution (5. 5) and Clinical Pharmacology (12. 3, 12. 5). Avoid administering UGT1A1 inhibitors with TRODELVY. UGT1A1 Inducers Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers see Warning and Precaution (5. 5) and Clinical Pharmacology (12. 3, 12. 5). Avoid administering UGT1A1 inducers with TRODELVY.","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"sacituzumab govitecan","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS UGT1A1 inhibitors or inducers: Avoid concomitant use. (7) 7. 1 Effect of Other Drugs on TRODELVY UGT1A1 Inhibitors Concomitant administration of TRODELVY with inhibitors of UGT1A1 may increase the incidence of adverse reactions due to potential increase in systemic exposure to SN-38 see Warning and Precaution (5. 5) and Clinical Pharmacology (12. 3, 12. 5). Avoid administering UGT1A1 inhibitors with TRODELVY. UGT1A1 Inducers Exposure to SN-38 may be reduced in patients concomitantly receiving UGT1A1 enzyme inducers see Warning and Precaution (5. 5) and Clinical Pharmacology (12. 3, 12. 5). Avoid administering UGT1A1 inducers with TRODELVY.","recommendation":"Avoid concomitant use.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"codeine sulfate","ingredient2":"diuretics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"sage","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"prop","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"tramadol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"alcohol","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"carbamazepine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"morphine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"fat","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"but","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"nalbuphine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"mirtazapine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"metaxalone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"fluoxetine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"methylene blue","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"ritonavir","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"choline","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"protease","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"cyclobenzaprine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"tranylcypromine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"phenytoin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"oxycodone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"maoi","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"erythromycin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"thy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"naloxone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"met","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"monoamine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"bupropion","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"others","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"antibiotics","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"paroxetine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"epinephrine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"gre","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"trazodone","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"maois","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"phenelzine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"codeine","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"ors","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"methy","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"interactions","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"ketoconazole","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"linezolid","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"pro","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"codeine sulfate","ingredient2":"diuretic","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 1 includes clinically significant drug interactions with codeine sulfate tablets. Table 1: Clinically Significant Drug Interactions with Codeine Sulfate Tablets Inhibitors of CYP3A4 C li n i cal Impact: The concomitant use of codeine sulfate tablets with CYP3A4 inhibitors, may result in an increase in codeine plasma concentrations with subsequently greater metabolism by cytochrome CYP2D6, resulting in greater morphine levels, which could increase or prolong adverse reactions and may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose of codeine sulfate tablets is achieved see Warnings and Precautions ( 5. 7 ). After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, it may result in lower codeine levels, greater norcodeine levels, and less metabolism via CYP2D6 with resultant lower morphine levels see Clinical Pharmacology ( 12. 3 ), resulting in decreased opioid efficacy or a withdrawa","recommendation":"Cautions ( 5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sumatriptan","ingredient2":"maoa","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and IMITREX tablets within 24 hours of each other is contraindicated. 7. 2 Monoamine Oxidase-A Inhibitors MAOA inhibitors increase systemic exposure by 7-fold. Therefore, the use of IMITREX tablets in patients receiving MAOA inhibitors is contraindicated see Clinical Pharmacology (12. 3). 7. 3 Other 5-HT1 Agonists Because their vasospastic effects may be additive, coadministration of IMITREX tablets and other 5HT1 agonists (e. G. , triptans) within 24 hours of each other is contraindicated. 7. 4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitor","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"sumatriptan","ingredient2":"imitrex","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Ergot-Containing Drugs Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and IMITREX tablets within 24 hours of each other is contraindicated. 7. 2 Monoamine Oxidase-A Inhibitors MAOA inhibitors increase systemic exposure by 7-fold. Therefore, the use of IMITREX tablets in patients receiving MAOA inhibitors is contraindicated see Clinical Pharmacology (12. 3). 7. 3 Other 5-HT1 Agonists Because their vasospastic effects may be additive, coadministration of IMITREX tablets and other 5HT1 agonists (e. G. , triptans) within 24 hours of each other is contraindicated. 7. 4 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitor","recommendation":"Cautions (5.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"buprenorphine hcl","ingredient2":"gabapentin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine Sublingual Tablets Benzodiazepines or other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and n","recommendation":"Monitoring in a higher level of care for taper may be appropriate.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"buprenorphine hcl","ingredient2":"pregabalin","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine Sublingual Tablets Benzodiazepines or other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and n","recommendation":"Monitoring in a higher level of care for taper may be appropriate.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"buprenorphine hcl","ingredient2":"gaba","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS Table 3 includes clinically significant drug interactions with Buprenorphine Sublingual Tablets. Table 3. Clinically Significant Drug Interactions with Buprenorphine Sublingual Tablets Benzodiazepines or other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or CNS depressant or decreasing to the lowest effective dose may be appropriate. Before co-prescribing benzodiazepines for anxiety or insomnia, ensure that patients are appropriately diagnosed and consider alternative medications and n","recommendation":"Monitoring in a higher level of care for taper may be appropriate.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"digoxin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"choline","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"gepotidacin","ingredient2":"blujepa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inhibitors: Increase gepotidacin exposure. (7. 1) Strong CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors. (5. 1, 7. 1) Moderate CYP3A4 inhibitors: Avoid concomitant use of BLUJEPA with moderate CYP3A4 inhibitors in patients with uncomplicated urogenital gonorrhea. (5. 1, 7. 1) CYP3A4 Inducers: Decrease gepotidacin exposure. (7. 1) For uUTI: Avoid concomitant use of BLUJEPA with strong CYP3A4 inducers. (7. 1) For uncomplicated urogenital gonorrhea: Avoid concomitant use of BLUJEPA with strong and moderate CYP3A4 inducers. (7. 1) CYP3A4 Substrates: Avoid concomitant use of BLUJEPA with drugs that are extensively metabolized by CYP3A4 where minimal concentration changes may lead to serious adverse reactions. (7. 2) Digoxin: Due to an increase in digoxin exposures, consider monitoring digoxin serum concentration, as appropriate, with concomitant administration of BLUJEPA. (7. 2) 7. 1 Effect of Other Drugs on BLUJEPA CYP3A4 Inhibi","recommendation":"Avoid concomitant use of BLUJEPA with strong CYP3A4 inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"acoramidis hydrochloride","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS UDP-glucuronosyltransferases (UGT) Inducers and Strong CYP3A Inducers Acoramidis is metabolized by UGT enzyme-mediated glucuronidation. Concomitant use of UGT inducers can potentially decrease acoramidis exposure. While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers. Sensitive Cytochrome P450 2C9 (CYP2C9) substrates Acoramidis inhibits CYP2C9 and may result in an increase in CYP2C9 substrate concentrations when these drugs are co administered. Consider more frequent monitoring of patients for evidence of increased exposure (for example, signs of exposure related toxicity) when ATTRUBY is co administered with sensitive CYP2C9 substrates.","recommendation":"Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"acoramidis hydrochloride","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS UDP-glucuronosyltransferases (UGT) Inducers and Strong CYP3A Inducers Acoramidis is metabolized by UGT enzyme-mediated glucuronidation. Concomitant use of UGT inducers can potentially decrease acoramidis exposure. While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers. Sensitive Cytochrome P450 2C9 (CYP2C9) substrates Acoramidis inhibits CYP2C9 and may result in an increase in CYP2C9 substrate concentrations when these drugs are co administered. Consider more frequent monitoring of patients for evidence of increased exposure (for example, signs of exposure related toxicity) when ATTRUBY is co administered with sensitive CYP2C9 substrates.","recommendation":"Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"acoramidis hydrochloride","ingredient2":"attruby","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS UDP-glucuronosyltransferases (UGT) Inducers and Strong CYP3A Inducers Acoramidis is metabolized by UGT enzyme-mediated glucuronidation. Concomitant use of UGT inducers can potentially decrease acoramidis exposure. While acoramidis is not metabolized by CYP3A, strong CYP3A inducers can also induce UGT enzymes. Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers. Sensitive Cytochrome P450 2C9 (CYP2C9) substrates Acoramidis inhibits CYP2C9 and may result in an increase in CYP2C9 substrate concentrations when these drugs are co administered. Consider more frequent monitoring of patients for evidence of increased exposure (for example, signs of exposure related toxicity) when ATTRUBY is co administered with sensitive CYP2C9 substrates.","recommendation":"Avoid concomitant use of ATTRUBY with UGT inducers and strong CYP3A inducers.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cedazuridine and decitabine","ingredient2":"cedazuridine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. (7) 7. 1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs see Clinical Pharmacology (12. 3). Avoid coadministration of INQOVI with drugs that are metabolized by CDA.","recommendation":"Avoid coadministration with INQOVI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cedazuridine and decitabine","ingredient2":"inqovi","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. (7) 7. 1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs see Clinical Pharmacology (12. 3). Avoid coadministration of INQOVI with drugs that are metabolized by CDA.","recommendation":"Avoid coadministration with INQOVI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cedazuridine and decitabine","ingredient2":"met","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. (7) 7. 1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs see Clinical Pharmacology (12. 3). Avoid coadministration of INQOVI with drugs that are metabolized by CDA.","recommendation":"Avoid coadministration with INQOVI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cedazuridine and decitabine","ingredient2":"cytidine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. (7) 7. 1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs see Clinical Pharmacology (12. 3). Avoid coadministration of INQOVI with drugs that are metabolized by CDA.","recommendation":"Avoid coadministration with INQOVI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cedazuridine and decitabine","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. (7) 7. 1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs see Clinical Pharmacology (12. 3). Avoid coadministration of INQOVI with drugs that are metabolized by CDA.","recommendation":"Avoid coadministration with INQOVI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"cedazuridine and decitabine","ingredient2":"uridine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS Drugs Metabolized by Cytidine Deaminase: Avoid coadministration with INQOVI. (7) 7. 1 Effects of INQOVI on Other Drugs Drugs Metabolized by Cytidine Deaminase Cedazuridine is an inhibitor of the cytidine deaminase (CDA) enzyme. Coadministration of INQOVI with drugs that are metabolized by CDA may result in increased systemic exposure with potential for increased toxicity of these drugs see Clinical Pharmacology (12. 3). Avoid coadministration of INQOVI with drugs that are metabolized by CDA.","recommendation":"Avoid coadministration with INQOVI.","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"ribociclib","ingredient2":"sage","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates may need to be reduced when given concurrently with KISQALI. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of strong CYP3A inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for","recommendation":"Avoid concomitant use of KISQALI with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ribociclib","ingredient2":"met","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates may need to be reduced when given concurrently with KISQALI. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of strong CYP3A inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for","recommendation":"Avoid concomitant use of KISQALI with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ribociclib","ingredient2":"ors","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates may need to be reduced when given concurrently with KISQALI. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of strong CYP3A inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for","recommendation":"Avoid concomitant use of KISQALI with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ribociclib","ingredient2":"interactions","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates may need to be reduced when given concurrently with KISQALI. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of strong CYP3A inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for","recommendation":"Avoid concomitant use of KISQALI with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ribociclib","ingredient2":"pro","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates may need to be reduced when given concurrently with KISQALI. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of strong CYP3A inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for","recommendation":"Avoid concomitant use of KISQALI with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ribociclib","ingredient2":"kisqali","severity":"moderate","severity_confidence":0.5,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors: Avoid concomitant use of KISQALI with strong CYP3A inhibitors. If strong inhibitors cannot be avoided, reduce KISQALI dose. (2. 2, 7. 1) CYP3A4 Inducers: Avoid concomitant use of KISQALI with strong CYP3A inducers. (7. 2) CYP3A Substrates: The dose of CYP3A substrates may need to be reduced when given concurrently with KISQALI. (7. 3) Drugs Known to Prolong QT Interval: Avoid concomitant use of drugs known to prolong QT interval, such as anti-arrhythmic medicines. (7. 4) 7. 1 Drugs That May Increase Ribociclib Plasma Concentrations CYP3A4 Inhibitors Coadministration of strong CYP3A inhibitors increases ribociclib exposure see Clinical Pharmacology (12. 3). Increased ribociclib concentrations may increase the incidence and severity of adverse reactions, including QTcF prolongation see Warnings and Precautions (5. 3). Avoid concomitant use of strong CYP3A inhibitors with KISQALI and consider alternative concomitant medications with less potential for","recommendation":"Avoid concomitant use of KISQALI with strong CYP3A inhibitors.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alpelisib","ingredient2":"protein","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. (7. 1) Breast Cancer Resistance Protein (BCRP) Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7. 1) 7. 1 Effect of Other Drugs on PIQRAY CYP3A4 Inducer Coadministration of PIQRAY with a strong CYP3A4 inducer decreases alpelisib concentration see Clinical Pharmacology (12. 3), which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. Breast Cancer Resistance Protein Inhibitors Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration see Clinical Pharmacology (12. 3), which may increase the risk of toxicities","recommendation":"Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alpelisib","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. (7. 1) Breast Cancer Resistance Protein (BCRP) Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7. 1) 7. 1 Effect of Other Drugs on PIQRAY CYP3A4 Inducer Coadministration of PIQRAY with a strong CYP3A4 inducer decreases alpelisib concentration see Clinical Pharmacology (12. 3), which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. Breast Cancer Resistance Protein Inhibitors Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration see Clinical Pharmacology (12. 3), which may increase the risk of toxicities","recommendation":"Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alpelisib","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. (7. 1) Breast Cancer Resistance Protein (BCRP) Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7. 1) 7. 1 Effect of Other Drugs on PIQRAY CYP3A4 Inducer Coadministration of PIQRAY with a strong CYP3A4 inducer decreases alpelisib concentration see Clinical Pharmacology (12. 3), which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. Breast Cancer Resistance Protein Inhibitors Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration see Clinical Pharmacology (12. 3), which may increase the risk of toxicities","recommendation":"Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alpelisib","ingredient2":"bcrp","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. (7. 1) Breast Cancer Resistance Protein (BCRP) Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7. 1) 7. 1 Effect of Other Drugs on PIQRAY CYP3A4 Inducer Coadministration of PIQRAY with a strong CYP3A4 inducer decreases alpelisib concentration see Clinical Pharmacology (12. 3), which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. Breast Cancer Resistance Protein Inhibitors Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration see Clinical Pharmacology (12. 3), which may increase the risk of toxicities","recommendation":"Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alpelisib","ingredient2":"piqray","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. (7. 1) Breast Cancer Resistance Protein (BCRP) Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7. 1) 7. 1 Effect of Other Drugs on PIQRAY CYP3A4 Inducer Coadministration of PIQRAY with a strong CYP3A4 inducer decreases alpelisib concentration see Clinical Pharmacology (12. 3), which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. Breast Cancer Resistance Protein Inhibitors Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration see Clinical Pharmacology (12. 3), which may increase the risk of toxicities","recommendation":"Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"alpelisib","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A4 Inducers: Avoid coadministration of PIQRAY with a strong CYP3A4 inducer. Consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. (7. 1) Breast Cancer Resistance Protein (BCRP) Inhibitors: Avoid the use of BCRP inhibitors in patients treated with PIQRAY. If unable to use alternative drugs, closely monitor for increased adverse reactions. (7. 1) 7. 1 Effect of Other Drugs on PIQRAY CYP3A4 Inducer Coadministration of PIQRAY with a strong CYP3A4 inducer decreases alpelisib concentration see Clinical Pharmacology (12. 3), which may reduce alpelisib efficacy. Avoid concomitant use of strong CYP3A4 inducers and consider an alternative concomitant drug with no or minimal potential to induce CYP3A4. Breast Cancer Resistance Protein Inhibitors Coadministration of PIQRAY with a breast cancer resistance protein (BCRP) inhibitor may increase alpelisib concentration see Clinical Pharmacology (12. 3), which may increase the risk of toxicities","recommendation":"Avoid coadministration of PIQRAY with a strong CYP3A4 inducer.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"norgestrel and ethinyl estradiol","ingredient2":"met","severity":"minor","severity_confidence":0.3,"effect":"8. Nursing Mothers Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"norgestrel and ethinyl estradiol","ingredient2":"milk","severity":"minor","severity_confidence":0.3,"effect":"8. Nursing Mothers Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"norgestrel and ethinyl estradiol","ingredient2":"pro","severity":"minor","severity_confidence":0.3,"effect":"8. Nursing Mothers Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"norgestrel and ethinyl estradiol","ingredient2":"others","severity":"minor","severity_confidence":0.3,"effect":"8. Nursing Mothers Advise the nursing mother to use other forms of contraception, when possible, until she has weaned her child. COCs can reduce milk production in breastfeeding mothers. This is less likely to occur once breastfeeding is well-established; however, it can occur at any time in some women. Small amounts of oral contraceptive steroids and/or metabolites are present in breast milk.","recommendation":"","source":"DailyMed","quality_validated":true,"confidence_score":1.0},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"valsartan","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"amiloride","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"diuretics","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"nsaid","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"iron","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"anti-inflammatory","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"prop","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"triamterene","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"spironolactone","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"nsaids","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"epa","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"eru","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"simvastatin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"non-steroidal","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"heparin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"pine o","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"ace inhibitors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"sildenafil","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"aliskiren","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"electrolytes","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"bet","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"gre","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"rifampicin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"potassium","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"bee","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"renin-angiotensin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"tacrolimus","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"amlodipine","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"cyclosporin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"diuretic","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"amlodipine besylate and valsartan","ingredient2":"potassium i","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS No drug interaction studies have been conducted with Exforge and other drugs, although studies have been conducted with the individual amlodipine and valsartan components. Amlodipine Impact of Other Drugs on Amlodipine CYP3A Inhibitors Coadministration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12. 3). CYP3A Inducers No information is available on the quantitative effects of CYP3A inducers on amlodipine. Blood pressure should be closely monitored when amlodipine is coadministered with CYP3A inducers (e. G. Rifampicin, St. Johns Wort). Sildenafil Monitor for hypotension when sildenafil is coadministered with amlodipine see Clinical Pharmacology (12. 2). Impact of Amlodipine on Other Drugs Simvastatin Coadministrati","recommendation":"Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment see Clinical Pharmacology (12.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"tadalafil","ingredient2":"adcirca","severity":"contraindicated","severity_confidence":1.0,"effect":"7 DRUG INTERACTIONS 7. 1 Nitrates Administration of nitrates within 48 hours after the last dose of ADCIRCA is contraindicated see Contraindications (4. 1). 7. 2 Alpha-Blockers PDE5 inhibitors, including ADCIRCA, and alphaadrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin see Clinical Pharmacology (12. 2). 7. 3 Antihypertensives PDE5 inhibitors, including ADCIRCA, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the bloodpressurelowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendroflumethiazide, enalapril, and metoprolol). Small reductions in blood pressure occurred following coadministrat","recommendation":"Contraindications (4.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"grape","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"sage","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"zykadia","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"grapefruit juice","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"grapefruit","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"midazolam","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"warfarin","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"ors","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"interactions","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"ketoconazole","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9},{"ingredient1":"ceritinib","ingredient2":"pro","severity":"severe","severity_confidence":0.9,"effect":"7 DRUG INTERACTIONS CYP3A Inhibitors and Inducers: Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers. If concurrent use of a strong CYP3A inhibitor is unavoidable, dose reduce ZYKADIA. (2. 4, 7. 1) CYP3A Substrates: Avoid coadministration of ZYKADIA with sensitive CYP3A substrates. (7. 2) CYP2C9 Substrates: Avoid coadministration of ZYKADIA with CYP2C9 substrates for which minimal concentration changes may lead to serious toxicities. (7. 2) 7. 1 Effect of Other Drugs on ZYKADIA Strong CYP3A Inhibitors A strong CYP3A4/P-gp inhibitor (ketoconazole) increased the systemic exposure of ceritinib see Clinical Pharmacology (12. 3), which may increase the incidence and severity of adverse reactions of ZYKADIA. Avoid concurrent use of strong CYP3A inhibitors during treatment with ZYKADIA. If concurrent use of strong CYP3A inhibitors is unavoidable, reduce the ZYKADIA dose see Dosage and Administration (2. 4). Do not consume grapefruit and grapefruit juice as they may inhi","recommendation":"Avoid concurrent use of ZYKADIA with strong CYP3A inhibitors or inducers.","source":"DailyMed","quality_validated":true,"confidence_score":0.9}]}